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Abstract 
Mesenchymal stem cells (MSCs) are a common transfusion cell therapy that have been 
used in over 300 clinical trials to treat over 2000 patients with diseases ranging from 
Crohn’s disease to heart failure. These cells are frequently cryopreserved to better 
coordinate the timing of cell administration with patient care regimes and to 
accommodate transport of samples between different sites of collection, processing, and 
administration. However, cryopreservation with DMSO (the current gold standard) can 
result in poor cell function post-thaw and adverse reactions upon infusion.  
 
We hypothesize that non-DMSO cryopreservative molecules, including sugars, sugar 
alcohols, amino acids, and other small molecule additives, can be used in combination to 
protect cell viability and function post-thaw. This research demonstrates that some 
combinations of non-DMSO cryopreservatives preserve cell functionality better than 
others, and these effects are dependent not on osmotic or physical changes in solution, 
but on biological changes that affect the cell during the freezing process.  We observe 
that there is likely a sweet spot concentration combination that produces maximum 
recovery for each combination of molecules, and demonstrate that an evolutionary 
algorithm can be used to identify optimized combinations of molecules that yield high 
cell recovery post-thaw.  Additionally, we demonstrate that these novel solutions 
maintain MSC functionality when evaluated using surface markers, attachment, 
proliferation, actin alignment, RNA expression, and DNA hydroxymethylation. These 
advances in cryopreservation can improve cell therapy, and ultimately patient care. 
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Chapter 1 
Introduction 
1.1 Motivation 
Mesenchymal stem cells (MSCs) are currently being investigated as a therapeutic 
treatment for a growing number of diseases due to their unique ability to independently 
home to sites of injury, differentiate, secrete bioactive molecules, and immuno-modulate 
the host environment[1]. To date, more than 600 clinical trials involve the use of MSCs 
[2] and more than 2000 patients have been safely treated for a variety of conditions that 
use MSC traits to fill a missing niche, ranging from bone and muscle 
regeneration/maintenance to immuno-modulation for immune disorders such as graft vs. 
host and crohn’s disease [3].  In addition, MSCs can be easily harvested from adult 
tissues (most commonly bone marrow and adipose tissue), and as such are an ethically 
superior alternative to embryonic stem cells for cell therapy.  
 
In attempts to increase the availability of this promising treatment, freshly isolated and 
expanded MSCs can be cryopreserved and stored in low temperature cell banks[4]. 
Cryopreserved samples can be batch processed, allowing for more efficient use of 
resources at cell therapy processing facilities by reducing staff required for culture 
maintenance, culture costs, and risk of contamination.  Bio-banks of cryo samples can be 
tracked easily with barcodes and require minimal human intervention, as temperature and 
liquid nitrogen levels can be monitored with automated instruments and alarms. At liquid 
nitrogen temperatures, cells are stable for long periods of time [5, 6] and can be 
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transported to sites of administration using liquid nitrogen charged dry shippers or dry 
ice.   
 
However, to survive freezing, cell samples must be combined with cryopreservatives to 
draw water out of and limit ice crystal formation within cells[7].  Dimethyl sulfoxide 
(DMSO) has become the gold standard cryopreservative used for cell freezing in the last 
50 years.  However, DMSO is systemically toxic in humans and can result in side effects 
ranging from mild (such as nausea and vomiting) to severe (including cardiovascular and 
respiratory complications) when transfused in even trace amounts with thawed cells [8]. 
As some treatments require multiple infusions of cryopreserved cells, non-toxic 
cryopreservative alternatives to DMSO are desirable.  Aside from these negative systemic 
side effects, it has also been suggested that current freezing with DMSO produces sub-
optimal functioning post-thaw stem cell products[9, 10].  As the cell therapy industry 
expands, it will be important to identify alternative methods of freezing cell types whose 
functions are sensitive to cryopreservation in DMSO. 
 
A non-DMSO cryopreservative solution with biologically non-toxic solution components 
could improve cell function post-thaw and make cell therapy accessible to more patients, 
as non-DMSO solutions would likely require less post-thaw cell processing to be 
administered as a safe, functional product.  
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1.2 Hypothesis and Aims 
This research proposes to eliminate DMSO for the cryopreservation of MSCs, and 
hypothesizes that a combination of non-DMSO cryopreservative agents will act in 
concert to maintain cellular viability and function throughout the freezing process. This 
hypothesis produced the following aims: 
Aim 1 – Identify combinations of solution components likely to result in high post-
thaw cell recovery, and establish potential mechanisms of cryo-protection for these 
combinations.   
Aim 1.1 –Identify solution combinations most likely to result in high post-thaw cell 
recovery. 
Candidate solutions that include compounds from several cryoprotective categories will 
be screened in Chapter 5 to identify compositions that maximize recovery in cells after 
undergoing freezing and thawing. 
Aim 1.2 – Identify mechanisms of cryoprotection for multicomponent solutions. 
In Chapter 6, solutions containing components identified as promising in Aim 1.1 will be 
combined with cells and evaluated to determine the mechanisms by which they protect 
cells during cryopreservation.  
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Aim 2 - Establish and validate differential evolution algorithm for predictive 
optimization of solution components, concentrations, and freezing rates. 
In Chapter 7, a MATLAB algorithm based on the Storn and Price differential evolution 
algorithm[11] will be validated for subsequent application to MSC functional 
cryopreservative optimization in Aim 3.  
Aim 3 – Iterate algorithm to optimize cryopreservation solutions for MSCs, and 
confirm optimized solutions maintain cellular function post-thaw. 
In Chapter 8, MSC freezing solutions will be optimized using the algorithm for functional 
attachment post-thaw, and subsequently analyzed for additional functionality metrics. 
 
In addressing these specific aims, we will determine whether it is possible to optimize 
non-DMSO cryopreservation of MSCs using an evolutionary algorithm, and establish 
whether the cells resultant from freezing in these multicomponent solutions display 
functional behavior that is maintained or improved compared to DMSO freezing.  The 
outcomes of this work will assist us in understanding and improving MSC freezing, 
contributing to the long-term goal of increasing the number of patients who are 
successfully treated with transfused stem cell products. 
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Chapter 2 
Background 
2.1 Mesenchymal Stem Cells 
Much of the text, figures, and tables in this section have previously appeared in the 
publication below, included here with copyright permission from John Wiley and Sons: 
 
Sharma RR, Pollock K, Hubel A, McKenna DH. Mesenchymal Stem/Stromal Cells: A 
Review of Clinical Applications and Manufacturing Practices. Transfusion 2014; 54 (5): 
1418-1437 
 
 
MSCs were isolated in 1968 by Friedenstein et al[12], who characterized them as 
adherent fibroblast-like cells in the bone marrow (BM) capable of differentiating into 
bone. MSCs have since been isolated from various other tissues including adipose tissue 
(AT)[13] and umbilical cord blood (UCB)[14]. However, source tissue can influence 
isolated MSC behavior, and several laboratories have used different strategies to identify, 
isolate, and culture MSCs to obtain optimal properties for indication-specific 
applications.[15–17] 
The minimal criteria required to define MSCs were defined by Dominici et al in 
2006[18], and can be summarized as follows: 
1. MSCs must be adherent to plastic under standard tissue culture conditions;  
2. MSCs must have positive expression of certain cell surface markers such as 
CD73, CD90, and CD105, and negative expression of other markers including 
CD45, CD34, CD14, CD11b, CD79α, or CD19 and HLA-DR surface molecules;  
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3. MSCs must be capable of differentiating into osteoblasts, adipocytes, and 
chondroblasts under defined in vitro conditions. 
Based on current literature[1, 19], MSCs are believed to exert their therapeutic effects by 
several mechanisms including:  
1. Homing to sites of inflammation after tissue injury;  
2. Differentiation into multi-lineage cell types;  
3. Secretion of bioactive molecules capable of stimulating recovery of injured 
cells and inhibiting inflammation;  
4. Ability to immunomodulate the host environment (and non-immunogenicity) 
These four potential modes of therapeutic efficacy have been demonstrated in various 
preclinical animal model studies[20]. The first clinical trial in humans using culture-
expanded MSCs was carried out in 1995; in this study, 15 hemato-oncology patients 
received injections of autologous (BM-MSCs) cells as part of a safety and feasibility 
study[21]. Since then, the use of MSCs has been further explored. In October 2012, the 
clinical trials database displayed 218 clinical trials using MSCs for a wide range of 
therapeutic applications internationally, and this number has since grown to 607 trials as 
of September 2016[2]. An analysis of the studies underway in October 2012 reveals that 
most trials were in Phase I (safety studies, n = 42), Phase II (proof of efficacy, n = 57), or 
combined Phases I and II studies (n = 105). A much smaller number of trials were in 
Phase III (comparison to gold standard, n = 8) or combined Phases II and III (n = 6). The 
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disease conditions, phase, and enrollment of trials are listed in Table 1 and their sources 
are summarized in Figure 1.  
 
 
 
 
 
 
 
 
Encouraging results from these clinical trials have increased research into MSC therapy 
for a variety of clinical disorders including: bone and cartilage disorders, bone 
neoplasms, hematologic disorders, diabetes, liver diseases, cardiovascular disorders, 
gastrointestinal diseases, autoimmune or skin disorders, lung diseases, neuromuscular 
diseases, limb ischemia, and renal diseases. 
Total = 218
Bone marrow
Umbilical cord blood
Adipose tissue
Trademarked products
Other
Not specified
Figure 1: Distribution of sources for MSCs in Table 1. 
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TABLE 1. Current status and enrollment of MSC clinical trials*
Targeted condition
Phases, number of studies [targeted enrollment]
I I/II II II/III III
Bone/cartilage disorders
Bone cysts 1 [6] 1 [10]
Bone neoplasms 1 [50]
Cartilage defect 1 [50] 2 [38] 1 [100]
Degenerative osteoarthritis 2 [30] 1 [25]
Distraction osteogenesis 1 [6]
Fractures 2 [16] 1 [24] 1 [40]
Ligament injury 1 [24] 1 [10]
Meniscectomy 2 [110]
Osteoarthritis 5 [42] 2 [45] 4 [222] 1 [104]
Osteodysplasia 1 [8]
Osteogenesis imperfecta 1 [9]
Osteonecrosis 1 [21] 2 [39] 1 [10]
Osteoporosis 1 [290]
Pseudoarthrosis 1 [50]
Spinal fusion 1 [62]
Hematologic disorders
Aplastic anemia 2 [60] 1 [30]
BMT 1 [125] 3 [40] 3 [125]
GVHD 2 [59] 6 [130] 6 [286] 1 [100] 1 [240]
Myelodysplastic syndrome 1 [30]
Diabetes
Type 1 1 [24] 5 [168] 1 [60] 1 [80]
Type 2 1 [24] 3 [170]
Liver diseases
Autoimmune hepatitis 1 [100]
Cirrhosis 3 [29] 7 [715] 5 [266]
Hypercholesterolemia 1 [1]
Liver failure 2 [228] 1 [120]
Liver transplant 1 [40] 1 [60]
Primary biliary cirrhosis 1 [100]
Cardiovascular diseases
Dilated cardiomyopathy 2 [66] 2 [80]
Heart failure 3 [172] 4 [160]
Myocardial infarction 1 [53] 2 [45] 2 [380] 1 [80] 2 [165]
Myocardial ischemia 2 [144] 3 [89] 1 [60]
Gastrointestinal diseases
Crohn’s disease 3 [56] 1 [10] 4 [696]
Fistula in ano 1 [10] 1 [40]
Ulcerative colitis 1 [50]
Autoimmune or skin disorders
Burns 1 [20]
Epidermolysis bullosa 1 [75]
HIV 1 [36]
SLE 1 [20]
Rheumatoid arthritis 2 [203]
Sjogren’s disease 1 [20]
Systemic sclerosis 1 [20]
Lung diseases
Bronchopulmonary dysplasia 3 [28]
COPD 1 [62]
Emphysema 1 [10]
Idiopathic pulmonary fibrosis 1 [8]
Neuromuscular diseases
ALS 1 [25] 1 [24] 1 [30]
Alzheimer’s 1 [9] 1 [30]
Brain injury 1 [2]
Cerebellar ataxia 1 [8] 1 [20]
Disc disease 3 [55]
Hereditary ataxia 1 [20]
ICSOL hemorrhage 1 [20]
Limbus insufficiency 1 [30]
Multiple sclerosis 1 [24] 5 [103] 1 [16]
Multiple sclerosis and NMO 1 [20]
Multiple system atrophy 1 [27]
Parkinson’s disease 1 [20]
Retinitis pigmentosa 1 [10]
Romberg’s disease 1 [5]
Spinal cord injury 4 [53] 2 [100] 2 [90] 1 [32]
Stroke 1 [30] 3 [203] 3 [100]
Muscular dystrophy 1 [15]
Neomyogenesis 1 [30]
Limb ischemia
Diabetic foot 1 [40] 1 [30]
Limb ischemia 9 [245] 2 [176]
Renal diseases
Kidney injury 1 [9] 1 [200]
Kidney transplant 3 [41]
Lupus nephritis 1 [20] 1 [25]
Miscellaneous
Endometriosis 1 [60]
Prostate cancer 1 [31]
Total: 218 [9757] 42 [923] 105 [3957] 57 [3285] 6 [367] 8 [1225]
* The data were searched on the website of ClinicalTrials.gov (http://www.clinicaltrials.gov) on October 22, 2012. The following key words including “mesenchymal stem cells,”
“mesenchymal stromal cells,” “multi-potent stromal cells,” “multi-potent progenitor cells,” “BM stromal cells,” and “connective tissue progenitor” were used.
ALS = amyotrophic lateral sclerosis; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; ICSOL = intracranial space–occupying lesion;
NMO = neuromyelitis optica; SLE = systemic lupus erythematosus.
MSC CLINICAL APPLICATIONS AND MANUFACTURING
Volume **, ** ** TRANSFUSION 3
Table 1: Status and enrollment of MSC clinical trials as of October 22, 2012. 
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2.1.1 Immunomodulatory effects of MSCs  
MSCs have unique immunologic characteristics, which promote their survival and 
growth in allogeneic or xenogeneic environments[22, 23]. They express low levels of 
major histocompatibility complex (MHC) Class I antigens and do not express MHC Class 
II antigens or costimulatory molecules such as CD40, CD80, and CD86[24]. These 
characteristics protect them from alloreactive natural killer (NK) cell–mediated lysis[25]. 
In addition, human MSCs express HLA-G, a non-classical MHC Class I antigen, which 
may prevent an immune response against MSCs (as shown by blocking experiments), 
although its expression seems to decrease in culture[26]. Culture conditions may also 
affect MSC immunogenicity due to internalization of protein molecules in the culture 
medium[27]. However, patients receiving treatment with allogeneic human MSCs do not 
show anti-allogeneic MSC antibody production or T-cell priming[28].  
MSCs act on both the adaptive and the innate immune systems by suppressing T 
cells[27], suppressing dendritic cell maturation[29, 30], reducing B-cell activation and 
proliferation[31, 32], inhibiting proliferation and cytotoxicity of NK cells[33], and 
promoting the generation of regulatory T cells via an interleukin (IL)-10 mechanism[34, 
35]. Secretion of prostaglandins and growth factors such as vascular endothelial growth 
factor, keratinocyte growth factor, and hepatocyte growth factor are also believed to 
influence immunomodulation and repair of various tissues[36]. When influenced by 
inflammatory cytokines, MSCs are capable of migrating to inflamed tissues and 
modulating the local inflammatory reactions at two levels via their effects on both innate 
and adaptive immunity[34, 37]. One level occurs locally via the secretion of mediators 
  10 
that inhibit proliferation of immune cells in the vicinity of MSCs, while the other induces 
a systemic response (either an anti-inflammatory Th-2 immune activation or the 
generation of regulatory T-cells). In addition, MSCs may recruit and support growth of 
local autologous stem cells within injured tissues, promoting cell survival and tissue 
repair[38]. Figure 2 summarizes the current known cell–cell interactions of MSCs with 
the immune system.  
 
Progenitor Immature DC 
TREG cell 
NK cells 
T cells 
B cells 
Neutrophils 
Mesenchymal 
stem cells 
Inhibits maturation in vitro 
Promotes 
expansion and 
function of TREG 
Alters phenotype of 
NK cells 
↓proliferation, 
cytokine secretion 
and cytotoxicity 
against HLA-class-I  
Suppresses cellular or 
mitogen induced T-cell 
proliferation.  Changes 
cytokine secretion profile of 
naïve and effector T-cells 
Inhibits Proliferation. 
Affects chemotaxis 
and terminal 
differentiation  
Inhibits neutrophil 
migration to site 
of injury and  
reactive O2 
species 
generation 
HLA-G 
PGE2 
IDO 
NO 
IL-6 
Figure 2: MSC cell-cell interactions	After activation, mesenchymal stem cells secrete soluble mediators 
– such as nitric oxide (NO), prostaglandin (PGE2), indoleamine 2,3-dioxygenase (IDO), IL-6, and human 
leukocyte antigen (HLA)-G. Production of these mediators regulates the proliferation and function of a 
variety of immune cells as well as the induction of regulatory T (TREG) cells either directly or indirectly 
through the generation of immature dendritic cells (DC). NK, natural killer. 
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2.1.2 MSC homing, engraftment, and differentiation. 
MSCs selectively home to sites of tissue injury and/or inflammation after systemic 
administration[37]. Once located at an inflammation site, MSCs can exert local 
functional effects in the resident tissue[37, 38]. Cell migration is dependent upon 
paracrine signaling from injured cells and local immune cells which release growth 
factors and chemokines [39]. In vitro migration assays suggest that MSC migration is 
specifically influenced by growth factors including platelet-derived growth factor 
(PDGF), insulin-like growth factor-1 (IGF-1), and chemokines such as CCR2, CCR3, 
CCR4, or CCL5 [40].   
MSCs can differentiate into mesodermal lineages such as bone, cartilage, adipocytes, and 
connective stromal cells[41]. It has been suggested that MSCs may also be capable of 
differentiating into endodermal lineage cells (e.g., hepatocytes)[42–44]. However, these 
results come from in vitro experiments, and the complex microenvironment of local 
tissue may alter how engrafted MSCs differentiate in vivo[45].  Based on current 
literature, engrafted MSCs appear to be capable of differentiating into at least three types 
of cells in vivo due to local tissue signaling:  
1. Tissue-specific cells necessary for repair. For example, cardiomyocytes, 
smooth muscle cells, and vascular endothelial cells when engrafted in cardiac 
tissue[46–48].  
2. Function-relative cells necessary for optimum growth and proliferation in local 
tissue. For example, in BM after stem cell transplantation[49].  
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3. Regulatory cells, which contribute to tissue repair and regeneration via trophic 
and immunomodulatory mechanisms[50]. 
There are currently several hypotheses to explain differentiation initiation for MSCs. 
Dennis et al [51] suggest a role for storage genes in MSCs that can adjust differentiation 
fate when exposed to different conditions. Phinney and Prockop[38] propose that MSCs 
are “equipped with motor proteins and a proteolytic arsenal that enables them to interact 
with and respond to signals from the extracellular matrix and differentiate into unique 
structures such as muscle, bone, cartilage, or other connective tissues”.  
The trophic effects of MSCs have also been implicated as significant in tissue 
regeneration[52, 53]. After engraftment, MSCs secrete a number of trophic molecules 
that include soluble extracellular matrix glycoproteins (collagen types I and II, 
osteopontin), cytokines (transforming growth factor [TGF]-β, IL-10, IL-6), and growth 
factors (vascular endothelial growth factor, hepatocyte growth factor, keratinocyte 
growth factor)[50]. These trophic molecules promote cell–cell connections[54], reduce 
inflammation, apoptosis, and fibrosis of damaged tissues, and can stimulate tissue cell 
regeneration.  
 
2.2 Mechanics of Cell Freezing and Damage 
 
If cells are not frozen properly, large distortions in the cellular system (such as membrane 
deformation) can occur due to ice crystal formation[55, 56].  Free water exists both inside 
the cell in the cytoplasm and in the surrounding extracellular fluid.  Ice solidifies 
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anisotropically during the freezing process and rejects cells and proteins from the solid 
phase.  This ice formation (both extracellular and intracellular) can result in undesirable 
mechanical stresses on the membrane and cytoskeleton.  Solutes in the freezing media 
help to suppress the freezing temperature of water, resulting in more control over ice 
nucleation and formation of small extracellular ice crystals, which helps limit damage to 
cells. Freezing in these systems is stochastic, and controlling ice nucleation using a 
controlled rate freezer has been shown to result in higher cell viability for MSCs than 
other freezing methods, such as vitrification (high cooling rate, low volumes of 
cryoprotectant, no ice crystal formation)[57]. 
 
Intrinsic factors of different cell types and interaction with cryoprotectants help to 
determine cellular recovery after freezing[58].  Optimal cooling rates vary with different 
systems of cells and cryoprotectants[7].  In most systems, slow freezing rates (less than 
10°C/min in the linear phase) induce extracellular ice formation, which concentrates 
cryoprotectants in the extracellular fluid and increases the osmotic gradient across cell 
membranes to draw free water out of cells. This osmotic dehydration at slow cooling 
rates[59] helps to limit intracellular ice formation that can result in cell injury[7, 60] 
before total solidification takes place.   
 
Increasing concentrations of cryoprotectants can destabilize the plasma membrane of 
cells by inducing chemical, electrical, and ionic stresses[61]. However, as temperature 
decreases so do the metabolism of the cell and the kinetics of all reactions, mitigating 
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damage as the system cools. Samples must be cooled and stored at temperatures below 
the threshold of activity at which degradative processes occur in order to maintain 
maximum cellular viability and function over time[62]; typically this is achieved by 
storage in liquid nitrogen or liquid vapor phase nitrogen at a temperature of -196°C. 
Thawing of cells after storage is typically performed as quickly as possible by agitating 
cells in a 37°C water bath until just-thawed[63]. 
 
Cells can be damaged at any of the five steps in the freezing process: sample preparation, 
freezing, storage, thawing, and analysis. Cryoprotectants, controlled freezing, and rapid 
thawing help mitigate damage that occurs in the freezing and thawing phases where cells 
are undergoing the greatest changes. However, death and damage still result due to 
freezing[64], suggesting that current methods are suboptimal[9] as they can result in 
variably poor performing post-thaw products[10].  
 
Some forms of cellular damage result in cell death, which can be observed immediately 
post-thaw using membrane integrity fluorescent stains.  Determining latent damage 
present in viable cells post-thaw is less straightforward.  Thawed cells may still test 
positive for viability during the early stages of apoptosis, resulting in poorer than 
expected post-thaw function of the cell sample as a whole. Membrane and cytoskeletal 
damage may also be present in cells post-thaw.  Localized bulging (blebbing) of the 
plasma membrane is characteristic of stress[65] and is observed during both 
apoptosis[66], and under freezing stresses[67]. Rupture of the cell membrane and 
changes in actin distribution can also result from freezing[68].  
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2.3 Dimethyl Sulfoxide (DMSO) Cryopreservation 
Dimethyl Sulfoxide (DMSO) was first identified as an effective cryopreservative in 1959 
by Lovelock and Bishop[69], and has since become the standard cryopreservative used 
for cell freezing in the last 50 years. However, the mechanisms of DMSO cell 
stabilization during freezing are not fully understood.  DMSO is a small (78 Da) 
amphiphilic molecule, which makes it highly membrane permeable and allows for 
efficient osmotic equilibration across the cell membrane during freezing and thawing. It 
is also believed to act as a stabilizer during freezing by binding just inside in the head 
group region of the cell membrane, increasing spacing between phospholipids, thinning 
the membrane, and decreasing membrane rigidity[70].  This allows cells to adjust and 
accommodate rather than rupture when confronted with external mechanical stimuli (such 
as ice crystals), and reduces the energy cost required to form pores[70, 71]. However, 
DMSO is systemically toxic. Although many treatment protocols call for washing of 
thawed cell products to reduce DMSO content before transfusion (which can cause cell 
losses during centrifugation and aspiration steps), DMSO can induce side effects such as 
nausea, vomiting, and cardiovascular and respiratory complications when transfused in 
even trace amounts with thawed cells[8, 72]. As some treatments require multiple 
infusions of cryopreserved cells, non-toxic cryopreservative alternatives to DMSO are 
desirable and will become necessary as transfusion cell therapy advances.  
 
In addition to DMSO’s negative systemic side effects, it has also been suggested that 
current freezing with DMSO produces sub-optimal functioning post-thaw stem cell 
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products[9, 73]. Specifically, mesenchymal stem cells have demonstrated diminished 
indoleamine deoxygenase activity [10], altered cytoskeletal function [74], and impaired 
immunomodulatory properties [75] after DMSO freezing. Other studies have shown that 
natural killer cells used for immunotherapies may also exhibit diminished post-thaw 
function after DMSO cryopreservation [76].  
 
These decreases in function are accompanied by changes in gene expression caused by 
epigenetic alterations. DMSO increases the mRNA level of the de novo DNA 
methyltransferase Dnmt3a accompanied by hyper- or hypo-methylation of many genetic 
loci [77] making it unsuitable for use with reprogrammed cells of high therapeutic value, 
such as induced pluripotent stem cells or cells derived from them.  Epigenetic changes in 
cells including increased DNA hydroxymethylation[78] have also been linked to DMSO.   
Clearly, development of alternative methods of preserving cells to eliminate DMSO and 
improve post-thaw function is desirable. 
 
2.4 Non-DMSO Cryopreservatives 
Any molecule cocktails selected to replace DMSO should additively create an 
environment similar to the stabilizing environment that DMSO is able to provide.  DMSO 
mechanisms of protection during freezing dictate that at a minimum, new non-DMSO 
solutions should be able to draw water out of cells to regulate the osmotic environment 
during freezing, and stabilize the membrane of the cell to promote thinning and transient 
pore formation. Additionally, components should be selected to stabilize areas of the cell 
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that DMSO has not shown evidence of protecting, including the cytoskeleton and 
intracellular protein conformations. 
 
Organisms in nature provide insight into possible non-toxic alternatives for cell 
stabilization[79]. Extremophile bacteria produce and accumulate amino acid 
polymers[80] and other non-toxic compounds such as ectoine[81] to prevent osmotic 
dehydration at high salt concentrations, and plants accumulate sugars, polyols (sugar 
alcohols), and amino acids under osmotic stress without affecting cellular metabolism 
[82, 83]. 
 
Several well-researched molecules fall into these categories and exhibit different 
mechanisms of cryoprotection including osmoprotection, protein hydration, and 
membrane stabilization.  Sugars, specifically trehalose, have been studied extensively for 
the osmoprotective effects they exert and have shown moderate cryoprotectivity at 
appropriate concentrations [84–86].  Polyols (such as glycerol) have been used as 
cryoprotectants for proteins, functionally stabilizing protein structure by maintaining 
hydrogen bonding in protein-bound water[87, 88]. To address membrane stability, amino 
acids have been utilized for liposomal cryopreservation[89, 90], and ampholytic amino 
acid polymers have demonstrated cryoprotection and result in cellular recoveries similar 
to DMSO[91, 92]. Evidence from several groups indicates that the use of multiple 
cryoprotectants from different families above, such as trehalose and proline[90], and 
trehalose and glycerol[93] exhibit improved cellular survival than either cryopreservative 
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alone, suggesting additive[87] stabilizing effects are possible when multiple 
cryopreservatives are used[94]. However, the concentrations of these cryoprotectants 
dictate whether they will be stabilizing or destabilizing[95, 96] and concentrations that 
result in stabilization optimums may differ when cryoprotectants are combined. 
 
2.5 Cryopreservation Optimization 
2.5.1 Previous factorial cryopreservation optimization attempts 
Many groups in the field of cryobiology have attempted to optimize cryopreservation of a 
variety of cell types.  Most commonly, factorial protocol optimization is used to 
empirically determine optimums by varying a limited range of conditions.  Different 
aspects of the cryopreservation process can be altered to identify optimums, including: 
cryoprotectant identity, cryoprotectant concentration, rate of addition and removal of 
cryoprotectant, pre-freeze incubation time, pre-freeze incubation temperature, hold 
temperature, nucleation temperature, cooling rate, single vs. multistep cooling, storage 
temperature, and thawing rate. For example, Conrad et al[97] evaluated a total of 8 
different factorial combinations to determine how changes in concentration of trehalose, 
borate and pH affect recovery of Lactobacillus acidophilus freeze dried products.  
Dijkstra-Tiekstra et al[98] studied a total of 32 different factorial combinations to 
determine the effects of precooling, changes in DMSO concentration, freezing rate, and 
storage condition on hematopoietic progenitor cell quality. Dong et al[99] looked at 64 
total factorial combinations capturing differences in pre-cooling, cryoprotectants, 
cooling, and thawing conditions to optimize rhesus monkey sperm cryopreservation. 
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Freimark et al[100] assessed a total of 36 different factorial combinations of 
cryoprotectants, equilibration period, and cooling rate to optimize Mesenchymal stem cell 
cryopreservation. Kearney et al[101]evaluated a total of 36 factorial combinations of 
different cryoprotectants, permeation times, and cooling rates to optimize murine skin 
cell cryopreservation. Ting et al[102]studied a total of 16 factorial combinations of 
different vitrification solutions, incubation times, and polymer additions to optimize 
macaque ovarian tissue vitrification, as well as a total of 48 factorial combinations[103] 
of different vitrification solutions, concentrations, and post-thaw sugar dilutions to 
optimize vitrification of pre-antral macaque ovarian follicles.  At most, these factorial 
optimization schemes looked at 2-6 different values for 2-6 different variables, limiting 
the total conditions tested in each of these studies to a manageable experimental size. 
 
2.5.2 Differential Evolution Algorithm  
In order to increase the number of potential combinations that can be tested while 
avoiding factorial testing of all possible combinations within a given system, a more 
systematic optimization approach can be employed.  The differential evolution algorithm 
was developed by Storn and Price[11], and was used recently by Tsutsui et al[104] to 
optimize growth medium composition for embryonic stem cells.  When applied to 
solution optimization problems, the algorithm utilizes an objective (cost) function that 
models the problem as a maximization task.  For the cryopreservation applications 
described in this work, vectors containing information regarding the viability of cells 
frozen and thawed (dependent variable to be maximized) and the solutions in which they 
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are frozen (independent variables) populate the cost function.  The cost function is filled 
with discrete data vectors, and as such is non-linear and non-differentiable.  Solving 
requires the use of a stochastic direct search method, which generates variations by taking 
the difference between two existing vectors and perturbing a third vector with the result.  
After producing a vector variation, the algorithm makes a decision (based on the existing 
data points in the cost function) whether or not to accept the new vector by using the 
greedy criterion, and only accepts the result if it increases the value of the cost function. 
To avoid local maxima, parallel searches are run simultaneously.  This allows for faster 
and smoother convergence to a global maximum when compared to optimization 
algorithms that utilize probability distribution functions. 
 
It would take thousands of trials to determine the best concentration set of non-DMSO 
cryoprotectants for MSC freezing if every possible combination in large parameter ranges 
were tested.  The differential evolution algorithm will assist in identifying interactions 
between non-DMSO cryoprotectants, and in selecting new combinations and 
concentrations to test experimentally.   
 
  21 
Chapter 3 
Methods 
3.1 Materials and Equipment 
Table 2 lists all equipment described in the following methods section, along with 
manufacturer information and physical location where the equipment was used.  All 
products are from the USA unless otherwise indicated 
 
 
Table 3 lists all materials described in the following methods section, along with 
associated abbreviations and manufacturer information.  All products are from the USA 
unless otherwise indicated 
 
Table 2: Equipment. 
Chapter(s) Material Details Location used Manufacturer/location
4-8 Controlled rate freezer Planer series III 
Kryo 10
UMN
Hubel lab
Sunberry-on-Thames
Middlesex, UK
5,7 Biomek FX-96 liquid handler UMN
HTSS/ITDD
Beckman Coulter
Indianapolis, IN
5,7 Synergy HT multi-mode Biomek plate reader UMN
Bischof lab
Biotek
Winooski, VT
5,7 WellPro 96 liquid handler Model 3000 UMN
HTSS/ITDD
ProGroup Instrument Corporation
Alton, IL
6 100X air objective NA 0.90 UMN
CharFac
Nikon Instruments 
Melville, NY
6 Differential scanning calorimeter TA DSC Q1000 UMN
Macosko Lab
TA Instruments
New Castle, DE
6 Osmometer Osmette ™ UMN
Hubel lab
Precision systems
Natick, MA
6 Witec confocal RAMAN system UMN
CharFac
WITec 
Ulm, Germany
8 CFX384 Real-Time PCR detection system Mayo
van Wijnen lab
Bio-Rad
Hercules, CA
8 ChemiDoc ™ Touch Imaging System Mayo
van Wijnen lab
Bio-Rad
Hercules, CA
8 Flow cytometer LSRII UMN
UFCR
BD Biosciences 
San Jose, CA
8 Zeiss Axioplan 2 with 20x objective UMN
UIC
Carl Zeiss Microscopy
Maple Grove, MN
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Chapter(s) Material Details Abbrev Manufacturer/location
4 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid
HEPES Life Technologies 
Carlsbad, CA
4 7-amino-actinomycin D 7-AAD BD Biosciences 
San Jose, CA
4 Alpha-Modified Eagles 
Medium
αMEM Invitrogen 
Grand Island, NY
4 Annexin V/PI BD Biosciences 
San Jose, CA
4 Bone marrow MSC source BM-MSC Lonza 
Walkersville, MD
4 CD45 BD Biosciences 
San Jose, CA
4 CD90 BD Biosciences 
San Jose, CA
4 Dimethyl Sulfoxide DMSO Bioniche Pharma 
Belleville, ON, Canada
4 Dulbecco's Phosphate 
Buffered Saline
DPBS Invitrogen 
Grand Island, NY
4 Fetal bovine serum Hyclone - Thermo Scientific
Waltham, MA
4 Ficoll Paque Premium Density gradient 
centrifugation
Ficoll GE Healthcare 
Pittsburgh, PA
4 Glutamax 200mM/L Invitrogen 
Grand Island, NY
4 Hanks balanced salt solution No phenol red, calcium, 
or magnesium
HBSS Lonza 
Walkersville, MD
4 Human Serum Albumin 25% HAS Baxter 
Deerfield, IL
4 Plasmalyte A Baxter 
Deerfield, IL
4 t-Flasks Tissue culture treated Corning 
Corning, NY
4 TrypLE Select Invitrogen 
Grand Island, NY
4,8 Beta-glo assay Promega 
Madison, WI
4,8 Tert-butyl hydroperoxide 100mM t-BHP Sigma 
St. Louis, MO
4-8 Acridine Orange AO Life Technologies 
Carlsbad, CA
4-8 Cryovials Nunc/Nalge Thermo Scientific 
Waltham, MA
4-8 Neubauer hemocytometer Hausser Scientific 
Horsham, PA
4-8 Propidium Iodide PI Life Technologies 
Carlsbad CA
5 Arabitol A3506 Sigma 
St. Louis, MO
5 Erythritol E7500 Sigma 
St. Louis, MO
5 Inositol I5125 Sigma 
St. Louis, MO
5 Ribitol (Adonitol) A5502 Sigma 
St. Louis, MO
Table 3: Materials. 
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Chapter(s) Material Details Abbrev Manufacturer/location
5 Sorbitol S1876 Sigma 
St. Louis, MO
5 Valine V0500 Sigma 
St. Louis, MO
5 Xylitol X3375 Sigma 
St. Louis, MO
5,6,8 Creatine C0780 Sigma 
St. Louis, MO
5,6,8 Mannitol M4125 Sigma 
St. Louis, MO
5,7 Alanine A7469 Sigma 
St. Louis, MO
5,7 Biomek tips Fisher Scientific
Pittsburgh, PA
5,7 Black walled 96-well plates Corning 
Corning, NY
5,7 Calcein AM Fisher Scientific
Pittsburgh, PA
5,7 Ectoine 81619 Fluka analytical - Sigma 
St. Louis, MO
5,7 Taurine T0625 Sigma 
St. Louis, MO
5,7 WellPro tips Fisher Scientific
Pittsburgh, PA
5-7 Trehalose T5251 Sigma 
St. Louis, MO
5,8 Isoleucine I2752 Sigma 
St. Louis, MO
5-8 Alpha modified eagles 
medium base
with Glutamine αMEM Life Technologies 
Carlsbad, CA
5-8 Dimethyl Sulfoxide BP231-1 DMSO Fisher Scientific
Pittsburgh, PA
5-8 Fetal bovine serum Qualified FBS Life Technologies 
Carlsbad, CA
5-8 Glycerol (Glycerin) NDC 0395-1031-16 Humco
Austin, TX
5-8 H9 embryonic stem cell 
derived MSCs
H9 MSCs Hematti Lab
Madison, WI
5-8 Non-essential amino acids NEAA Life Technologies 
Carlsbad, CA
5-8 Normasol-R™ ph 7.4 Normasol Hospira 
Lake Forest, IL
5-8 Porcine gelatin Thermo Fisher Scientific 
Waltham, MA
5-8 Sucrose S5-3 Fisher Scientific
Pittsburgh, PA
5-8 Trypsin 0.05% Gibco - Thermo Fisher 
Waltham, MA
6 Glucose (Dextrose) 4908 Mallinckrodt
St Louis, MO
6 Kapton tape Dupont 
Wilmington, DE
6 Mica TED PELLA  
Redding, CA
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Chapter(s) Material Details Abbrev Manufacturer/location
7 Jurkat cells Jurkats ATCC TIB-1522 
Manassas, VA
7 Molded silicone round well 
covers
Laboratory supply distributers
Melville, NJ
7 RPMI 1640 High glucose Life Technologies 
Carlsbad, CA
8 6-well plates Corning
Corning, NY
8 Alcian blue Fisher Scientific
Pittsburgh, PA
8 Alizarin red Fisher Scientific
Pittsburgh, PA
8 anti-5hmC 39770 Active Motif
Carlsbad, CA
8 Bio-Dot ® microfiltration 
apparatus
Bio-Rad
Hercules, CA
8 Formaldehyde 37%, F1635 Sigma 
St. Louis, MO
8 miRNeasy Mini Kit Qiagen
Germantown, MD
8 mouse IgG1 anti-human 
CD105
clone 166707
PE conjugated
CD105 R&D systems
Minneapolis, MN
8 mouse IgG1 anti-human 
CD45
clone HI30
BV421 conjugated
CD45 BD Biosciences 
San Jose, CA
8 mouse IgG1 anti-human 
CD73
clone ad2 
APC conjugated
CD73 BD Biosciences 
San Jose, CA
8 mouse IgG1 anti-human 
CD90
clone 5E10
FITC conjugated 
CD90 Invitrogen 
Grand Island, NY
8 NanoDrop ® 2000 Thermo Fisher Scientific 
Waltham, MA
8 Nitrocellulose membranes Bio-Rad
Hercules, CA
8 Paraformaldehyde 32%, 15714 Fisher Scientific
Pittsburgh, PA
8 Phalloidin Thermo Fisher Life Technologies
Carlsbad, CA
8 Prolong gold anti-fade 
reagent+DAPI
Invitrogen 
Grand Island, NY
8 Qiagen Dneasy Blood & 
Tissue Kit
Qiagen
Germantown, MD
8 Qiazol Qiagen
Germantown, MD
8 QuantiTect SYBR Green PCR 
Kit
Qiagen
Germantown, MD
8 Stem-Pro chondrogenesis and 
osteogenesis medium
Thermo Fisher Scientific 
Waltham, MA
8 SuperScript III First-Strand 
Synthesis System 
Invitrogen 
Grand Island, NY
8
SuperSignal West Femto 
Maximum Sensitivity 
Substrate kit
Thermo Fisher Scientific 
Waltham, MA
8 Triton x-100 T8787 Sigma 
St. Louis, MO
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3.2: Cell culture 
3.2.1 Bone marrow isolation, plating, and culture 
The MSCs used for Chapter 4 were isolated from bone marrow (BM) that was shipped 
overnight on ice from Lonza. Mononuclear cells (MNCs) were isolated from the bone 
marrow using Ficoll density gradient centrifugation and separation. On initial receipt, the 
10mL bone marrow sample was diluted with 10mL of 0.9% saline. In a 50mL conical 
tube, this dilute marrow cell suspension was carefully layered over 15mL of Ficoll. The 
resulting layered suspension was centrifuged at 300xg for 25 min at room temperature 
with no brake. The cell layer was collected and was then washed with 50mL of HBSS 
and centrifuged at 300xg for 5 min. A second wash was performed using the same 
procedure described above. The supernatant was discarded after both washes.  
The MNCs isolated with this method were resuspended in BM-MSC complete culture 
medium (MSC CCM) composed of αMEM base, 16.5% FBS, and 1% Glutamax. Cells 
were seeded at a density of 1.0-1.5 x 105cells/cm2 in appropriately sized tissue culture 
treated t-flasks at a media depth of 1.6 mm. Cells were cultured in a 5% CO2, 37°C 
incubator. 
Media changes were performed every 2-4 days until cells reached the desired 70-80% 
confluence between days 8-12. When cells reached the desired confluence, they were 
passaged. BM-MSCs were washed with Dulbecco’s phosphate-buffered saline, removed 
from the culture surface with TrypLE select, diluted with MSC CCM to quench the 
action of TrypLE select and centrifuged. 
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3.2.2 Jurkat cell culture 
The lymphoblastoid cells used in this study (Jurkats) were cultured in medium composed 
of high-glucose RPMI 1640 and 10% fetal bovine serum. Jurkat cells were cultured to 
maintain cell density within 1 × 105– 3 × 106 cells/mL.  
3.2.3 H9 MSC cell culture 
H9 embryonic stem cell derived MSCs (H9-MSCs) were obtained from Dr. Brenda Ogle 
and from Dr. Peimann Hematti’s lab at the University of Wisconsin[105].  These cells 
have shown similar phenotypic expression to BM-MSCs, and exhibit appropriate 
migration and homing behavior in in-vivo mouse models[106].  Media used with H9 
MSCs was composed of αMEM base, 10% FBS, and 1% non-essential amino acids. 
Culture flasks were coated with 0.01% porcine gelatin for a minimum of 2 hours before 
H9 MSC seeding.  H9 MSCs were seeded in gelatin-coated flasks at a density of 
approximately 2500 cells/cm2.  Cells were split using 0.05% trypsin when they reached 
70% confluence and were used for experiments only from passages 8 to 12.   
 
3.3: Freezing 
3.3.1 Vial freezing of BM-MSCs 
At each passage harvest, 1-10 x106 cells were frozen down in a total volume of 1mL per 
cryovial. Cells were harvested, washed in DPBS and resuspended in 5% human serum 
albumin (HSA) to a concentration of 2-20x106 cells/mL (2x the desired freezing 
concentration). The cells were combined stepwise with an equal volume of 2x freezing 
media composed of 60% Plasmalyte A, 20% HSA, and 20% Dimethylsulfoxide (DMSO). 
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The final concentration of DMSO was 10% by volume. Cells were frozen in a controlled 
rate freezer with the use of the following protocol:  
1) Wait at 0.0°C (place sample in freezer at this step)  
2) Wait at chamber = 0.0°C until sample = 1.0°C.  
3) Ramp -1°C/min until sample = -12°C.   
4) Ramp -20°C/min until chamber = -60°C.  
5) Ramp +15°C/min until chamber = -18°C.  
6) Ramp -1°C/min until sample = -60°C.   
7) Ramp -3°C/min until sample = -100°C.   
8) End. 
 
After completion of the freezing protocol, cell vials were removed from the controlled-
rate freezer (with the use of insulated gloves) and transferred quickly (<30 seconds) to 
liquid nitrogen storage to minimize transient warming of the sample. Samples were 
stored in liquid nitrogen for 30-45 days before being thawed for post-thaw analysis.  
 
3.3.2 96-well plate freezing of Jurkats and H9-MSCs 
In both screening and DE algorithm experiments, cells were frozen in 96-well plates to 
limit the number of cells and volumes of reagent necessary, and to increase the number of 
samples that could be tested at one time. Solutions were made at 2× their final 
concentration in distilled water (diH2O). Cells were centrifuged and supernatant was 
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aspirated before cells were suspended in Normasol-RTM. Cells were combined 1:1 with 
2× solutions, using a single-step addition in clear-bottomed black 96-well plates to 
produce a 1× concentration of cryoprotectant solution with a total volume of 50 μl and a 
cell concentration of ~300, 000 cells/well (~6 million cells/mL). Actual seeding counts 
were confirmed by manual acridine orange/propidium iodide (AO/PI) counts of the cell 
stock added to each plate. As a control, wells of 10% DMSO solution were also included 
on each plate to normalize results between all experiments. All samples were run in 
triplicate wells on each plate. The plates were sealed with molded silicone round well 
covers to prevent desiccation during freezing and storage. The plates were placed in a 
rack in a controlled-rate freezer, and frozen using the profile below using a Planar Series 
III Kryo 10 controlled rate freezer: 
1 Starting temperature 20°C   
2 -10°C/min to 0°C   
3 Hold at 0°C for 15min   
4 -1°C/min to -8°C   
5 -50°C/min to -45°C   
6 +15°C/min to -12°C   
7 –0.5, -1, -3, -5 or -10°C/min to-100°C (as dictated  by the DE algorithm)   
The rapid cooling and rewarming in steps 5 and 6 are  included to promote ice crystal 
nucleation outside the cell before slow cooling proceeds, discouraging stochastic ice 
formation within the cells. A temperature of -8°C was selected for this step, as a 
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conservative temperature at which all possible solution compositions should have 
exceeded their freezing point (based on their predicted osmolarity) to ensure that this ice 
nucleation step would be successful.  
In order to validate this freezing format, freezing profiles (temperature versus time) were 
measured at center, edge, and corner wells of a 96 well plate to determine if freezing rate 
differences between locations on a plate were likely to alter cellular behavior.  A 96 well 
plate was loaded with 50 µl of cell culture media and covered with a silicone plate sealer.  
Thermocouple probes were placed in 3 wells of the plate: a center well, a column edge 
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Figure 3: Freezing profiles in a 96-well plate.  Corner, edge, and center well freezing profiles on a 96-
well plate were measured during programmed freezing routines with linear freezing rates of 1°C/min, 
3°C/min, and 10°C/min.  Well to well differences were largest for the 10°C/min freezing profile and 
differed most between edge and center.  Location freezing rate variations were not large enough to indicate 
problematic gradients exist. 
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well, and a corner well.  Temperatures experienced by each of the thermocouples were 
recorded with Labview acquisition software, and monitored as the plate was frozen three 
separate times in a controlled rate freezer at linear freeze rates of 1°C/minute, 
3°C/minute, and 10°C/minute according to the same protocol described earlier in this 
section (shown in Figure 3).   
The freezing behavior observed at different locations on the plate differed most between 
the center and the edge of the plate. Higher cooling rates resulted in increasing variation 
between different plate locations.  For cooling between -12°C to -40°C, the 1°C/minute 
cooling program resulted in a 0.94 ± 0.0036°C/minute cooling rate and the 10°C/minute 
cooling program resulted in a 2.52 ± 0.0532°C/minute cooling rate, a 15 fold increase in 
standard deviation. However, the standard deviations observed even for the 10°C/minute 
cooling program were less than 2% of the total rate, indicating that freezing rate 
variations across the plate are acceptable. 
To confirm that this freezing rate uniformity correlated to cell survival uniformity, a 96 
well plate of cells suspended in 10% DMSO in media was frozen and thawed to confirm 
that cellular recovery was not affected by well location. Calcein AM fluorescence, 
representative of the number of live cells present in each well, was uniform across the 
plate with no large differences between the edges of the readable area of the plate or the 
center (shown in Figure 4). 
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3.3.3 Vial freezing of Jurkats and H9-MSCs 
Solutions were prepared at 2x the final freezing concentration and added stepwise to cells 
in Normasol-R® at a 1:1 final volume ratio in a Nalgene freezing vial.  Control cells in 
media were similarly combined stepwise with DMSO at a 1:1 final volume ratio (final 
concentration of 10% DMSO).  Each of these vials was incubated at room temperature 
for 0, 1, or 2 hours. Vials were frozen using the same freezing protocol as plates (detailed 
in section 3.3.2) on a Planar Series III Kryo 10 controlled rate freezer. 
 
3.4: Thawing 
Both 96-well plate and vial samples were thawed using a 37°C water bath. Vials were 
submerged in a 37°C bath (to just under cap level) and agitated until only a small ice 
crystal was present.  
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Figure 4: 96 well plate profile of cells frozen in 10% DMSO. 
Fluorescence results correlate directly to cell content.  Roughly uniform 
fluorescence profile across the plate indicates that cells experience similar 
recovery in all wells. 
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Plates were also thawed using a 37°C water bath. Briefly, the plates were submerged to 
half their height and agitated for 1 min. At t = 1 min, they were removed from the bath 
and the silicone cover was removed to observe the samples as they thawed. The plates 
were returned to the 37°C water bath and again submerged to half their height. When 
opaque samples became transparent (~1 min after being returned to the water bath) the 
plates were removed for immediate addition of viability dye. Thermocouple probe 
analysis of the freezing and thawing rate in different wells of a 96-well plate showed that 
no significant difference existed in the temperature profiles of the wells tested in these 
experiments.  
 
3.5: Viability testing 
3.5.1 Acridine Orange/Propidium Iodide manual counting 
Cells were tested for viability using acridine orange (AO) and propidium iodide (PI). The 
final working solution with concentrations of 20mM/ L AO and 20mg/mL PI in DPBS 
was combined with cells in a 1:2-1:20 dilution. At least 100 cells were counted in a 
Neubauer hemocytometer under fluorescence. Under these conditions, viable live cells 
fluoresced green as the result of AO binding to nucleic acids through intercalation. 
Conversely, membrane impermeant PI caused only dead cells to fluoresce red. Sample 
viability percentage was calculated by dividing the number of live cells by the number of 
total cells (live + dead) and multiplying by 100.  
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3.5.2 Plate reader viability testing 
After the 96-well plates were thawed, a dye composed of calcein AM (ex/em = 494/520 
nm) and PI (ex/ em = 535/617 nm) was added to each well and the wells were covered to 
protect against light and placed in a 37°C incubator for 30 min to allow the live cells to 
cleave calcein AM; the latter was used for these experiments instead of acridine orange 
(which has multiple fluorescent peaks, one of which overlaps with the peak for propidium 
iodide), as it has narrow excitation/emission peaks that do not interfere with the peaks for 
propidium iodide. The plates were then analyzed for fluorescence on a plate reader, using 
existing filter sets with excitation/emission wavelengths of 485/528 nm to measure 
calcein fluorescence and 530/590 nm to measure PI fluorescence. Raw fluorescence 
values were used to calculate the number of live and dead cells present in each well, by 
correlating to a control curve of unfrozen cells generated using serial dilution of known 
live and dead (killed using heat shock at 60°C for 15 min) cell counts. The live cell 
recovery was calculated by dividing the number of live cells present in thawed samples 
(calcein AM plate reader fluorescence) by the number of live cells seeded pre-freeze 
(AO/PI counts visually observed on a hemocytometer for the seeded cell stock). To 
normalize results between different plates and different cooling rates, these raw 
recoveries were divided by a control well containing 10% DMSO on the same plate (to 
normalize for stochastic variations in freezing experienced by the plate as a whole), then 
multiplied by a standard DMSO recovery at each cooling rate to give the ‘scaled raw 
recovery’. After each experimental generation, the DMSO recovery for each cooling rate 
was averaged with all DMSO recoveries at that cooling rate from previous generations to 
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calculate the DMSO standard recovery for that cooling rate, and the scaled recovery for 
all data from all generations was recalculated at the conclusion of each generation, based 
on these new standards, before reiteration through the algorithm. The final DMSO 
standard recoveries for Jurkat cells at each cooling rate are listed in Table 12. The 
differences in DMSO recovery between cooling rates were noticeable and, although not 
statistically significantly different, consistently fell in the same order relative to one 
another at each generation, which is why simply scaling to the DMSO recovery on each 
plate without correcting for the cooling rate would give an incomplete picture of 
experimental recovery.  
 
3.6: Senescence testing 
Senescence in cells is associated with an inflammatory secretome, which can cause 
undesirable results for immunotherapies.  Cells were tested for senescence using the 
Beta-glo assay, which measures lysosomal β-galactosidase expression associated with 
senescence in cells. In contrast to the conventional, absorbance-based Miller method, this 
assay is well-suited for high-throughput screening and has been used in this context for 
other organisms [107, 108]. Cells were centrifuged at 300xg for 5 min and resuspended 
with 25mM 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) in 0.9% NaCl. 
In white-walled flat- bottom 96-well plates, 100mL of Beta-glo assay was added to 
100mL of cell solution in each well. The plates were allowed to incubate for 30 min at 
room temperature and were subsequently read for luminescence on a plate reader for 
studies described in Chapter 4.   
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In Chapter 8, thawed samples described in section 3.4 were re-suspended in 4mL of 
media and 1mL was added to each of four gelatin-coated 6-well plates. After 2 hours or 
24 hours, plates were washed with PBS and two plates were analyzed at a time, one for 
proliferation as described in section 3.14 below, and one for senescence. For the 
senescent plate, 1mL of Beta-glo luminescent dye was added, to the other, 1mL of 1µM 
calcein-am dye was added.  Beta-glo plates were incubated at room temperature for 30 
min, while calcein-am plates were incubated at 37°C for 30 min.  Plates were analyzed 
using a BioTek plate reader for luminescence (Beta-glo plate) and fluorescence 
(485ex/528em, calcein am plate) respectively.  A relative measure of senescence is 
reported in Chapter 8 by dividing the base-corrected luminescence (approximation of 
total senescent character) per well by the base-corrected fluorescence (approximation of 
total cells per well).  
A population of MSCs was forced into senescence by treatment with 100mM tert-butyl 
hydro peroxide (t-BHP) 1 hr/day for 5-7 days. After each treatment, cells were washed 
with DPBS and fresh media was replaced. This senescent positive control population was 
seeded in a 96-well plate and serially diluted to produce a control curve for Chapter 4, or 
into 6-well plates for Chapter 8. The linear best-fit line of this curve was used to calculate 
the percentage of β -galactosidase expressed by experimental populations compared with 
fully senescent populations of the same size for Chapter 4, and was used as a positive 
control reference for Chapter 8. 
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3.7: Flow cytometry 
Flow cytometry can be used to confirm appropriate cell surface marker expression.  Flow 
cytometry was performed on an LSRII at low flow rate with the fine adjust knob five 
turns from max. At least 15,000 events were recorded for each sample gating for forward 
and side scatter cell population as well as with a negative unstained control and a Jurkat 
CD45 positive control to gate fluorescent graphs. Cells were suspended to a 
concentration of 1x106 cells/mL in media and stained with a panel of antibodies for 30 
min at 4°C. Viability was assessed using a standard 7-amino-actinomycin D (7-AAD) 
test.  MSC samples were also characterized for cell surface phenotype. Specifically, cells 
were stained for the presence of CD45 and CD90 as markers for cells surface phenotype 
in Chapter 4, in addition to CD73 and CD105 in Chapter 8. The acceptance criteria 
included that MSCs were >85% CD45 negative, and >85% CD73, CD90, and CD105 
positive. Apoptosis was assessed using AnnexinV/PI staining; early apoptotic cells stain 
positive for AnnexinV only, while necrotic cells stain positive for both AnnexinV and PI.  
 
3.8: Karyotyping 
Samples were sent to an external facility for karyotyping.  G-banded karyotype analysis 
was performed on 20 metaphase cells to rule out the presence of any numerical or 
structural chromosomal abnormality. If one cell tested abnormal, additional cells were 
analyzed to rule out the presence of a clonal abnormality. Documented benign heritable 
heteromorphisms, such as 9 small-p small-h, were not considered abnormalities. Pre-
culture samples of marrow were available for comparison.  
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3.9: Liquid handling  
Liquid handling robots were used to perform plate transfers for cell freezing experiments 
involving 3-component solutions. These experiments were performed on WellPro (row 
and column transfers) and Biomek liquid handlers (full plate transfers) at the Institute for 
Therapeutics Discovery and Development (ITDD). 
 
3.9.1 WellPro serial dilutions for Chapter 7 
A dual serial dilution performed by the WellPro 96 creates a 6x6 matrix with a full array 
of combinations of solution components 1 and 2.  A 4x final concentration of component 
1 was loaded in the top wells of a 96-well plate, and Normasol blank was loaded in the 
remaining wells.  The WellPro serially diluted the concentrated top well down the plate 
vertically.  Subsequently, additional 4x final concentration of component 2 was loaded on 
the left hand side of the plate, in addition to an equal volume of Normasol blank in the 
remaining wells (diluting both component 1 and component 2 by a factor of two across 
the whole plate).  The WellPro serially diluted this left to right across the plate 
horizontally.  The final result was a 6x6 matrix of component 1 and component 2. This 
plate was transferred to the Biomek liquid handler for subsequent plate transfers. 
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3.9.2 Biomek plate transfers for Chapter 7 
Figure 5 shows an outline of the tip and plate layout for the transfer described in this 
section.  
 
Cells were suspended in a 2x final concentration of component 3 or Normasol for blank.  
These solutions were loaded into separate 96-well plates in the same 6x6 locations as the 
serial dilution of components 1 and 2 from the WellPro.  The Biomek was programmed 
to transfer cells diluted in 2x component 3 to the level 5 plate, and cells in Normasol to 
each of 5 remaining target plates.  Cells in component 3 were then serially diluted across 
the Normasol plates.  An equal volume of the 6x6 array of component 1 and 2 from the 
well pro serial dilution above was added to each of the plates, producing a full array of 
components and concentrations for a single 3 component solution.   
 
 
 
Figure 5: Biomek plate transfer layout. 
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3.9.3 Plate transfers for Chapter 5 
In order to test many different solution components together, a single intermediate 
concentration of each component was selected for testing.  Each of 8 plates were 
individually loaded with different sugar alcohols, in addition to a 9th plate that was loaded 
with an equal amount of Normasol.  An additive plate was prepared with a different 
additive in each column, including a column of Normasol.  These 10 plates were 
organized on the Biomek for plate transfers along with another plate containing cells 
suspended in a 2x concentration of sugar.  Plate transfers were performed to add additives 
and cells/sugar to each of the sugar alcohol plates.  Cells in DMSO were added to an 
empty column of each plate to act as a plate-to-plate control comparison. 
 
3.10: Raman 
Guanglin Yu performed all confocal Raman microscopy experiments.   
Confocal Raman Microspectroscopy (CRM) measurements were conducted using a 
Witec Confocal Raman Microscope System Alpha 300R with a UHTS300 spectrometer 
and DV401 CCD detector with 600/mm grating. The WITec spectrometer was calibrated 
with a Mercury-argon lamp. A wavelength of 532 nm Nd:YAG laser powered at 10 mW 
was used as an excitation source. The laser was transmitted to the microscopy in a singer 
fiber. A 100X air objective was used for focusing the 532-nm excitation laser to the 
sample.  Samples were frozen using a controlled temperature stage described in more 
detail elsewhere[59]. 
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3.10.1 Raman measurement of frozen MSC cells 
MSC cells were detached from the flask and washed with DPBS solution before being 
suspended in experimental solutions. Roughly 1 µL of cell suspension was placed on an 
aluminum sheet, covered with a piece of mica and sealed with Kapton tape, to prevent 
evaporation/sublimation during each experiment.  Cell suspensions were cooled to -6oC 
at which point the sample was seeded by a nitrogen-cooled needle. Subsequently, the 
solution was cooled down at 3oC/min to -50oC. Ten Raman images of 30 µm x 30 µm 
were collected. 
 
3.10.2 Raman image/spectral analysis 
Spectrums at each pixel were analyzed using characteristic wavenumbers of common 
intracellular and extracellular materials (Table 4), and were integrated with background 
subtraction to result in an image. Spectra for the osmolytes used in the investigation 
overlapped with each other, so a broad peak centered at 850 cm-1 was used to generate 
Raman images for all osmolytes. Data analysis was performed by Windows-based Project 
FOUR software plus version 4.0.  
Table 4: Peak assignments for molecules of interest detected using Raman spectroscopy. 
 
Component Frequency used for this study cm-1 Ref. 
Ice 3120 (O-H stretching) [59] 
Amide I  1659 (C=O stretching) [109] 
Glycerol 851 ( C-C stretching) [110] 
Sorbitol 878 ( C-C=O stretching) [111] 
Glucose 840 (C-C stretching) [112] 
Sucrose 836 (C-C stretching) [112] 
Creatine 840 (C-N torsion) [113] 
 
  41 
3.11: Differential Scanning Calorimetry 
Differential scanning calorimetry was performed on a TA Differential Scanning 
Calorimeter (DSC) Q1000. Experimental solutions without cells were frozen to -150°C 
using the following protocol: 
1. Set starting temperature to 20°C 
2. Cool to -150°C at 10°C/min 
3. Hold for 3 min at -150°C 
4. Warm to 20°C at 10°C/min 
 
3.12: Osmolarity testing 
Osmolarity of solutions was measured using an Osmette ™ osmometer (Precision 
Systems) for each solution and all measurements were repeated in triplicate.  
 
3.13: Algorithm iteration 
The DE algorithm used in this study was developed from strategy 2 (DE/local-to-best/1, 
which balances robustness and convergence) by Storn and Price [11] and was coded in 
MATLAB by modifying existing open source Storn and Price MATLAB code to accept 
discrete parameters, and output information about the test population and emergent 
population after each iteration. The DE algorithm utilizes stochastic direct search and 
independently perturbs population vectors to identify a global maximum within the user-
defined parameter space. Briefly, the DE algorithm randomly generates an initial 
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population (generation 0) that spans the entire parameter space. This population is 
composed of a given number of solutions expressed as vectors (a set of numbers). The 
number of different solution components being tested defines how many slots the 
population vectors have. Experimentally, these vectors correspond either to the different 
levels of solute in a solution or to different cooling rates. Cells are frozen at DE 
algorithm-dictated cooling rates with solutions made from these vector specifications, 
and the resulting experimental live cell recoveries (or other success metric) are iterated 
back into the DE algorithm.  
 
 
 
 
 
 
 
 
 
1. Random Vectors 
(Emergent Pop 0) 
A. Trial Generation 0 
2. Algorithm Trial Pop 1 
(Emergent Pop 1) 
B. Trial Generation 1 
3. Emergent 
Pop 2 
4. Algorithm Trial 
Pop 2 
C. Trial Generation 2 
5. Emergent 
Pop 3 
6. Algorithm Trial 
Pop 3 
D. Trial Generation 3 
7. Emergent 
Pop 4 
Figure 6: DE algorithm flowchart.  Black boxes represent DE algorithm 
steps and red boxes represent experimental steps. The DE algorithm 
produces a population in gen 0 that randomly spans the parameter space, 
and a trial population (gen 1) that is based on mutation of gen 0. These are 
both experimentally tested by the user and the live cell recovery results are 
input into the DE algorithm, producing an emergent population which is 
further mutated and iterated in subsequent experiments. As the algorithm 
converges, an optimum solution can be identified . 
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The DE algorithm utilizes this experimental information to modify the existing 
population vectors, and predicts solutions that may result in more favorable live cell 
recovery. Briefly, the algorithm mutates existing vectors to generate new test vectors, and 
performs head-to-head comparisons of the resulting experimental live cell recovery of 
each of the population slots. The best value from this comparison (either the original or 
the new mutant vector) is stored in an emergent population. This mutation/comparison 
process is repeated for all subsequent generations (Figure 6) and results an emergent 
population that changes less and less as the algorithm converges. The final emergent 
population contains a set of solutions that have all been independently optimized using 
stochastic direct search, and includes the best possible compositions for freezing cells 
within the defined parameter space. Convergence can be measured by observing an 
increase in cumulative best member live cell recovery, a decrease in the number of 
improved solutions within the emergent population after each generation, or by the 
generational average, which captures both metrics.  
 
3.14: Attachment and proliferation 
Cell attachment of samples post-thaw was measured using a fluorescent plate reader.  
Aspirated samples from the thawing section above were re-suspended in 2mL of media 
and split to seed 1mL in each of two gelatin coated 6-well plates.  After 2 hours or 24 
hours, these paired plates were washed with PBS and 1µM calcein AM dye was added, 
then analyzed for fluorescence on a plate reader.  Raw fluorescence values were used to 
calculate the number of live cells present in each well by correlating to a control curve of 
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serially diluted unfrozen cells seeded at known densities.  The live cell attachment was 
calculated by dividing the number of live cells present in 2-hour plated samples (calcein 
am plate reader fluorescence) by the number of live cells seeded pre-freeze (AO/PI 
counts).  
 
3.15: Actin staining and fiber alignment analysis 
After thawing, centrifugation and aspiration, cells were re-suspended in 1mL of media 
and plated in gelatin coated 6-well plates containing a cover slip.  After 2 hours, wells 
were washed with PBS, treated with 3.7% Formaldehyde to fix cells, then 0.1% Triton x-
100 to permeabilize the cell membranes, followed by addition of 250µM phalloidin for 
20 minutes.  Cover slips were removed from wells, inverted, and mounted on glass slides 
using prolong gold anti-fade reagent with DAPI.  Slides were imaged using a Zeiss 
Axioplan 2 scope with 20x objective.  A minimum of 5 fields of view were captured for 
each slide, and MATLAB edge detect analysis[114](a more computationally efficient 
alternative to FFT[115]) was used to isolate and analyze fiber orientation in 30 individual 
cells total from 5+ fields of view for each sample.  Triplicate biological samples were 
analyzed and results were averaged for 90 total cells from each sample. 
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3.16:  Multi-lineage differentiation 
Cells (both fresh and after freezing in experimental solutions or DMSO) were plated 
according to the Stem-Pro chondrogenesis and osteogenesis protocols for differentiation.  
 
3.16.1 Chondrogenesis 
Cells were suspended in MSC CCM at 1.6x107 cells/mL, and 5µl droplets were seeded to 
form micromass cultures for chondrogenesis.  After 2 hrs, pre-warmed chondrogenesis 
media was added to the micromass cultures.  Chondrogenesis media was changed every 3 
days for 14-21 days.  At 14-21 days post-seeding, cells were fixed with 4% 
paraformaldehyde for 10 min.  Cells were washed 3 times in PBS, then stained using 1% 
Alcian Blue solution in HCl for 1hr with gentle agitation. Samples were washed with 
0.1M HCl, and subsequently imaged for analysis. 
 
3.16.2 Osteogenesis 
Cells were suspended in MSC CCM and seeded at 5x103 cells/cm2.  After 4 hrs, cultures 
were washed with PBS, and pre-warmed osteogenesis media was added.  Osteogenesis 
media was changed every 3 days for 14-21 days.  At 14-21 days post-seeding, cells were 
fixed with 4% paraformaldehyde for 10 min.  Cells were washed 3 times in PBS, then 
stained using 2% Alizarin red solution at pH 4.2 for 1hr with gentle agitation. Samples 
were washed with diH20, and subsequently imaged for analysis. 
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3.17: DNA hydroxymethylation 
3.17.1 DNA isolation and quantification 
After PBS washing and centrifugation, pellets of fresh and thawed samples were flash 
frozen in liquid nitrogen, then transferred to -80°C (dry ice transport) for further DNA 
isolation and processing. Genomic DNA was isolated using QIAGEN DNeasy Blood & 
Tissue Kit according to the manufacturer’s protocol. The purified DNA was quantified 
using a NanoDrop® 2000. The purity of the DNA was verified by the A260/A280 ratio, 
and all samples were ~1.8. 
 
3.17.2 DNA hydroxymethylation by dot blotting 
DNA samples were prepared by diluting total DNA to final concentrations of 2 µg, 1 µg, 
0.5 µg, and 0.25 µg with 0.1M NaOH. The samples were denatured at 95⁰C for 10 min 
and cooled quickly on an ice bath followed by neutralization with ammonium acetate. 
Loading sample volumes of 400 µl were prepared by adding equal volumes of 0.1 M 
NaOH and 2M ammonium acetate to the denatured DNA. Nitrocellulose membranes 
were pre-wet in distilled water and placed on a Bio-Dot® Microfiltration Apparatus and 
assembled as per the manufacturer’s recommendations.  Vacuum was applied and the 
screws re-tightened to hold the apparatus together. The membrane was rehydrated with 
0.1 M NaOH and prepared for sample application. With the vacuum off, 400 µl of 
denatured DNA was added for each sample. All other wells were filled with the same 
volume of distilled water to obtain homogenous filtration. Gentle vacuum was applied to 
pull samples through the filter, followed by the addition of 400 µl of 0.1M NaOH to all 
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wells. The vacuum was applied again until all wells were empty. The apparatus was 
disassembled followed by membrane rinsing with 2x Saline Sodium Citrate (SSC) buffer. 
After air-drying, the membrane was blocked with 5% skimmed milk in PBS for 1 hour. 
The membranes were washed three times with PBS and incubated with anti-5hmC 
overnight. The next day, the membrane was washed three times with PBS and incubated 
with anti-rabbit secondary antibody. The blots were washed and developed using the 
SuperSignal West Femto Maximum Sensitivity Substrate kit by auto-exposure settings on 
the ChemiDoc™ Touch Imaging System.  Data were quantified by densitometry and 
analyzed using Image Lab software by applying background subtraction and 
approximation for linearity across the multiple dilutions of DNA seeded. 
 
3.18: Gene expression analysis by real time quantitative PCR 
Pellets of thawed samples described above were re-suspended in Qiazol and transferred 
to -80C (dry ice transport) for further RNA isolation and processing. RNA was isolated 
using the miRNeasy Mini Kit as per the manufacturer’s protocol for cultured cells and 
cell pellets. The purified RNA was quantified using NanoDrop® 2000 to determine 
concentration, and 800ng of RNA was used for reverse transcription to make cDNA 
using SuperScript III First-Strand Synthesis System.  The cDNA was diluted to a 
concentration of 4 ng/µl and real-time qPCR was performed with 10 ng cDNA per 10 µl 
reaction with QuantiTect SYBR Green PCR Kit on a CFX384 Real-Time PCR detection 
system.  The list of genes tested and their primer sequences are provided in Table 5 Melt 
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curves were analyzed using the comparative CT method[116] with GAPDH as an internal 
control gene. 
 
Table 5: PCR primers. 
 
 
3.19: Statistical Analysis 
At a minimum, technical triplicates of all experimental samples were performed.  Where 
noted, technical triplicates of biological replicates were performed.  Samples were 
compared using a students paired t-test with a 95% confidence interval.  Significance 
markers indicate p <0.05.  Error bars are specified in each figure as standard deviation or 
standard error of the mean.  Ralph Moller-Trane performed the more complex linear 
mixed effects statistical analysis presented in Chapter 5. 
Gene Name Function Primer Sequence (5'->3') NM reference ID
Forward CACGAACACAGCTTTTTGCC
Reverse GGGGGAATAGAATGGCCCAC
Forward ACTCGCGTTGCAAGATGTG
Reverse GGACTGTTCTGTCGATGGTGA
Forward GCTGTACTGCAAAAACGGGG
Reverse CCGTAACACATTTAGAAGCCAGT
Forward GCCGGAGACCTAGATGTCATT
Reverse CCCACGCCCTGTTTCTTTGA
Forward CAGAGCGACGAGATGGACAA
Reverse ATTCAGAATCTCCTCCTGGCG
Forward CCGCCAAGACATATGAGCCC
Reverse GTTCTGCCTCCTGCAGTCTT
Forward AGATTGTAGCCCGGCTGAAG
Reverse CAGGCCCTTCCCTAACACTG
Forward CCTGACGCTAAGAGCTTCGT
Reverse GGAAGGGAAAGACAGCCTCC
Forward GGAGGCTGGGATGCCTTTGT
Reverse CAGCCTGCAGCTTTGTTTCAT
Forward ACCCCTCTGTCTACTATTAAGGC
Reverse TGGGACTGGTAGCTGGTATTG
Forward TCAGCGACGGAAAGAGTATGA
Reverse CCACTGGTTTCTGACTGGATGT
Forward ATGGCGCTGAGATTGTGTCA
Reverse CCCGGTACACCACGTTCTTC
Forward TGTTTGCAGCTTCTCAAGCTTTT
Reverse GATGTGGTCCCCTCATTCGT
Forward AGCCCAAGTTGTTGGGCATA
Reverse GGAGTCCAGTACACGGTGAG
HGF
VEGF
FGF2
CXCL12
TWIST1
TWIST2
MSX2
CD54 
(ICAM1)
CD106 
(VCAM1)
EGR1
GAL
BCL2
NFE2L2
AKT1
Hepatocyte growth factor
Vascular endothelial growth factor
Fibroblast growth factor
CXC motif chemokine ligand 12
twist-basic helix-loop-helix 
transcription factor 1
twist-basic helix-loop-helix 
transcription factor 2
MSH homeobox 2
Intracellular adhesion molecule 1
Vascular cell adhesion molecule 1
early growth response 1
Galanin and GMAP protopeptide
b-cell cll/lymphoma 2
erythroid like nuclear factor
AKT serine threonine kinase
immunomodulation, 
antiapoptosis
angiogenesis, antiapoptosis
support of progenitor cells, 
angiogenesis, antiapoptosis
chemoattraction
mesoderm related marker
mesoderm related marker
osteogenic regulator
cell adhesion
cell adhesion/signal 
transduction
differentiation, mitogenesis, 
stress
osmotic regulation and water 
balance
anti-apoptotic
antioxidant transcription 
regulator
survival
NM_001010934
NM_001025369.2
NM_002006.4
NM_000609.6
NM_000474.3
NM_057179.2
NM_002449.4
NM_000201
NM_001078.3
NM_001964
NM_002305
NM_000633.2
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Chapter 4 
Clinical Mesenchymal Stem Cell Products Experience 
Functional Changes in Response to Freezing in DMSO 
Much of the text and figures in this chapter have previously appeared in the publication 
below, included here with copyright permission from Elsevier. 
 
Pollock K, Sumstad D, Kadidlo D, McKenna DH, Hubel A.  Clinical mesenchymal stem 
cell products experience functional changes in response to freezing.  Cytotherapy 2015; 
17(1): 38-45 
 
4.1 Introduction 
Development of MSC- based therapies requires standardization of methods of culture and 
cryopreservation. MSCs are typically cultured ex vivo and expanded to a sufficient cell 
number before patient administration. Uniform, optimized methods of cell expansion 
have not been developed, and media composition (basal media, serum and additional 
supplements), seeding density, expansion vessel and in vitro population doublings can 
vary considerably among investigators.  
Ex vivo culture of cells has been associated with changes in cell phenotype [117, 118] 
One such change observed in MSCs is the development of a senescent phenotype [119]. 
Senescent cells exhibit an inflammatory secretome [120], and, as such, may cause 
undesirable results in immunomodulatory therapies. Ex vivo culture of cells can also 
influence freezing response. Both hematopoietic progenitors and lymphocytes exhibited 
changes in subzero water transport and intracellular ice formation tendencies after ex-vivo 
culture [121, 122], which in turn can influence freezing response. Francois et al. [10] 
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quantified diminished response for indoleamine 2,3-dioxygenase (critical to 
immunomodulatory cell function) for frozen and thawed MSCs when compared with 
fresh non-frozen cells. A recent study by Moll et al. [123] also showed that cryopreserved 
MSCs had reduced immunomodulatory and blood regulatory properties immediately after 
thaw.  
 
These temporal and freezing-induced changes in cell behavior can lead to confounding 
outcomes for clinical studies with the use of cryopreserved MSCs. One investigator 
hypothesized that poor post-thaw MSC function may have been responsible for the 
failure of a recent clinical trial [73]. The objective of this chapter was to determine the 
influence of ex vivo cell expansion on phenotype of MSCs at harvest and the response of 
resulting phenotypes to freezing and thawing. This information will help to clarify the 
influence of culture conditions on the biological characteristics of MSC products and 
identify potential shifts in composition or behavior resulting from the freezing process.  
 
4.2 Methods 
The MSCs used in this chapter were isolated from bone marrow (obtained from Lonza) 
using ficoll gradient separation and seeded in tissue culture flasks according to the 
methods described in section 3.2.1. Volume, cell count and viability of samples were 
recorded immediately upon arrival, and again after MNC isolation along with flow 
cytometry testing for the negative marker CD45 and positive marker CD90.   
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At 24 hr and 48 hr after seeding, non-adherent cells were removed by media change. In 
these culture conditions, only MSCs from the mononuclear cell population were surface 
adherent. Cell enumeration and characteristics (doubling time, viability, senescence and 
apoptosis) taken on and after the first harvest reflect only MSC characteristics. At 70-
80% desired confluence, cells were harvested, re-suspended in MSC CCM and analyzed 
for viability, senescence and apoptosis. Half of the remaining cells not used for assays 
were seeded in new flasks at densities of 40-50 cells/cm2, and the rest were frozen down 
at each passage according to the procedure outlined in section 3.3.1. A total of 6 passages 
were performed, which corresponds to approximately 35-40 population doublings in 
healthy cells.  
Frozen vials were thawed according to the procedure outlined in section 3.4.1.  A portion 
of these cells was analyzed immediately for viability and senescence. Remaining cells 
were plated and analyzed for viability and senescence after 48 h.  
Cells were measured for viability using AO/PI according to the procedure outlined in 
section 3.5.1.  Cells were tested for senescence using the beta-glo assay from Promega 
according to the procedure outlined in section 3.6.  Flow cytometry was performed to 
assess viability, cell surface phenotype and apoptosis of MSC samples according to the 
procedures outlined in section 3.7.  
In this chapter, error bars represent standard deviations of triplicate measurements. A 
Student’s t-test was used to compare populations, and P values reported are considered 
significant at P < 0.05. Triplicate β-galactosidase measurements for senescence were 
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compared between individual passages, whereas individual data points for passage 
viability, recovery and apoptosis were pooled for all passages and compared between 
samples.  
 
4.3 Results 
4.3.1 Characterization pre-culture  
Each initial marrow sample from Lonza had high viability (98% ± 2%). However, 
samples varied widely in initial concentration and total cell number. Initial samples had 
average concentrations of 2.40x107 ± 1.28x107 cells/mL with total cell counts of 3.27x108 
± 1.85x108.  
Initial samples underwent density gradient centrifugation to isolate MNCs. Total MNC 
counts averaged 1.24x108 ± 7.24x107 total cells. The MNC populations (Table 6) 
constituted similar proportions of their respective initial bone marrow population (38% ± 
4%), and had similar viability (98% ± 1%). Senescence was low in the MNC population 
of all samples, with an average of 0.62% ± 0.63%. It is interesting to note that sample 2 
had the lowest viability and total cell count before and after centrifugation and exhibited 
the highest senescence percentage.  
 
widely in initial concentration and total cell number.
Initial samples had average concentrations of 2.40 !
107 " 1.28 ! 107 cells/mL with total cell counts of
3.27 ! 108 " 1.85 ! 108.
Initial samples underwent density gradient
centrifugation to isolate MNCs. Total MNC counts
averaged 1.24 ! 108 " 7.24 ! 107 total cells. The
MNC populations (Table I) constituted similar
proportions of their respective initial bone marrow
population (38% " 4%), and had similar viability
(98% " 1%). Senescence was low in the MNC
population of all samples, with an average of 0.62%
" 0.63%. It is interesting to note that sample 2 had
the lowest viability and total cell count before and
after centrifugation and exhibited the highest senes-
cence percentage.
Characterization of in vitro expansion cultures
MSCs were isolated from the MNC population ob-
tained after density gradient isolation through attach-
ment to the culture surface. Flow cytometry
performed on MSC populations conﬁrmed appro-
priate expression for all markers in all samples at each
passage (Table II). Population doublings were set to
zero for passage 1. Further population doublings were
calculated on the basis of cells seeded andharvested on
each subsequent passage. Population doublings were
consistent over time (as shown by a constant slope in
Figure 1A) for samples 1 and 3. Both had relatively
constant rates of doubling, undergoing approximately
0.7 population doublings per day for the duration of
their culture through passage 6. Sample 2 exhibited
slowing growth at passage 3, and population doublings
plateaued in passages 4 and 5 at around 19.5, just over
half of the total doublings in samples 1 and3. Passage 6
of sample 2 could not be performed because of sample
growth arrest.
Viability for each sample remained high as culture
time and population doublings increased when
measured by both AO/PI and 7AAD (Table II).
Samples 1 and 3 showed viabilities of >70% through
35þ population doublings, with a consistent gradual
decrease in viability over time. Sample 2 exhibited a
Table I. Patient data and initial mononuclear cell characterization.
Sample
Patient
age, years
Patient
sex
Total isolated
MNCs
Fraction of
initial population
MNC viability
(AO/PI)
MNC b-galactosidase
(senescence)
1 36 M 9.55 ! 107 34% 99% 0.00%
2 41 F 6.98 ! 107 41% 97% 1.27%
3 29 F 2.06 ! 108 39% 99% 0.60%
Average 1.24 ! 108 38% 98% 0.62%
Standard deviation 7.24 ! 107 4% 1% 0.63%
Table II. Pre-freeze MSC characterization at each passage.
Sample Passage
Surface marker
characterization, % Viability, %
Apoptosis, %
Karyotype resultsCD45 CD90 AO/PI 7-AAD AnnexinVþ/PI$
1 P1 1.80 99.55 99 93 9.54 Normal
P2 0.33 99.76 99 90 3.73 Normal
P3 0.12 99.85 99 83 2.00 Normal
P4 0.21 99.41 98 77 6.54 Normal
P5 0.55 99.14 97 80 5.03 Duplication of
chromosome 17 in 6%
P6 0.24 98.67 93 77 3.94 Duplication of
chromosome 17 in 6%
2 P1 2.09 98.92 94 90 2.74 Normal
P2 0.42 99.84 99 81 1.41 Normal
P3 0.47 99.47 92 83 2.31 Normal
P4 0.74 99.58 95 80 3.68 Normal
P5 0.52 90.16 88 34 21.61 e
3 P1 9.72 92.63 94 92 0.89 Normal
P2 0.19 99.88 98 86 2.71 Normal
P3 0.22 99.81 97 91 1.61 Normal
P4 1.31 99.95 96 91 1.55 Normal
P5 0.22 99.67 96 85 5.67 Normal
P6 0.24 97.35 93 93 2.83 Normal
MSC functional response to freezing 41
Table 6: Patient data and initial mononuclear cell characterization. 
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4.3.2 Characterization of in vitro expansion cultures  
MSCs were isolated from the MNC population obtained after density gradient isolation 
through attachment to the culture surface. Flow cytometry performed on MSC 
populations confirmed appropriate expression for all markers in all samples at each 
passage (Table 7). Population doublings were set to zero for passage 1.  
Further population doublings were calculated on the basis of cells seeded and harvested 
on each subsequent passage. Population doublings were consistent over time (as shown 
by a constant slope in Figure 7A) for samples 1 and 3. Both had relatively constant rates 
of doubling, undergoing approximately 0.7 population doublings per day for the duration 
of their culture through passage 6. Sample 2 exhibited slowing growth at passage 3, and 
population doublings plateaued in passages 4 and 5 at around 19.5, just over half of the 
total doublings in samples 1 and 3. Passage 6 of sample 2 could not be performed 
because of sample growth arrest.  
widely in initial concentration and total cell number.
Initial samples had average concentrations of 2.40 !
107 " 1.28 ! 107 cells/mL with total cell counts of
3.27 ! 108 " 1.85 ! 108.
Initial samples underwent density gradient
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averaged 1.24 ! 108 " 7.24 ! 107 total cells. The
MNC populations (Table I) constituted similar
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constant rates of doubling, undergoing approximately
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35þ population doublings, with a consistent gradual
decrease in viability over time. Sample 2 exhibited a
Table I. Patient data and initial mononuclear cell characterization.
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Total isolated
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(AO/PI)
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1 36 M 9.55 ! 107 34% 99% 0.00%
2 41 F 6.98 ! 107 41% 97% 1.27%
3 29 F 2.06 ! 108 39% 99% 0.60%
Average 1.24 ! 108 38% 98% 0.62%
Standard deviation 7.24 ! 107 4% 1% 0.63%
Table II. Pre-freeze MSC characterization at each passage.
Sample Passage
Surface marker
characterization, % Viability, %
Apoptosis, %
Karyotype resultsCD45 CD90 AO/PI 7-AAD AnnexinVþ/PI$
1 P1 1.80 99.55 99 93 9.54 Normal
P2 0.33 99.76 99 90 3.73 Normal
P3 0.12 99.85 99 83 2.00 Normal
P4 0.21 99.41 98 77 6.54 Normal
P5 0.55 99.14 97 80 5.03 Duplication of
chromosome 17 in 6%
P6 0.24 98.67 93 77 3.94 Duplication of
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2 P1 2.09 98.92 94 90 2.74 Normal
P2 0.42 99.84 99 81 1.41 Normal
P3 0.47 99.47 92 83 2.31 Normal
P4 0.74 99.58 95 80 3.68 Normal
P5 0.52 90.16 88 34 21.61 e
3 P1 9.72 92.63 94 92 0.89 Normal
P2 0.19 99.88 98 86 2.71 Normal
P3 0.22 99.81 97 91 1.61 Normal
P4 1.31 99.95 96 91 1.55 Normal
P5 0.22 99.67 96 85 5.67 Normal
P6 0.24 97.35 93 93 2.83 Normal
MSC functional response to freezing 41
ble 7: Pre-freeze MSC ch racterization at each passage. 
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Viability for each sample remained high as culture time and population doublings 
increased when measured by both AO/PI and 7AAD (Table 7). Samples 1 and 3 showed 
viabilities of >70% through 35+ population doublings, with a consistent gradual decrease 
in viability over time. Sample 2 exhibited a more rapid drop in viability as population 
doublings increased, with a final viability in passage 5 below threshold viability criteria 
for lot release when measured with the 7-AAD assay.  
 
The β -galactosidase percentage (used as a measure of total population senescence) 
tended to increase over time (Figure 7B). Other than the reading for sample 3 in P3 
(20.8%), the β -galactosidase percentages for samples 1 and 3 remained low (below 10%) 
and slowly increased over time after the first passage. Sample 2 displayed a trending 
increase in β -galactosidase over time with final values in P4 of >30%. Sample 2 values 
were also significantly higher (P < 0.05) than either of the other samples. Samples 1 and 
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Figure 7: Pre-freeze MSC population doublings and β-galactosidase percentage. (A) Population 
doublings over time. Samples 1 and 3 show robust growth; sample 2 exhibits growth arrest beginning in 
passage 3. (B) β-Galactosidase expression percentage indicative of senescence in population for MSCs 
in ex vivo culture. β-Galactosidase expression tended to increase over time in all samples. Sample 2 had 
significantly higher values (P < 0.05) at each passage than did samples 1 and 3. Error bars represent 
standard deviations of triplicate β-galactosidase measurements.  
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3 did not have significantly different values (P > 0.05). β -Galactosidase testing could not 
be performed on P5 of sample 2 because of low cell recovery at harvest.  
Karyotyping performed on these initial samples showed no mutations in any passage of 
samples 2 and 3. Sample 1 presented with duplication on the long arm of chromosome 17 
in 6% of cells in P5 and P6. Karyotyping could not be performed on P5 of sample 2 
because of low cell recovery at harvest. 
 
Figure 8: Post-thaw MSC recovery and β-galactosidase characterization. (A) Recovery of MSCs 
post-thaw. Recovery = (viable cells pre freeze)/(viable cells post-thaw) * 100 and is used to account 
for cellular losses during freezing. Recovery does not vary significantly between samples and was 
consistently high (>80% for almost all samples). (B) Population doublings in thawed cells after 48 h 
in culture. Sample 2 had low to no population doublings in every passage, with P4 showing cellular 
losses (negative doublings). Growth in samples 1 and 3 was higher in early-passage samples and 
declined with increasing passage number. (C) Immediate pre-freeze β-galactosidase expression. 
Sample 2 had significantly higher initial post-thaw expression than did samples 1 and 3. Trends 
observed in post-thaw samples matched those seen in pre-freeze data and were significantly higher in 
samples 1 and 3 (P < 0.05) when compared with pre-freeze values. (D) 48 hour post-thaw β-
galactosidase expression. Expression values dropped significantly (P < 0.05) after 48 h in culture for 
all samples when compared with immediate post-thaw values.  
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Apoptosis results for pre-freeze cells were low, with <10% of cells testing positive for 
apoptosis in all passages of all samples except for P5 of sample 2 (Table 7). There was 
not compelling evidence of an increase in apoptotic percentage over time in culture for 
the number of samples tested.  
4.3.3 Post-thaw characterization  
Total cell counts as well as viability, senescence and apoptosis measurements were taken 
immediately on thawing and after 48 h in culture after thaw. Immediate post-thaw 
recovery was calculated by dividing the total number of viable cells post-thaw by the 
total number of viable cells pre-freeze in each frozen passage. Recovery was similar for 
all samples and passages (Figure 8A), with no obvious trending as a function of pre-freeze 
population doublings. The majority of the data points fell between 80-100% recovery.  
Although there was no visible trending in the initial recovery of cells post-thaw, after 48 
hr of culture the population doublings tended to decrease with increasing pre-freeze 
passage number in all 3 samples (Figure 8B). Samples 1 and 3 had greater population 
doubling than sample 2, with a significant difference between samples 2 and 3 (P < 0.05). 
Sample 2 had very little growth in its first 3 passages post-thaw in addition to a decrease 
in cell number in P4 (as evidenced by the negative population doubling). In contrast, 
samples 1 and 3 showed almost a full population doubling in thawed samples from P1, 
which decreased as passage number increased. Sample 3 exhibited an increase in 
population doublings in P5 and P6.  
Every passage of samples 1 and 3 (except sample 3 P3) had a significant (P < 0.05) 
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senescent enrichment after thaw when individual passages were compared before freeze 
and after thaw (Figure 8C). Sample 2 had a significant decrease in its senescent fraction of 
cells in P1 and P3 but showed the same trends as pre-freeze populations of increasing 
senescence with increasing population doublings. These senescent percentages dropped 
significantly (P < 0.05) for each sample and passage at 48 h after thaw compared with 
immediate post-thaw percentages (Figure 8D).  
 
4.4 Discussion 
The wide variation in cell behavior observed among the 3 separate samples characterized 
in this study is likely a result of sample quality differences and donor-to-donor variability 
[124, 125]. Variability on initial receipt could result from differences in donor age, 
hemodilution of the sample or variability in shipping time or temperature. The older age 
of the donor of sample 2 (41 years old) could explain the initial lower cell counts and 
expression of higher levels of senescence in culture. In the future, quality control metrics 
such as total cell count, viability and senescence measured on whole marrow could be 
used to screen samples on initial receipt.  
Flow cytometry performed on the MSCs confirmed that the cells used in the study 
expressed the cell surface phenotype consistent with MSCs (CD45 [<15%] and CD90 
[>85%]) in all passages of each sample. This appropriate expression indicates that MSCs 
were successfully isolated in this study, and the results presented are representative of 
MSC freezing behavior. Karyotyping abnormalities were low, with only 6% of cells in 
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sample 1 showing duplication in the long arm of chromosome 17 in passages 5 and 6. 
The limited chromosomal abnormality observed is consistent with the literature [126]. 
Because of the similar post-thaw behavior observed in samples 1 and 3, the chromosomal 
abnormalities present do not appear to affect proliferative post-thaw sample behavior.  
Population doublings are a metric for assessing cellular health. Previous research by 
Bertolo et al. [127] has proposed the use of in vitro expansion scores for grading cells 
intended for transfusion. Cellular age has also been proposed as a metric for grading 
MSCs [128]. Growth kinetics for sample 2 were relatively normal initially (i.e., rates 
were the same as other samples for the first 2 passages), but even these early passages 
had growth arrest post-thaw. Samples that have this type of growth arrest should not be 
used as transfusion products but can go undetected with current selection criteria. This 
latent growth behavior may explain the poor performance of some cellular transfusion 
products in vivo. It is important to develop screening criteria to identify sub-standard 
products such as sample 2 before transfusion, as growth arrest may not be observed or 
predicted before administration with current techniques.  
Pre-freeze viability remained high among all samples at all passages (well above the 70% 
viability selection criterion for infusion) and did not predict cellular vigor or proliferative 
potential. Pre-freeze apoptosis also did not appear to be correlated with post-thaw 
behavior. However, pre-freeze senescence increased over time in all samples, and 
senescence β-galactosidase values were significantly higher in sample 2 both pre-freeze 
and immediately post-thaw. Senescence may provide a valuable metric for sample 
screening in the future; even in early passages with normal population doublings and 
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viability, sample 2 (which had poor post-thaw cellular performance even at early 
passages) had significantly higher senescence than other populations. We suggest that 
future studies be performed to evaluate introducing pre-freeze senescence as additional 
lot selection criteria for BM-MSCs intended for clinical use. Additional studies with a 
larger sample size are necessary to determine whether pre-freeze senescence is 
statistically indicative of poor post-thaw function, and, if so, establish a maximum 
acceptable senescence threshold for pre-freeze populations.  
Several groups have previously analyzed MSC response to cryopreservation. Bruder et al. 
[129] showed that cryopreserved MSC samples grown for extended passages in culture 
have growth kinetics and ATPase activity similar to that in unfrozen cells. Mamidi et al. 
[130] showed that multiple rounds of cryopreservation did not functionally alter MSCs 
when compared with MSCs that had undergone cryopreservation only once. Dariolli et al. 
[131] performed experiments to analyze porcine MSCs by measuring growth kinetics, 
senescence and ability to respond to chemical cues. This previously published work as a 
whole suggests that cryopreservation does not alter the growth or differential behavior of 
cells. However, freezing can induce changes in MSC phenotype and proliferation, which 
has also been shown by Francois et al. [10] and Moll et al. [123].  
In post-thaw populations, recovery was high for all cellular products, with most showing 
80-100% recoveries independent of sample or passage number. However, when cells 
were cultured for 48 hr post-thaw, differences in cellular population doublings became 
more apparent. If researchers or clinicians look solely at immediate post-thaw recovery 
and viability, this potential for growth arrest may not be observed.  
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Senescence immediately post-thaw was consistent with the trends seen in pre-freeze 
populations. There was a significant enrichment of senescent cells in the post-thaw 
populations of samples 1 and 3 and a significant decrease in several passages of sample 2.  
 
4.5 Conclusion 
The studies in this chapter show that high pre-freeze MSC senescence appears to 
correlate with poor post-thaw performance. To maximize the future success of clinical 
trials involving frozen MSC samples, future studies with larger sample size should be 
performed to statistically evaluate the effects of freezing and storage on the regenerative 
and immunomodulatory properties of MSCs. A better understanding of cell behavior in 
response to freezing may improve lot selection criteria and enhance the effectiveness of 
transfused MSCs.   
 
However, the differences in these samples indicate that donor variability may play a large 
role in sample behavior, and make it difficult to draw conclusions about cell freezing 
response without significantly higher sample sizes.  Future studies described in 
subsequent chapters utilized culture cell lines to make batch-to-batch comparisons 
possible for large scale screening (Chapter 5) and iterative optimization experiments 
(Chapter 7, 8). 
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Chapter 5 
Screening and Statistical Analysis of non-DMSO 
Cryopreservation Combinations 
 
5.1 Introduction 
We have identified potential groups of cryopreservatives (Sugars, Sugar Alcohols, 
Additives), which might together replicate the cryopreservative function of DMSO, but it 
is important to determine which combinations have the highest probability of high 
recovery before optimizing their concentrations in solution. In addition to solution 
composition, cooling rate also needs to be considered, as cooling rate may alter the 
effectiveness of different combinations. 
 
5.2 Methods 
A combination of 1-3 solution components in Table 8 below (no more than one from 
each column) and cells were combined using the Biomek liquid handler as described in 
section 3.9.3 above.  These combinations were tested with H9 MSCs at 4 different 
cooling rates: 1, 3, 5, and 10°C/min. 
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Table 8: Components tested. 
Sugar Sugar Alcohol Additive 
Sucrose 
Trehalose 
 
Arabitol 
Erythritol 
Glycerol 
Inositol 
Mannitol 
Ribitol 
Sorbitol 
Xylitol 
Alanine 
Creatine 
Ectoine 
Isoleucine 
Proline 
Taurine 
Valine 
 
 
After this large dataset was collected, it was sent to Ralph Moller-Trane who performed 
linear mixed effects (LME) modeling to assess the importance of the four explanatory 
variables of interest (Sugar, Rate, Additive and Alcohol), without neglecting the variation 
between each batch and between each plate within the batches.  
The LME model was defined as: !! = !!! + !!! +  !! 
Where yi is the i’th outcome of the response, Xi represents the corresponding values of 
the covariates, β is a vector for fixed effects, γ is a vector for random effects normally 
distributed with mean 0, Zi is the design matrix for the random effects, and εi is the error 
term, normally distributed with mean 0. 
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Backward elimination based on the Bayesian Information Criterion (BIC) was performed 
to select the most fitting model.  The initial model included all variables and second order 
interactions as well as two random variables to account for batch effect and effect of each 
plate within the batch: !! = !!,!"#$%!!"#$% +  !!,!"#$!!"#$ + !!,!"#$!!"!!"#$!!" + !!,!""#$#%&!!""#$#%&+  !!,!"#$%&'$()!!"#$%&'$() +  !!,!"#$%&'(()*)+,!!"#$%&'(()*)+,+  !!,!"#$%&'()*!!"!!"#$%&'()*!!" + !!,!"#$%&''(#()$!!"#$%&''(#()$+ !!,!"#$%&'()!!"!!"#$%&'()!!" + !!,!""#$#%&'!"#$!!"!!""#$#%&'!()*!!"+ !!,!"#$!!!"#$! + !!,!"#$%!!"#$% + !! 
where x’s are the covariates, β’s are the corresponding fixed effects, z’s are covariates for 
the random effects, γBatch ~ N(0,σBatch) is the random batch effect variable, γPlate ~ 
N(0,σPlate) is the random plate effect variable, and εi~ N(0,σε)  is the error term. 
 
The models were fitted using the lmer function from the R package lme4.  Elimination of 
terms from the model was made using the step function from the lmerTest R.  Table 9 
Sum Sq Mean Sq NumDF DenDF F.value elim.num Pr(>F)
Rate:Alcohol 0.019 0.00077 24 28.5 1.3 1 2.8e-01
Sugar 0.786 0.39300 2 2160.0 639.0 kept 0.0e+00
Rate 0.014 0.00483 3 3.8 7.8 kept 4.2e-02
Alcohol 0.025 0.00315 8 53.9 5.1 kept 8.9e-05
Additive 0.164 0.02346 7 3091.2 38.1 kept 0.0e+00
Sugar:Rate 0.059 0.00989 6 2136.3 16.1 kept 0.0e+00
Sugar:Alcohol 0.058 0.00363 16 2117.5 5.9 kept 8.2e-13
Sugar:Additive 0.064 0.00456 14 3091.2 7.4 kept 1.8e-15
Rate:Additive 0.065 0.00311 21 3091.2 5.1 kept 4.3e-13
Alcohol:Additive 0.137 0.00244 56 3091.2 4.0 kept 0.0e+00
Table 1: ANOVA table from result of the step function applied to the full
model. The column "elim.num" indicates whether or not the given variable
is kept in the model
The tendency spotted on the plot of the studentized residuals versus the
fitted values indicates a clear trend in the residuals. To accomodate this,
we try to refit the model using the square root of the recovery rate as the
response variable. I choose to transform the data using the square root
instead of a logarithmic transformation, since we have recovery rates of 0 in
the data set.
As we can see on Figure 2, using the square root of the recovery rate as
the respsonse variable improves the model. We get overall smaller residuals,
the correlation with the fitted values has decreased, and the QQ-plot looks
better.
Results
So, for our final model, we have dropped the interaction between Rate and
Alcohol, and we have transformed the response variable using the square
root transformation.
To find the optimal combination of Rate, Sugar, Alcohol and Additive,
we predict the value of the recovery rate for each combination using our
model. Predictions are found using bootstrapping, which enables us to find
confidence intervals as well.
The predictions and confidence intervals for all combinations are plotted
on Figure 3 and Figure 4. The 10 combinations which yields the highest
predicted recovery rates can be found on Figure 5.
2
Table 9: Anova table with results of step function application to the full model. 
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shows the resulting ANOVA table, and only the interaction between Rate and Alcohol 
was dropped.   
 
Even after dropping the Rate:Alcohol term, the residuals of this model were still large 
and correlated strongly with the fitted values.  To combat this phenomenon, the model 
was refit to the square root of the recovery values; square root transformation was chosen 
instead of a logarithmic transformation because the dataset included recovery rates of 0.  
Figure 9 shows that this transformation improved the model, giving smaller residuals and 
reduced correlation with fitted values, and tightening up the qq-plot which compares the 
probability distribution of the actual data residuals to the theoretical values predicted by 
the model. 
Figure 9: Studentized residuals plotted against fitted values.  (A) Residuals vs. fitted values of original 
recovery values. (B) Residuals vs. fitted values of square root transformed recovery values. (C) QQ-plot of 
original recovery values vs. model. (D) QQ-plot of square root transformed recovery values vs. model. 
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Figure 1: Studentized residuals plotted against fitted values (top) and QQ-
plot (bottom).
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Figure 2: Studentized residuals plotted against fitted values (top) and QQ-
plot (bottom).
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Figure 1: Studentized residuals plotted against fitted values (top) and QQ-
plot (botto ).
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Figure 2: Studentized residuals plotted against fitted values (top) and QQ-
plot (bottom).
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5.3 Results 
The model used bootstrapping to predict the value of the recovery for each combination 
of rate, sugar, alcohol, and additive.  Figure 10 and Figure 11 show the models 
predictions and confidence intervals for each different combination. 
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Figure 3: Predictions with Confidence Intervals
It can be hard to conclude much based on Figure 3 and Figure 4. There
are many combinations to keep track of. So, to get a better idea of which
combinations give better recovery rate, I have taken a look at all combina-
tions for which the confidence interval contains the highest predicted recovery
rate.
There are 76 combinations for which the confidence interval contains the
highest predicted recovery rate. As can be seen from Table 2, by far the
most of the top combinations uses one of two combinations of Sugar and
Rate - 30 times is the combination 3C with Sucrose observed and 23 times
is the combination 5C and Sucrose observed. So, using one of these two
combinations definitely increased the expected recovery rate.
Now, let us take a closer look at these two combinations. First, the com-
bination of 3C and Sucrose. Table 3 shows a contingency table of the values
of Alcohol and Additive. Here, we see that no combination of Alcohol and
5
Figure 10: Predictions and confidence intervals for: 0, Alanine, Creatine, Ectoine. 
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There were 76 combinations for which the confidence interval contained the highest 
predicted recovery rate. A contingency table (Table 10) of rate vs. sugar shows that most 
of these 76 combinations contained sucrose and were frozen at 3°C or 5°C/min. 
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Figure 4: Predictions with Confidence Intervals
Additive is present more than once. So it is hard to say which combination
gives the best outcome. However, if we look at the last row and last column,
we see the total number of times each alcohol and additive is present. Here
we see that the additives Proline and Valine are present 0 and 1 times, re-
spectively. For the alcohols we see that Glycerol and Sorbitol are present
5 and 6 times, respectively. So using Proline or Valine as the additive
seems to decrease the expected recovery rate, while using either Glycerol
or Sorbitol as the alcohol seems to increase it.
Let us turn to the other combination of Sugar and Rate that showed
better results. Table 4 shows a contingency table of the values of Alcohol and
Additive. Here we see that using Proline or Valine as the additive never
results in a top performing combination. Using Glycerol as the alcohol again
seems to increase the expected recovery rate, while using either Erythritol
or Ribitol both seems to decrease it.
6
Figure 11: Predictions and confidence intervals for: Isoleucine, Proline, Taurine, and Valine. 
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Further evaluation of a contingency table of additives vs. alcohols within the 3°C/min 
sucrose dataset (Table 11) shows that some alcohols and additives occur more frequently 
in these high performing solutions than others.  
 
5.4 Discussion 
The best selection of sugar, alcohol, and additive is still unclear as there is massive 
overlap in recovery performance of the different combinations.  However, this analysis 
makes it easier to rule out low performing solution components that negatively impact 
recovery, and rationally select high performing combinations for further study.    
It is clear from both the predictions and contingency tables above that inclusion of 
sucrose and trehalose improves recovery vs. no-sugar solutions.  Combinations including 
sucrose accounted for 53 of the 76 top performing combinations, and all of these 
0 Sucrose Trehal se
10C 0 1 14
1C 0 0 0
3C 0 30 0
5C 1 23 7
Table 2: Contingency table (Rate vs. Sugar)
0 Arabitol Erythritol Glycerol Inositol Mannitol Ribitol Sorbitol Xylitol Sum
0 0 0 1 1 1 1 1 1 1 7
Alanine 1 0 0 1 0 0 0 0 0 2
Creatine 0 1 1 0 1 1 1 1 0 6
Ectoine 1 1 1 1 1 1 1 1 1 9
Isoleucine 0 0 0 1 1 0 0 1 0 3
Proline 0 0 0 0 0 0 0 0 0 0
Taurine 0 0 0 1 0 0 0 1 0 2
Valine 0 0 0 0 0 0 0 1 0 1
Sum 2 2 3 5 4 3 3 6 2 30
Table 3: Contingency table for the top predictions with the combination
"3C" and "Sucrose" (Alcohol vs. Additive)
just once. It is hard to spot any alcohol or additive that are more present
than others. However, it is easy to spot alcohols and additives that are less
present than the rest. Looking at the last row and last columns, we see ’sum
of zeros’, i.e. how many times a given additive of alcohol is NOT present.
We see that Proline is absent in combination 4 of the alcohols when the
’Rate/Sugar’ combination is 10C/Sucrose and it is absent in combination
with 3 of the alcohols when the ’Rate/Sugar’ combination is 10C/Trehalose.
Now, what does all this tell? It seems like choosing the combination of
rate and sugar is the most important factor in getting the best predicted re-
covery rate, while the alcohol and additive has a much smaller influence. One
exemption is when we use the 10C/Sucrose or 10C/Trehalose combination.
In this case we want to avoid using the Proline additive.
8
Table 11: Additive vs. Alcohol contingency table for 3°C/min Sucrose. 
0 Sucrose Trehalose
10C 0 1 14
1C 0 0 0
3C 0 30 0
5C 1 23 7
Table 2: Contingency table (Rate vs. Sugar)
0 Arabitol Erythritol Glycerol Inositol Mannitol Ribitol Sorbitol Xylitol Sum
0 0 0 1 1 1 1 1 1 1 7
Alanine 1 0 0 1 0 0 0 0 0 2
Creatine 0 1 1 0 1 1 1 1 0 6
Ectoine 1 1 1 1 1 1 1 1 1 9
Isoleucine 0 0 0 1 1 0 0 1 0 3
Proline 0 0 0 0 0 0 0 0 0 0
Taurine 0 0 0 1 0 0 0 1 0 2
Valine 0 0 0 0 0 0 0 1 0 1
Sum 2 2 3 5 4 3 3 6 2 30
Table 3: Contingency table for the top predictions with the combination
"3C" and "Sucrose" (Alcohol vs. Additive)
just once. It is hard to spot any alcohol or additive that are more present
than others. However, it is easy to spot alcohols and additives that are less
present than the rest. Looking at the last row and last columns, we see ’sum
of zeros’, i.e. how many times a given additive of alcohol is NOT present.
We see that Proline is absent in combination 4 of the alcohols when the
’Rate/Sugar’ combination is 10C/Sucr e an it is absent in combination
with 3 of the alcohols when the ’Ra e/Sugar’ combination is 10C/Trehalose.
Now, what do s all this tell? It se ms like ch osing the combin tion of
rate and sugar is the most important factor in getting the best predicted re-
covery rate, while the alcohol and additive has a much smaller influence. One
exemption is wh n we u e the 10C/Sucrose or 10C/Trehalose combination.
In this case we want to avoid using the Proline additive.
8
Table 10 Rate vs. Sugar contingency table 
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occurred at cooling rates of 3°C/min and 5°C/min.  This unbalanced distribution of 
optimums suggests that the selection of sugar and cooling rate has a high impact on the 
recovery of a given solution.  
The contingency comparison of sugars and sugar alcohols within the sucrose 3°C/min 
group (Table 11) shows a more even distribution of optimum solutions among the 
different components than the sugar/cooling rate contingency table.  This suggests that 
selection of alcohol and additive make less of a difference if a high performing sugar and 
cooling rate have already been selected.  
Observing the last row and last column of Table 11, we see the total number of times 
each alcohol and additive is present.  The additives proline and valine are present 0 and 1 
times, respectively, while the additives ectoine, creatine, and isoleucine are present 9, 6, 
and 3 times, respectively. Based on this information, using proline or valine as the 
additive seems to decrease the expected recovery rate while using ectoine, creatine, or 
isoleucine as the additive seems to increase recovery.  The alcohols sorbitol, glycerol, and 
mannitol are present 6, 5, and 3 times respectively, while the alcohols ribitol and xylitol 
are present 2 times each.  This suggests that using sorbitol, glycerol, or mannitol is 
expected to increase the recovery, while using ribitol or xylitol may decrease recovery.   
 
5.5 Conclusion 
The screening and analysis in this chapter showed that selection of cooling rate and sugar 
in solution appears to predict solution recovery more strongly than either alcohol or 
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additive.  Additionally, multicomponent solutions exhibited higher recovery than single 
component solutions.  Due to the high performance of sucrose at 3°C/min, this cooling 
rate was selected for future use in Chapters 6 and 8.  Based on the selection of 3°C/min as 
the only cooling rate, the favorable multicomponent combinations of 
Sucrose/Glycerol/Creatine (SGC), Sucrose/Mannitol/Creatine (SMC), and 
Sucrose/Glycerol/Isoleucine (SGI) were selected for future analysis and concentration 
optimization.
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Chapter 6 
Combinatorial Effects of Incubation, Osmolarity, and Solution 
Composition on Mesenchymal Stem Cell Survival During 
Freezing 
 
Much of the text and figures in this chapter will appear in a future publication: 
Pollock K*, Yu G*, Moller-Trane R, Koran M, Dosa PI, McKenna DH, Hubel A. 
Combinations of osmolytes acting in concert to improve post-thaw viability of 
mesenchymal stem cells. 2016. In Review. 
 
*These authors contributed equally.  Yu G performed all Raman experiments. 
 
6.1 Introduction 
There is demand for non-DMSO cryoprotective agents that maintain cell viability without 
causing systemic toxicity or poor post-thaw function.  Single molecule replacement of 
DMSO has been explored, but results have been sub-optimal.  Multi-component solutions 
have also been explored, and work in the previous chapter as well as factorial 
experiments by other groups to identify favorable combinations and freezing protocols 
have shown increased success [99, 100] 
 
The focus of this chapter involves expanding our understanding of multicomponent 
osmolyte solutions and their ability to preserve cell viability during freezing.  The study 
characterizes interactions between solutes using surface plots to describe how 
concentrations of multiple components contribute to recovery.   Differences in single cell 
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response to freezing using different experimental parameters (incubation time, 
composition) were captured using low temperature Raman spectroscopy.  These studies 
help expand our understanding of these solutions and the manner by which they enhance 
post-thaw recovery. 
 
6.2 Methods 
H9-MSCs were cultured according to the methods described in section 3.2.3.  Freezing 
and thawing of samples were carried out according to sections 3.3.3 and 3.4 respectively, 
followed by viability and recovery analysis according to sections 3.5.1.  Physical testing 
of solutions at their final freezing concentration was performed using a differential 
scanning calorimeter according to section 3.11 and an osmometer according to section 
3.12. Confocal Raman spectroscopy was performed on samples according to section 3.10.  
Statistical analysis represents technical triplicates of biological replicates, with error bars 
representing standard error of the mean.  Two-tailed t-tests were considered significant 
with p<0.05.   
 
6.3 Results 
6.3.1 Permeation/partitioning of solute 
Several of the osmolytes studied here are large (> ~300 Da) and, as a result, may take 
longer to enter the cell than smaller solutes traditionally used like DMSO (78 Da).  Other 
large molecules including trehalose are known to have very limited penetration[132].  In 
order to determine the proper incubation time for the cells in the multicomponent 
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osmolyte solutions, solutions of SMC (sucrose = 150mM, mannitol = 125mM, creatine = 
12.5mM) and SGC (sucrose = 150mM, glycerol = 2.5%, creatine = 12.5mM) were 
incubated with cells at room temperature in Normasol ® for 0 min, 30 min, 1 hour, 2 
hours, or 4 hours before undergoing freezing at 3°C/min (Figure 12A).  Live cell recovery 
increased and experienced a maximum at 1 hour for SGC samples, and 2 hours for SMC 
samples.  Longer incubation times (4h) decreased the viability.  As expected, incubation 
times of more than 30 minutes resulted in a decrease in viability for cells in DMSO.   
 
Increased 
incubation times have a profound influence on cell response to freezing as imaged using 
Raman spectroscopy (Figure 12B).  MSCs were incubated for 30 and 120 minutes in the 
same SMC composition described above, frozen to -50oC and imaged using low 
temperature Raman spectroscopy.  Cells incubated for 30 minutes exhibited large internal 
ice crystals for 10/10 of the cells imaged.  In contrast, cells incubated for 120 minutes 
exhibited ice in only 3/10 cells imaged.  The formation of ice inside the cell is considered 
Figure 12: Recovery reaches a maximum with appropriate incubation time for slow penetrating 
components (A) Fraction of live cells recovered for DMSO-free solutions SMC and SGC and DMSO 
solutions as a function of incubation time prior to freezing at 3°C/min; (B) Raman images obtained of 
MSCs frozen at 3°C/min in SMC solution after 30 and 120 minutes of incubation prior to freezing.  
Raman images are rendered for both –CH and ice.  
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to be a damaging event, and the ice formation observed here is consistent with the poorer 
post-thaw viability observed in Figure 12A for cells incubated only 30 mins.  
 
Influence of osmolarity and composition 
The range of solution compositions studied is important.  It is common for 
cryopreservation solutions to contain high concentrations of cryoprotective agents and 
therefore exhibit high solution osmolarity.  For example, a 10% DMSO solution has an 
osmolarity of ~1400 mOsm.  MSCs suspended in different combinations of sucrose, 
mannitol and creatine (SMC), and sucrose, glycerol and creatine (SGC) were frozen at 
3oC/min, thawed and post-thaw recovery measured.  The post-thaw recovery of SGC and 
SMC were plotted as a function of total osmolarity for a range of different tested 
compositions (Figure 13).  For SMC solutions, the range of solution osmolarities is low   
(< 500 mOsm) and there is a weak negative correlation between osmolarity and post-
thaw recovery of MSCs (Figure 13A). In contrast, SGC solutions were evaluated over a 
higher range of osmolarities (< 1200 mOsm) and exhibited a weak positive correlation 
Figure 13: Post thaw recovery of MSCs cryopreserved in SGC and SMC as a function of total solution 
osmolarity.  Linear best fit is given with correlation coefficient. (A) Recovery of cells has slight negative 
correlation for different osmolarity sucrose-mannitol-creatine solutions.  (B) Recovery of cells has slight 
positive correlation for different osmolarity sucrose-glycerol-creatine solutions. 
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with the compositions tested (Figure 13B). These weak correlations suggest that higher 
solution concentration does not necessarily correlate to higher levels of post-thaw 
recovery.  
 
For the same 3-component solution compositions used in Figure 13, MATLAB was used 
to generate scattered interpolant plots that mapped the post-thaw recovery measured as a 
function of solution composition for two of the three components present in solution 
using 20-25 experimental points (recovery was averaged for vectors with same values for 
the 2 components being plotted). As described previously, the post-thaw recovery varied 
significantly with composition for solutions containing the same three components 
(Figure 14).   It is noteworthy that the variation in the fraction of recovered cells post-
thaw exhibited an inverted “U” shaped behavior. For example, the relationship between 
sucrose and creatine exhibits a maximum cell recovery for concentrations ~150 mOsm of 
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Figure 14: Scattered interpolant meshgrid plots.  Plots show recovery vs. two of three components for 
SGC (A,B,C) and SMC (D,E,F) solutions.  
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sucrose (Figure 14B,E).  The fraction of recovered cells diminishes for concentrations 
above and below that optimum.  Similar behavior is observed in Figure 14D where the 
optimum concentration of mannitol ~150 mOsm and the fraction of recovered cells 
increases with increasing sucrose concentration to the highest concentration tested (300 
mOsm).    
 
In order to understand differences in freezing response for different combinations of the 
same three osmolytes, freezing studies using two different compositions of SGC  (SGC-A 
and SGC-B) were repeated (Figure 15). MSCs were frozen under the same conditions 
(total osmolarity and 3oC/min cooling rate) and imaged using low temperature Raman 
confocal microscopy.  Cells frozen in SGC-B exhibited ice inside the cells for 10/10 cells 
imaged and the formation of ice inside the cell is known to be damaging[61].  
Contrastingly, fewer cells cryopreserved in SGC-A exhibited intracellular ice formation 
(3/10 cells imaged). Post-thaw recovery trends (average of biological replicates ± SEM, 
Solution Composition Ice Osmolytes 780-920cm-1 CH(cell) 
Intracellular 
ice formation 
SGC-A 
150mM Sucrose 
684mM Glycerol 
25mM Creatine 
3/10 
SGC-B 
300mM Sucrose 
684mM Glycerol 
12.5mM Creatine 
10/10 
Figure 15: Low temperature Raman microscopy of MSCs cryopreserved at 3°C/min 
in SGC with two different compositions.  Images are rendered on ice, osmolyte mixture 
and –CH.  The fraction of cells with ice is described for 10 cells measured. 
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n=4) for cells frozen in SGC-A (0.82 ± 0.07) and SGC-B (0.71 ± 0.05) using 
conventional controlled rate freezing were consistent with the ice formation trends 
observed using Raman, in that SGC-A had higher recovery and fewer cells with ice 
crystal formation than SGC-B. 
 
Solidification behavior 
It is common to formulate cryopreservation solutions to result in full or partial 
vitrification (see [133] for review).  The next phase of the investigation involved 
characterizing the solidification behavior of the solutions tested. SMC solutions with 
similar osmolarity and significantly different (p<0.05) recovery (recovery ± SEM, n = 4; 
SMC-A = 0.73±0.03, SMC-B = 0.62±0.02) were seeded for ice crystal nucleation at -6oC, 
cryopreserved without cells (solution only) at 3oC/min and imaged using Raman 
microscopy.  Representative images are given in Figure 16A. There is little difference in 
the macroscopic solidification patterns observed between the two solutions imaged (in 
spite of the significant difference in post-thaw viability observed between the two 
solutions). There is also no statistical difference in the area of ice crystals between the 
two solutions. As a control, a DPBS solution was seeded at 0°C, cryopreserved at 
3°C/min and imaged using Raman microscopy. Only very small amount of solution was 
incorporated into ice and hydrohalite could be found in the narrow solution gap based on 
Raman spectra.  
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Additional studies were performed using DSC to determine whether the different 
compositions exhibited differences in glass forming tendency (Figure 16B). No change in 
the melting curves was observed for either pair, and no signs of full or partial vitrification 
of the solutions were observed using DSC.  
 
Component substitution 
There has been considerable interest in the use of sugars (specifically trehalose) for the 
preservation of cells[132].  The next phase of the investigation involved determining 
whether the structure of the sugar has a significant influence on post-thaw recovery. 
Specifically, a monosaccharide, glucose, was substituted for sucrose at the same 
concentration (solution compositions: SMC (sugar = 150mM, mannitol = 125mM, 
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Figure 16: Physical behavior of multicomponent solutions associated with different recovery. (A) 
Low temperature Raman spectroscopy of two SMC solutions at -50oC.  Two different compositions with 
similar osmolarity were studied:  one associated with high recovery (SMC-A) and the other associated with 
lower recovery (SMC-B) (B) DSC thermograph for the same SMC solutions during warming.  The melting 
curves are almost identical and display a large exotherm associated with melting of the solution, and no 
glass formation is observed for either solution. 
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creatine = 12.5mM), SGC (sugar = 150mM, glycerol = 2.5%, creatine = 12.5mM)). 
When a monosaccharide is substituted for a disaccharide for both of the solution 
compositions tested, the post-thaw recovery of MSCs is reduced and those differences are 
statistically significant (Figure 17A).  Cells in SMC and GMC were cryopreserved and 
imaged using Raman spectroscopy. For cells cryopreserved in SMC, Raman images 
demonstrated that a small fraction of the cells exhibited ice during freezing (4/10) when 
compared to cells cryopreserved in a solution containing GMC exhibited ice inside the 
cell during freezing (6/10) (Figure 17B).  Images of the cell freezing response are 
consistent with the controlled rate freezing experiments described in Figure 17A. 
 
 
 
6.4 Discussion 
6.4.1 Permeation/partitioning of solutes 
 
Conventional cryoprotective agents (DMSO and glycerol) have small molecular weights 
Figure 17: Sugar substitution results in different recovery and ice formation behavior. (A) post thaw 
recovery of MSCs cryopreserved in glycerol+creatine and mannitol+creatine solutions with either sucrose 
or glucose (n=9, error bars represent standard error of the mean) (B) Low temperature Raman microscopy 
of MSCs cryopreserved at 3oC/min in SGC and GGC concentrations listed.  Images are rendered on ice, 
osmolyte mixture and –CH.  The fraction of cells with ice is consistent with cell recovery described in (A). 
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(78 and 92 Da respectively) and permeate the cell in a matter of minutes (see [134] for 
review).  Little has been done to characterize the uptake of osmolytes with the exception 
of trehalose [135], which appears to penetrate poorly into the cell.  The results of this 
investigation suggest that longer incubation times may be needed for cells frozen with 
non-DMSO cryoprotectants to allow for penetration of larger components and elicit 
maximum cell recovery. Raman measurement of mannitol indicated that permeation for 
this molecule takes ~90 mins (data not shown), which is consistent with the results of this 
study.  The observation that post-thaw recovery increases and the prevalence of ice inside 
the cell decreases with increasing incubation time also suggests that the presence of 
osmolytes inside the cell is needed for protection.  This observation is consistent with 
previous studies of the protective effect of trehalose [136], which demonstrated a similar 
outcome. 
 
 
6.4.2 Influence of osmolarity and composition 
 
It has been postulated that one mechanism of action for cryoprotective agents results 
from a colligative effect [137]. Specifically, higher concentrations of cryoprotectants 
reduce concentrations of damaging solutes and thereby protect the cell.  In contrast, the 
outcome of this investigation suggests that there is little relationship between total 
osmolarity of the solution and post-thaw recovery for multi-osmolyte solutions (Figure 
13).  Similarly, the solidification behavior of the solutions (crystallization patterns and 
DSC thermograms) for the different compositions tested does not exhibit significant 
differences from one SGC or SMC composition to the other. 
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Based on the results in Figure 13, osmolarity alone is not enough to predict cell recovery. 
Additionally, as shown in Figure 16, there was no change in the physical solution 
behavior at these low osmolarity solution concentrations below -30°C.  There is no 
eutectic peak indicating that a glass transition occurred in any of the samples at these 
concentrations (it would be expected around -80°C if it existed).  Because this physical 
change is absent, we hypothesize that the mechanism of protection for these solutions is 
biological.  This suggests that there is a biological ‘sweet spot’ solution composition that 
results in maximum cell recovery. 
 
One reason these solution compositions may be successful could be the result of their 
interactions to stabilize proteins within the cell. Osmolytes are well known for stabilizing 
protein folding by providing a thermodynamically unfavorable environment for 
denatured proteins [138], including during cryopreservation[139] Additionally, mixtures 
of two different osmolyte monomers have been found to have better stabilization effects 
than that of a single type of monomer at the same molar concentrations [140]. Thus, 
literature supports the possibility that different osmolytes could stabilize different 
proteins and different parts of the cell to result in increased viability. Within mixtures of 
osmolytes, each osmolyte exerts independent protein stabilization effects[141].  This 
effect is due to the low binding affinity between osmolytes and proteins, resulting in 
neither competition nor cooperation between osmolytes[141].  Therefore, the activity of 
each osmolyte should be considered individually without cooperation between them.  
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Different combinations of osmolytes may also stabilize the cell membrane. Both surface 
and internal membranes are main areas of injury regardless of cooling rate[7].  Normal 
cells have a layer of water surrounding the cell surface, which helps maintain surface 
protein folding[55]. During freezing the concentration of liquid water is decreased, which 
can lead to destabilization of these proteins [55]. Combined with observations that 
membrane proteins are denatured and lost post-thaw [55], stabilization of proteins in the 
membrane is very important to the success of cryopreservation.  Meryman proposed that 
conformational stability of surface macromolecules depends on the interactions of solute 
and water at the cell surface [55], and osmolytes themselves have been postulated to 
replace water in the cell membrane during freezing[142]. Osmolytes also play a role in 
preferential exclusion, which has been associated with protein stabilization caused by 
increases in surface tension due to sugars and amino acids present in solution [143]. In 
the solutions used in this study, each component could differ in location (intracellular or 
extracellular), the macromolecules it stabilizes, and the surface area it stabilizes. These 
differences could help to protect multiple critical structures, thus decreasing the 
cumulative damage to the cell. 
 
It is well established in literature that larger sugar osmolytes provide better stabilization 
[96, 140, 144], due to their increased polar contact area [140]. Sugars can provide 
stabilization by replacing water surrounding membranes during dehydration [139, 140]. 
The trend observed for improved disaccharide behavior may be due insertion between the 
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phospholipid heads of the lipid membrane, creating more space than monosaccharides for 
additional binding [144]. Binding of sugars to membranes can increase the rigidity of the 
membrane, which provides greater resistance to disruption [144]. Cells dehydrate at slow 
cooling rates, making stabilization with osmolytes important. During thawing, changes in 
the protein environment could induce denaturing, but osmolytes, including sugars, can 
assist with stabilization. This can reduce damage to membrane proteins, as well as 
internal proteins. 
 
In a study that supplemented cryopreservation media with monosaccharides or 
disaccharides during freezing of boar sperm, glucose was found to be the most effective 
of the monosaccharides in maintaining post-thaw sperm quality[145].  Gomez et al found 
that disaccharides containing the same monomers with different links had similar results 
[145]. Additionally, disaccharides are known for being better stabilizers than 
monosaccharides [145][140], and this is supported by the results presented herein Figure 
17. 
 
 
 
6.5 Conclusion 
As the field of cryobiology expands to include new applications that require non-toxic 
alternatives to DMSO, it is important to understand the role of multicomponent solutions 
in preserving cell function.  In this chapter, we demonstrate that incubation time must be 
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sufficient for penetration of components, concentration of components (not total 
osmolarity) determines recovery, and molecular substitution results in changes in 
recovery.  We hypothesize that these differences are biological, as we have found no 
evidence of physical changes in ice crystal formation between these solutions.  
Ultimately, these observations increase our understanding of multicomponent solution 
behavior, and move the field closer to clinically acceptable DMSO alternatives for 
cryopreservation of MSCs and other cryo-sensitive cell types. 
 
Because we hypothesize that differences in concentration of components and not total 
osmolarity determines recovery, it is important to identify the concentrations of 
components in solution that result in optimum recovery.  Factorial optimization limits the 
number of experimental conditions that can be tested, and in Chapter 7, we validate that 
an algorithm can be used to optimize solution concentrations with significantly fewer 
experiments than traditional factorial strategies. 
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Chapter 7 
Algorithm-Driven Optimization of Cryopreservation Protocols 
for Transfusion Model Cell Types Including Jurkats and 
Mesenchymal Stem Cells 
Much of the text and figures in this chapter have previously appeared in the publication 
below, included here with copyright permission from John Wiley & Sons Ltd: 
 
Pollock K, Budenske JW, McKenna DH, Dosa PI, Hubel A.  Algorithm-driven 
optimization of cryopreservation protocols for transfusion model cell types including 
Jurkat cells and mesenchymal stem cells.  J Tissue Eng Reg Med, Published online May 
2016, doi: 10.1002/term.2175 
 
7.1 Introduction 
Survival for many cell types is strongly influenced by cooling rate, with a narrow range 
of cooling rates over which post-thaw survival is optimal [56]. Freezing solution 
composition also influences cell survival [7], and changing the composition of the 
cryopreservation solution may change the cooling rate at which optimum survival is 
observed. Cryopreservation protocols are most often determined empirically by changing 
the composition and cooling rate until the desired outcome is obtained [97–101]. This 
process is typically expensive, time-consuming and may not result in an optimized 
protocol.  
A variety of strategies can be used to optimize processes with multiple inputs 
(composition of the freezing solution and cooling rate) and outputs (recovery and 
viability). The objective of this chapter was to validate the use of the differential 
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evolution (DE) algorithm [11] to optimize compositions and cooling rates for 
cryopreservation solutions. Other investigators have successfully used DE for other 
applications, including Tsutsui et al. [104], who used this approach to optimize the 
formulation of embryonic stem cell media. In the experiments described here, DE is 
applied to determine optimum DMSO-free cryopreservation solution formulations for 
different cell types (lymphoblasts and mesenchymal stem cells). The approach was also 
used to optimize composition and cooling rate simultaneously. The methods involved 
have been adapted to a high-throughput format: small numbers of cells are used and a 
small number of experiments are required for optimization. This type of approach will 
transform the development and optimization of freezing protocols by reducing the 
number of cells and experiments required, thus accelerating optimization over a 
multiparameter space.  
7.2 Methods 
Culture of Jurkats and Mesenchymal Stem Cells was performed according to sections 
3.2.2 and section 3.2.3 respectively.   
The algorithm was operated according to the procedures outlined in 3.12.  For these 
experiments, the generation size was set to either 18 or 27, the crossover set to 1 and the 
weight set to 0.85. The concentration of each component was allowed to vary discretely 
between 0 and the maxima that were identified from the literature or dictated by   
solubility limits. The concentrations used for each discrete level are listed in Table 12.  
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Cells were frozen in 96 well plates according to section 3.3.2 for all results in this section 
except for Figure 22, in which cells were frozen in vials according to section 3.3.3.  All 
samples were thawed according to section 3.4, and analyzed for viability according to 
section 3.5.2 for plates and 3.5.1 for vials.  To evaluate whether the optimum identified 
by the algorithm was the optimum of the system, liquid handling experiments according 
to sections 3.9.1 and 3.9.2 were performed to fully characterize the parameter space at a 
single cooling rate. Error bars represent standard deviations (SDs) of a minimum of nine 
sample measurements, taken from experiments performed in batches of three to six over a 
minimum of 3 different days. Statistical significance was determined using Student’s t-
test, with a significance level of p = 0.05.  
7.3 Results 
7.3.1 Optimizing a solution composition for a given cooling rate  
The first phase of this study involved using the DE algorithm to optimize a three-
component cryopreservation solution used at a single cooling rate (1°C/min). Three 
components, trehalose, glycerol and ectoine (TGE), were selected to comprise the 
freezing medium used for the preservation of Jurkat cells (a hematopoietic model cell 
type) based on prescreening of multiple non-DMSO components. For this single cooling-
mutation/comparison process is repeated for all subse-
quent generations (Figure 1) and results an emergent
population that changes less and less as the algorithm
converges. The ﬁnal emergent population contains set of
solutions that have all been independently optimized
using stochastic direct search, and contains the best possi-
ble compositions for freezing cells within the deﬁned pa-
rameter space. C nvergence can be measured by
observing an increase in cumulative best member live cell
recovery, a decrease in the number of improved solutions
within the emergent population after each generation, or
by the generational average, which captures both these
metrics.
For these experiments, the generation size was set to ei-
ther 18 or 27, the crossover set to 1 and the weight set to
0.85. The concentration of each component was allowed
to vary discretely between 0 and the maxima that were
identiﬁed from the literature or dictated by solubility
limits. The concentrations used for each discrete level
are listed in Table 1.
2.3. High-throughput 96-well plate freezing
In both scr ening and DE algori h experiments, cells
were frozen in 96-well plates to limit the number of cells
and volumes of reagent necessary, and to increase the
number of samples that could be tested at one time. Solu-
tions were made at 2× their ﬁnal concentration in dis-
tilled water (diH2O). Cells were centrifuged and
supernatant was aspirated before cells were suspended
in Normasol-R™. Cells were combined 1:1 with 2× solu-
tions, using a single-step addition in clear-bottomed black
96-well plates (Corning, NY, USA) to produce a 1× con-
centration of cryoprotectant solution with a total volume
of 50 μl and a cell concentration of ca. 300, 000
cells/well (~6 million cells/ml). Actual seeding counts
were conﬁrmed by manual acridine orange/propidium
iodide (AO/PI) counts of the cell stock added to each
plate. As a control, wells of 10% DMSO solution were
also included on each plate to normalize results
between all experiments. All samples were run in tripli-
cate wells on each plate. The plates were sealed with
molded silicone round well covers (Laboratory Supply
Distributers, Millville, NJ, USA) to prevent desiccation
during freezing and storage. The plates were placed in
a rack in a controlled-rate freezer, and frozen using
the proﬁle below:
1 Starting temperature 20°C
2 !10°C/min to 0°C
3 Hold at 0°C for 15 min
4 !1°C/min to !8°C
5 !50°C/min to !45°C
6 +15°C/min to !12°C
7 –0.5, !1, !3, !5 or !10°C/min to !100°C (as dictated
by the DE algorithm)
The rapid cooling and rewarming in steps 5 and 6 are
included to promote ice crystal nucleation outside the cell
before slow cooling proceeds, discouraging stochastic ice
formation within the cells. A temperature of !8°C was
Table 1. Discrete concentration levels and cooling rates used for each component in the DE algorithm
Component
Level 0
(0)
Level 1
(1/100)
Level 2
(1/50)
Level 3
(1/10)
Level 4
(1/2)
Level 5
(1)
Trehalose (mM) 0 3 6 30 150 300
Glycerol (%) 0 0.1 0.2 1 5 10
Ectoine (%) 0 0.01 0.02 0.1 0.5 1
Sucrose (mM) 0 3 6 30 150 300
Ethylene glycol (mM) 0 3 6 30 150 300
Alanine (mM) 0 3 6 30 150 300
Taurine (mM) 0 0.5 1 5 25 50
Cooling rate (different scaling) (°C/min) 0 0.5 1 3 5 10
DMSO standard recovery ± standard deviation.
(for cooling rates in
same column above)
0 0.09 ± 0.03 0.13 ± 0.03 0.12 ± 0.04 0.12 ± 0.04 0.09 ± 0.01
Figure 1. DE algorithm ﬂow chart, with black boxes representing
DE algorithm steps and grey boxes representing experimental
steps. The DE algorithm produces a population in gen 0 that ran-
domly spans the parameter space, and a trial opulation (gen 1)
that is based on mutation of gen 0. These are both experimen-
tally tested by the user and the live cell recovery results are input
into the DE algorithm, producing an emergent population which
is further mutated and iterated in subsequent experiments. As
the algorithm converges, an optimum solution can be identiﬁed
Algorithm-driven optimization of freezing
Copyright © 2016 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2016.
DOI: 10.1002/term
Table 12 Discrete concentration levels and cooling rates used for each component in the DE algorithm 
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rate study, the DE algorithm was programmed to output 18 vector solutions/generation, 
with weight = 0.85 and crossover =1. Jurkat cells cryopreserved in 10% DMSO at a 
cooling rate of 1°C/min were used as a control. For each generation of solutions tested, 
the scaled raw recovery of the best solution increased or remained constant (Figure 18A), 
while the number of solutions that demonstrated improved recovery tended to decrease 
for each generation (Figure 18B).       
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Figure 18: Trehalose, glycerol, ectoine 1°C/min DE algorithm results for Jurkat cells. (A) Cumulative 
best member solution; recovery associated with the best solution increases and plateaus as the algorithm 
converges. (B) Number of improved solutions/generation; the number of improved solutions in each 
generation decreases and reaches zero when the algorithm has converged. (C) Emergent population with 
the generational average overlaid: the emergent population improves and eventually stops changing as the 
DE algorithm converges; this is reflected in the generational average, which increases and begins to plateau 
as the algorithm converges. The optimum composition identified by this run of the algorithm was 150mM 
trehalose, 10% glycerol, 0.1% ectoine for Jurkat cells frozen at 1°C/min.  
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These results together (Figure 18C) indicate that the DE algorithm converged after six 
generations (e.g. seven freezing experiments) to an optimum solution composition of 
150mM trehalose, 10% glycerol and 0.1% TGE (Figure 18). The recovery of Jurkat cells 
frozen in the TGE solution was 32%, almost twice as high as the recovery of the control 
(16% = highest observed recovery in 10% DMSO at 1°C/min).  
7.3.2 Optimizing both composition and cooling rate   
Cooling rate influences cell survival [56] and optimal cooling rate varies with the 
composition of the freezing medium and the cell type being frozen [146]. Therefore, the 
optimal TGE solution composition identified for Jurkat cells at a constant cooling rate of 
1°C/min may not be the optimum composition at other cooling rates, and thus may not 
produce the highest recovery possible. To optimize both composition and cooling rate in 
this study, the DE algorithm was programmed to output 27 vector solutions/generation 
with weight = 0.85 and crossover =1, using cooling rate as an additional optimization 
variable. Solutions were separated into categories based on their DE algorithm defined 
cooling rate, and were frozen in batches at these cooling rates (0, 0.5, 1, 3, 5 and 
10°C/min). The results were normalized and scaled raw recovery is reported, allowing 
results from all cooling rates and all generations to be compared directly. 
As with previous generations, the best member scaled raw recovery increased or 
remained constant with increasing iterations (Figure 19A) and the number of improved 
solutions within each generation tended to decrease (Figure 19B). The number of 
solutions frozen at given cooling rates is described by pie charts overlaid at the average 
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recovery of each generation in Figure 19C.  
These pie charts show that the DE algorithm quickly identifies poor recovery in solutions 
frozen at 0°C/min (no freezing, recovery = 0) and 0.5°C/min and eliminates these rates 
after 2 generations. In early generations, the majority of solutions with high recovery 
used cooling rates of 5 and 10°C/min. However, a spike in the number of 1°C/min 
solutions occurs in generation 4 after the DE algorithm identifies the same high recovery 
1°C/min composition from the constant cooling rate study described in Figure 18 above. 
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Figure 19: Trehalose, glycerol, ectoine cooling-rate DE algorithm results for Jurkat cells. (A) 
Cumulative best member solution; this increases and plateaus as the DE algorithm converges. (B) Number 
of improved solutions/generation; this decreases until it reaches zero as the DE algorithm converges. (C) 
Emergent population with the generational average overlaid: pie charts at each average show the cooling 
rate distribution within each generation. The optimum composition identified by this run of the DE 
algorithm was 300 mM trehalose, 10% glycerol, 0.01% ectoine at 10°C/min cooling.  
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Ultimately, at convergence, this DE algorithm run identified that a TGE solution 
containing 300mM trehalose, 10% glycerol, 0.01% ectoine at a cooling rate of 10°C/min 
resulted in optimum cell recovery for Jurkat cells (35% recovery in TGE at 10°C/min vs. 
16% = highest observed recovery in 10% DMSO at 1°C/min). The DE algorithm 
converged after seven generations (or eight freezing experiments).  
7.3.3 Confirmation of the optimum using high-throughput screening over the range of 
concentrations tested   
High-throughput screening of solution compositions was used to confirm that the DE 
algorithm converged on the true optimum solution composition for a given cooling rate 
and component concentrations. Samples were frozen and thawed at 10°C/min. Serial 
dilutions of glycerol and ectoine were combined with dilutions of trehalose and cells 
suspended in Normasol-RTM in 96-well plates. The final concentrations in each well were 
equal to the full factorial array of concentrations used in the DE algorithm. The results 
from each well were normalized to a DMSO control included on each plate. This 
experiment was repeated in triplicate and the recovery results from each individual 
composition were averaged and are plotted in Figure 20(SDs were typically <5%). This 
study confirmed that a composition of 300mM trehalose, 10% glycerol, 0.01% ectoine 
resulted in the highest recovery for the array tested, indicating that the DE algorithm 
correctly identified the optimum of the system at 10°C/min.  
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7.4.1 DE algorithm can be applied to different cell types, using different compositions 
and different numbers of solution components  
The previous studies describe a three-component TGE solution tested with Jurkat cells. 
To show that the DE algorithm is capable of converging to freezing solution 
compositions using different solution components and different cell types, a five-
component combination of sucrose, ethylene glycol, alanine, taurine and ectoine (SEGA) 
was tested with mesenchymal stem cells at DE algorithm-defined concentrations and 
cooling rates. These components were selected based on pre-screening experiments 
performed to identify combinations with high potential recovery. The DE algorithm was 
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Figure 20: High-throughput concentration study confirmation of Jurkat DE algorithm results. 
Shades corresponding to recovery values are plotted in squares corresponding to solution compositions 
within the algorithm parameter space. This concentration study, performed at 10°C/min, identified the 
solution composition associated with maximum recovery to be 300mM trehalose, 10% glycerol and 
0.01% ectoine (corresponds to the points 5-trehalose, 5-glycerol, 1-ectoine in the heat map above). This 
composition is the same as the composition identified by the DE algorithm, confirming that it is indeed the 
optimum within the parameter space at 10°C/min.  
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programmed to output 27 vector solutions/generation with weight = 0.85 and crossover 
=1. Experimental testing and result normalization were similar to the methods described 
above.  
 
 
As with previous experiments, the cumulative best member composition increased and 
the number of improved solutions decreased with each generation. At convergence, this 
run of the DE algorithm identified that a SEGA solution of 300mM ethylene glycol, 1mM 
taurine and 1% ectoine resulted in optimum cell recovery for MSCs (40% recovery at 
1°C/min vs. 21% recovery in 10% DMSO at 1°C/min). Total convergence occurred after 
nine generations (10 freezing experiments), as evidenced by the increase and plateau of 
the best member recovery (Figure 21A) and the decrease in the number of improved 
solutions/generation (Figure 21B). It is noteworthy that two of the components tested 
(sucrose and alanine) were not present in the final solution formulation, indicating that 
the presence of these additives did not improve post-thaw survival at this cooling rate.  
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Figure 21: Sucrose, ethylene glycol, alanine, taurine, ectoine cooling-rate algorithm results for MSCs. 
(A)Cumulative best member solution; this increases and plateaus as the DE algorithm converges. (B) 
Number of improved solutions/generation; this decreases until it reaches zero as the DE algorithm 
converges. The optimum composition identified by this run of the DE algorithm included 300 mM ethylene 
glycol, 1 mM taurine, 1% ectoine with a 1°C/min cooling rate.  
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3.5. Convergence results obtained for 96-well studies scale to larger volumes and are 
unique to the cell type being frozen   
Freezing experiments were performed in 1mL vials to determine whether the results with 
low volumes and small cell numbers in 96-well studies were reproducible when using 
larger, more clinically relevant volumes.  
 
 
Figure 22: Scale-up viability and recovery of Jurkat cells (A, B) and mesenchymal stem cells (C, D) 
frozen in DE algorithm-optimized solutions. Each cell type was frozen at 10°C/min in a TGE solution 
optimized for Jurkat cells (TGE 10°C) and a SEGA solution optimized for MSCs (MSC 10°C). Results 
were compared to cells frozen in DMSO at 1°C/min (DMSO 1°C), as it represents the current gold standard 
for both cell types. Jurkat cells performed well in both the SEGA 10°C and TGE 10°C solutions, and Jurkat 
cell viability was significantly higher in TGE 10°C than both SEGA 10°C and the DMSO 1°C control (A). 
MSCs also performed well in both SEGA 10°C and TGE 10°C solutions, and had significantly higher 
recovery in the SEGA 10°C solution than both TGE 10°C and the DMSO 1°C control (D). Significance 
markers indicate p < 0.05.  
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DE algorithm solutions that resulted in maximum recovery were identified for both Jurkat 
cells and MSCs at 10°C/min. These solutions are identified as TGE 10°C (300mM 
trehalose, 10% glycerol and 0.01% ectoine at 10°C/min optimized as above for Jurkat 
cells) and SEGA 10°C (150mM sucrose, 300mM ethylene glycol, 30mM alanine, 0.5mM 
taurine and 0.02% ectoine at 10°C/min optimized for MSCs). These solutions were 
combined with cells, frozen, thawed and analyzed for viability. A minimum of nine 
samples was analyzed for each solution (batches of three or more on at least 3 different 
days). These were compared to solutions of cells in 10% DMSO frozen at 1°C/min (the 
gold standard for both cell types, labeled DMSO 1°C).  
The TGE 10°C solution resulted in significantly higher viability than SEGA 10°C and the 
DMSO 1°C control (Figure 22A; DMSO 1°C = 0.90 ± 0.02; TGE 10°C = 0.95 ± 0.03; 
SEGA 10°C = 0.89 ± 0.03; p < 0.05) for Jurkat cells. Recovery was high across the board 
(> 88%) but not statistically significantly different for any of the solutions tested with 
Jurkat cells (Figure 22B; DMSO 1°C = 0.91 ± 0.04; TGE 10°C = 0.88 ± 0.15; SEGA 
10°C = 0.88 ± 0.13; p < 0.05). Conversely, MSC viability testing showed no statistically 
significant differences between solutions (Figure 22C; DMSO 1°C = 0.96 ± 0.02; TGE 
10°C = 0.92 ± 0.07; SEGA 10°C = 0.96 ± 0.02; p < 0.05), while the SEGA 10°C solution 
produced significantly higher recovery than either TGE 10°C or DMSO 1°C (Figure 
22D; DMSO 1°C = 0.90 ± 0.12; TGE 10°C = 0.88 ± 0.11; SEGA 10°C = 1.03 ± 0.15; p < 
0.05). This indicates that optimization results for individual cell types are unique and can 
result in significantly higher viability (Figure 22A) or recovery (Figure 22D). However, 
both TGE and SEGA solutions produced acceptable viability and recovery in cell types 
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for which they were not optimized, indicating that DE algorithm-optimized solutions may 
be used to freeze multiple cell types successfully. Follow-up studies currently being 
performed suggest that cells frozen with these solutions proliferate post-thaw at rates 
similar to cells frozen in DMSO.  
Figure 22 also shows that DE algorithm optimization results are scalable. Although the 
improvement in recovery for optimized solutions in comparison to DMSO is smaller in 
vial studies than in 96-well studies, this result is expected because of the limited 
difference that is possible when recovery and viability are high. Cumulatively, these 
results support DE algorithm testing of small volumes of cells and solutions, as optimized 
solutions produce high viability and recovery at larger volumes.  
7.4 Discussion 
Current methods of optimizing cryopreservation solutions most often use empirical 
methods, by testing a given composition and cooling rate and measuring post-thaw 
recovery [97, 99–101, 147]. Our studies show that optimization of freezing solutions can 
be performed using a DE algorithm. The DE algorithm can be used for different cell 
types and can concurrently optimize both solution composition and cooling rate.  
The three variables examined in this study (cryoprotectants, cryoprotectant concentration 
and cooling rate) represent only a subset of the variables that can be considered when 
optimizing a cryopreservation protocol. In the future, rate of addition and removal of 
cryoprotectants, temperature of nucleation, incubation time, hold temperature, single vs. 
multistep cooling, storage temperature and thawing rate are all parameters that could be 
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incorporated into this type of algorithm optimization.  
The use of DE to optimize over a multiparametric space has been used in a wide variety 
of fields. Recently, Tsutsui et al. [148] used this approach to optimize a defined medium 
for the culture of human embryonic stem cells.  
The investigation described above utilizes DE as part of an innovative method to 
optimize both cooling rate and composition for the cryopreservation of therapeutic cell 
types. This DE algorithm used a total of seven to nine experiments to optimize a three- or 
five-component solution. The DE algorithm as implemented rapidly optimized both 
solution composition and cooling rate with <200 unique experimental points; without the 
aid of the DE algorithm, ~7000 unique experimental data points would have been 
required to optimize the compositions tested above. Best member solutions increased and 
the number of improved solution compositions steadily decreased with advancing 
generation, consistent with convergence of the DE algorithm. Convergence to a local 
optimum was confirmed by high-throughput studies using the same components and the 
same range of concentrations as the DE algorithm. The data here suggest that the DE 
algorithm can reliably optimize at least six parameters at a time (Figure 21 shows that the 
DE algorithm optimized five solute concentrations and a cooling rate) and more 
parameters could theoretically be added if the population size within each generation is 
increased and the number of generations tested is increased to ensure that convergence is 
achieved.  
 
  97 
The ability to cryopreserve cells in a 96-well format enabled the testing of generations 
with a large number of solutions (18–27). Freezing of cells in 96-well format has been 
used to improve the post-thaw recovery of anchorage-dependent cells [149]. Cells 
cryopreserved in a 96-well format are also available commercially and used for drug 
screening and other applications. In this study, post-thaw recovery of cells frozen in 
DMSO was lower for cells frozen in 96-well plates vs. vials. The same was true for cells 
frozen in DMSO-free solutions. One possible explanation for this reduced viability is the 
slower warming rates observed for plates vs. vials; 96-well plates had an average sample 
warming rate of 1.30°C/s (-196°C to 0°C in 150 s), while vials had an average sample 
warming rate of 1.63°C/s (-196°C to 0°C in 120 s). A second possible explanation for the 
reduction in recovery observed in 96-well plates could be due to the extended post-thaw 
incubation time for cells in 96-well plates. Cells in 96-well plates were subject to an 
additional 30 min of incubation post-thaw in 0.5× cryopreservation solutions after 
viability dye was added (allowing it time to be metabolized by live cells), while 1mL 
vials were assessed for recovery immediately using AO/PI. However, the recovery trends 
observed in 96-well plates were scalable to larger volumes, in that the differences in 
viability and recovery between experimental solutions and DMSO were comparable. 
Cumulatively, these results support DE algorithm testing of small volumes of cells and 
solutions, as optimized solutions produced high viability and recovery at larger, more 
clinically relevant volumes. Additional metrics of cryopreservation success, such as 
attachment, proliferation, alignment, gene expression, etc., could easily be incorporated 
as the input of the algorithm, rather than using recovery.  
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Preservation of Jurkat cells and MSCs is principally performed using 10% DMSO and a 
cooling rate of 1°C/min. A limited number of studies have examined vitrification of 
MSCs [57, 150] and the use of polymers to replace DMSO [92].  This investigation 
describes novel formulations in which solutions with multiple components are known to 
preserve cell viability. Glycerol is used for the cryopreservation of red blood cells [151] 
and was the first cryoprotective agent discovered[152].  Similarly, trehalose has been 
shown to be an effective cryoprotective agent [153]. What makes this investigation 
noteworthy is that the combination of two or more cryoprotectants is effective and that 
effectiveness is not necessarily observed at the highest concentrations tested. 
Additionally, these multi-component compositions result in cell viability and recovery 
significantly higher than 10% DMSO, which is an important step forward towards 
DMSO-free cryopreservation. Additional studies will be needed to characterize the 
methods of action for these multicomponent solutions. These studies are enabled by the 
development and implementation of the DE algorithm, which permits optimization of a 
multicomponent solution in a rational, accelerated fashion. 
7.5 Conclusion 
This chapter validates the DE algorithm and confirms that the optimums identified by the 
algorithm are indeed the optimums of the system.   However, the iterations described in 
here optimized cell recovery only, and do not address cell functionality.  In the next 
chapter, the algorithm will be applied to optimize a metric of cell functionality, and 
subsequent measures of cell health will be evaluated. 
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Chapter 8 
Mesenchymal Stem Cell Post-Thaw Function is Maintained or 
Improved by Freezing with Algorithm Optimized non-DMSO 
Solutions 
The text and figures in this chapter will appear in a future publication:  
 
Pollock K, Samsonraj RM, Stumbras A, McKenna DH, Dosa PI, van Wijnen A, Hubel 
A. Mesenchymal stem cell post-thaw cell function is maintained or improved by freezing 
with algorithm optimized non-DMSO solutions.  In Preparation 2016. 
 
8.1 Introduction 
Assessment of cellular function post-thaw for MSCs is often limited to the minimal 
criteria defined by Dominici et al[154].  Previous work has been performed to define 
other minimal potency criteria[155], but there is not consensus within the field regarding 
functional characterization metrics[156] due to the limited understanding of the specific 
therapeutic mechanisms of action of these cells in vivo[157].  
 
MSCs have known immunomodulatory behavior in vivo[52, 158, 159], and 
cryopreservation with DMSO has been associated with functional changes in cells, 
including reduced suppression of t-cell proliferation caused by changes in the 
indoleamine 2,3 deoxygenase signaling cascade[10, 160–162].  In addition, 
cryopreservation in DMSO has been associated with reduced engraftment, and has been 
correlated to a disruption of the actin cytoskeleton[67, 68, 74], and to rapid clearance via 
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a blood mediated inflammatory reaction after systemic delivery to patients[75].  DMSO 
has also been implicated in epigenetic changes in cells[77, 78]. These post-thaw 
functional alterations may be to blame for the failure of a recent phase 3 clinical trial 
using cryopreserved MSCs [73], and highlight the need for improved cryopreservation 
methods that are free of DMSO and maintain MSC viability and functionality post-thaw.   
The work that follows describes optimization of non-DMSO cryopreservative solutions 
for functionality, and subsequent relevant analysis of MSC functional metrics based on 
previously identified cryopreservation issues detailed above. These functional metrics 
include attachment, actin alignment, RNA expression, and DNA hydroxymethylation.   
 
8.2 Methods 
Culture, freezing, and thawing of cells was performed according to the same methods 
referenced in Chapter 6.  Algorithm optimization was performed with cells in vials 
according to section 3.13, using cell attachment as a functional return metric.  Optimized 
solutions identified by algorithm iteration were frozen with cells and analyzed post-thaw 
for attachment and proliferation according to section 3.14, senescence according to 
section 3.6, flow cytometry according to section 3.7, actin alignment according to section 
3.15, multi-lineage differentiation according to section 3.16, DNA hydroxymethylation 
according to section 3.17, and gene expression according to section 3.18.  Rebekah 
Samsonraj helped design primers, helped perform qRT-PCR, and performed DNA 
hydroxymethylation dot blotting.    
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8.3 Results 
8.3.1 Algorithm optimization  
Algorithm optimization was performed for three different combinations of sugars, sugar 
alcohols, and small molecule additives and identified concentrations of components in 
solution which, when combined with cells, resulted in maximum cell attachment at 2 
hours post-thaw/seeding.  Figure 23 shows a representative generational progression of 
the algorithm for a solution of sucrose/glycerol/isoleucine (SGI).   
 
 
Over multiple generations, the recovery of live cells increases, and the percentage of 
those recovered cells that are able to attach to a surface also increases.   The optimums 
identified for three separate iterations of the algorithm using different components in 
solution are listed in Table 13. 
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Figure 23: Recovery and attachment of cells during algorithm optimization of SGI solution. 
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Table 13: Optimized solution compositions. 
Solution (vector) Sugar Sugar alcohol Additive 
SGC (025) Sucrose 
(0mM) 
Glycerol 
(1.25%) 
Creatine 
(25mM) 
SGI (151) Sucrose 
(30mM) 
Glycerol 
(5%) 
Isoleucine 
(7.5mM) 
SMC (322) Sucrose 
(150mM) 
Mannitol 
(62.5mM) 
Creatine 
(6.25mM) 
 
The optimum solution formulations listed in Table 13 were combined with cells and 
tested for attachment and recovery using statistical triplicates of biological replicates.  
Figure 24 shows that samples frozen in experimental solutions have different attachment 
and recovery behavior.  High performing combinations, such as SGI, display recovery 
and attachment that is not statistically different (p>0.05) from fresh cells and DMSO 0hr 
incubation frozen samples. Other experimental combinations including SGC and SMC 
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Figure 24: Optimized solution performance.  Algorithm optimized solutions were combined with cells 
and assessed for recovery and attachment at 2hrs post thaw. 
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displayed significantly worse recovery (p<0.05) compared to fresh samples, but had 
attachment values that approached their total recovery.   
 
Conversely, extended pre-freeze DMSO incubation did not reduce cell recovery, but 
significantly reduced the attachment of cells. This diminished attachment behavior 
appears to correlate with increasing pre-freeze DMSO incubation time (Figure 25) and 
this diminished attachment potential is still present in cells incubated with DMSO that do 
not undergo freezing (Figure 24). 
 
8.3.2 MSC characterization 
Both fresh and frozen H9 MSCs showed normal expression of positive (CD73, CD90, 
CD105) and negative (CD45) markers, summarized in Table 14 below, and were within 
the release thresholds for clinical samples.  Freezing with DMSO and with experimental 
solutions did not change the expression of these markers significantly.  
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Figure 25: DMSO recovery and attachment as a function of pre-freeze incubation time. 
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Table 14 MSC surface marker expression 
 
Fresh SMC SGC SGI DMSO 0Hr 
CD105 (+) 99.9% 99.9% 99.8% 99.6% 99.6% 
CD90 (+) 99.9% 99.9% 99.8% 99.6% 99.6% 
CD73 (+) 99.8% 99.8% 99.6% 99.7% 99.9% 
CD45 (-) <1% <1% <1% <1% <1% 
 
Cells displayed normal multi-lineage differentiation in all samples, as shown in Figure 
26.  Micromass cultures treated with chondrogenic differentiation media all showed 
characteristic blue color after staining with Alcian blue, indicating that these cultures 
accumulated proteoglycans appropriately.  Cell monolayers treated with osteogenic 
differentiation media all showed characteristic red color after staining with Alizarin red, 
indicating these cultures accumulated calcium deposits appropriately. 
 
Figure 26 Multilineage differentiation staining of MSCs. Error bars in 10X images = 100µm 
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Analysis of proliferation (Figure 27) showed that proliferative capacity was maintained in 
SGI samples and was similar to both fresh and DMSO frozen samples, but was slightly 
reduced in SMC and SGC samples based on the reduced slope of their growth curves 
between 2hrs and 24hrs.   
 
Senescence (Figure 28) did not vary significantly between samples.  There were slight 
differences in senescence per cell at 2hrs, and these differences were reduced after 24hrs. 
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Figure 27: Proliferation of MSCs.  Total cells were calculated from hemocytometer counts before 
freezing (seeding) and immediately after freezing (0hr), as well as from plate reader fluorescence 
values at 2hrs and 24hrs after thawing and plating.  Values were normalized to initial seeding 
counts. 
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Figure 28: Senescence of MSCs.  Beta-glo luminescence values and calcein fluorescence 
values from two identical plates were used to calculate luminescence/fluorescence, 
representing relative senescence per cell. 
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All samples showed significantly lower senescence than the positive control t-BHP  
treated cells.  
 
8.3.3 Actin alignment analysis  
MSCs cryopreserved in DMSO have demonstrated reduced engraftment, and this has 
been correlated to a disruption of the actin cytoskeleton[67, 68, 74]. Actin alignment in 
fresh low passage MSCs tends to be unidirectional (Figure 29A), with a majority of fibers 
oriented in a single direction along the axis of the cell as it undergoes extension. Visually, 
experimentally frozen cells (Figure 29B) more closely resemble fresh cells, while DMSO 
frozen cells (Figure 29C) have disrupted actin alignment.   
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Figure 29: Actin images and representative histograms.  Actin images represent (A) Fresh cells, (B) 
SGI frozen cells, and (C) DMSO 1hr frozen cells.  Representative images from a (D) highly aligned cell 
from image A and a (E) poorly aligned cell from image C show that binned fiber alignment angle 
histograms for highly aligned cells have lower standard deviation and higher peak strength than fiber 
alignment angle histograms for poorly aligned cells. 
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A quantitative analysis of fiber alignment was performed for fresh and frozen samples by 
isolating fibers in Matlab, and binning each fiber alignment angle into a histogram.  For 
highly aligned cells, this fiber alignment histogram has a clear peak (Figure 29D), while 
poorly aligned cells have no discernable peak (Figure 29E) with comparatively lower 
standard deviation and peak strength (peak strength = highest/lowest binned histogram 
value).   
 
 
 
 
 
 
 
 
 
 
Me
dia
 0h
r f
res
h
DM
SO
 1h
r f
res
h
Me
dia
 1h
r f
res
h
SM
C
SG
C
SG
I
DM
SO
 1h
r
DM
SO
 0h
r
0
1
2
3
4
5
Pe
ak
 S
tre
ng
th
Peak strengthA B 
C 
* 
* 
* 
Me
dia
 0h
r f
res
h
DM
SO
 1h
r f
res
h
Me
dia
 1h
r f
res
h
SM
C
SG
C
SG
I
DM
SO
 1h
r
DM
SO
 0h
r
40
45
50
St
an
da
rd
 D
ev
ia
tio
n
Standard Deviation
* 
* * 
* * 
Me
dia
 0h
r f
res
h
DM
SO
 1h
r f
res
h
Me
dia
 1h
r f
res
h
SM
C
SG
C
SG
I
DM
SO
 1h
r
DM
SO
 0h
r
0
5000
10000
15000
20000
C
el
l a
re
a 
(µ
m
2 )
Cell Area
* 
* 
Figure 30: Quantitative actin alignment histogram analyses. (A) Peak strength (histogram 
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The average peak strength (Figure 30A) and standard deviation (Figure 30B) for 90 
individual cells were not statistically different between SMC, SGC, SGI samples and 
fresh samples, but were significantly worse for SMC and DMSO frozen samples 
regardless of incubation time.  Additionally, the average cell size (Figure 30C) was 
significantly reduced for DMSO frozen cells compared to fresh samples, while and 
experimentally frozen samples were not significantly different from fresh.   
 
8.3.4 qRT-PCR- Gene expression analysis 
H9-MSCs subjected to different freezing approaches were assayed immediately post-
thaw for the expression of genes related to trophic factor secretion such as HGF, VEGF, 
FGF-2, CXCL12 (SDF-1α), mesodermal lineage markers TWIST1, TWIST2 
(DERMO1), MSX2, anti-apoptotic marker BCL-2, surface markers for cell adhesion such 
as CD106 and CD54, the osmotic regulator marker GAL-1, and stress-response markers 
such as EGR1 and NFE2L2 (NRF2). The gene expression data for these genes is 
summarized in Figure 32.  These data show that the levels of HGF, an anti-scarring and 
anti-apoptotic factor, showed no differences between different freezing treatments and, as 
expected, the fresh media 0hr control showed the highest level of HGF expression. 
Similarly, different freezing conditions did not appear to have any marked effects in the 
expression of VEGF or FGF-2. In particular, FGF-2 levels were maintained at the same 
levels in all groups of H9 MSCs.  
 
In a similar fashion, the expression levels of the mesodermal gene TWIST1 showed no 
significant variation between groups. On the other hand, the expression of TWIST2 was 
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elevated in almost all of the frozen groups (SMC, SGI, and DMSO freezing for 1 hour) 
except for SGC, which presented TWIST2 transcript levels comparable to fresh samples. 
Likewise, when comparing fresh and frozen samples, MSX2 levels were upregulated in 
all the frozen groups with no significant differences between freezing treatments.  
 
H9-MSCs in fresh media showed no upregulation in CXCL12 gene expression. However, 
for frozen SMC and DMSO 1hr conditions, the levels were significantly higher. On the 
other hand, SGC did not affect CXCL12 expression and showed levels similar to that of 
fresh/unfrozen cells.  
 
SMC, SGC and SGI treatments showed comparably high levels of GAL expression 
immediately post-thaw. Likewise, the expression of BCL-2, an apoptotic marker, showed 
a similar pattern in which frozen sample groups displayed higher BCL-2 expression than 
fresh cells. 
 
The gene expression levels of MSC surface markers CD106 and CD54 for VCAM1 and 
ICAM1 were also evaluated. Both markers were present in H9-MSCs frozen with SMC, 
SGC and SGI, suggesting that the MSC adhesion molecule phenotype was not negatively 
altered for non-DMSO freezing conditions.  
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Figure 31: Gene expression profiles for H9 MSCs immediately post-thaw. 
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This study also included the assessment of stress-response genes such as EGR1 and 
NFE2L2. Intriguingly, EGR1 levels were highly expressed in the fresh media 1hr group 
and were significantly lower in the fresh 1hr DMSO incubated samples and in all frozen 
groups. The expression of NFE2L2 was uniformly similar among all the treatment groups 
and was not affected by different freezing methods. 
 
8.3.5 Epigenetics - DNA hydroxymethylation 
Visual inspection of DNA hydroxymethylation dot blotting (Figure 33A) shows that as 
predicted, the control fresh media 0hr incubation state displays the lightest staining and 
thus the lowest degree of hydroxymethylation.  The darkest dots appear for SMC and 
DMSO 1hr (fresh and frozen) incubated samples.  This indicates that extended incubation 
in these solutions causes increases in DNA hydroxymethylation, and that these epigenetic 
changes may be responsible for some of the negative functional behavior observed for 
these conditions.  
 
Quantification of these dot-blots (Figure 33B) shows that only SMC frozen samples 
exhibit statistically significantly higher DNA hydroxymethylation than fresh media 0hr 
control cells (p<0.05).  None of the other samples showed hydroxymethylation 
significantly higher than fresh controls.  
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Figure 32: Dot blotting for DNA hydroxymethylation. (A) Representative dot blot 
of one of the three biological triplicates performed. Darker dots indicate greater 
DNA hydroxymethylation. (B) Quantified DNA hydroxymethylation results, scaled 
for dilution linearity within each biological replicate, normalized to Media 0hr fresh, 
and averaged for three biological replicates. SMC was the only sample significantly 
different from Media 0hr fresh (p<0.05). 
* 
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8.4 Discussion 
MSCs are known to exhibit impaired function after cryopreservation in DMSO, and 
systematic algorithm optimization of non-DMSO freezing solutions may result in more 
functional post-thaw cell products. Care must be taken to rationally select a return metric 
for the algorithm that optimizes crucial post-thaw cellular potency characteristics.  In this 
case, cryopreserved MSCs have shown impaired homing and engraftment potential[163] 
that may be related to cytoskeletal structural problems[74], and selecting attachment as a 
return metric ensures that the optimized solution will at least partially promote healthy 
cytoskeletal assembly and function.  This chapter confirms that functionality metrics such 
as attachment can be used for algorithm iteration as opposed to recovery, the metric used 
in Chapter 7. Using this strategy, both attachment and recovery improved with increasing 
generations, and resulted in more functional post thaw cells as confirmed by the 
additional functionality testing performed in this chapter.   
 
The attachment and recovery of cells frozen in optimized SGI solutions were similar to 
the attachment and recovery observed for fresh and DMSO 0hr frozen samples.  
Recovery was lower in SMC and SGC samples, indicating that the maximum recovery 
possible differs for optimized solutions containing different components.  However, the 
differences between attachment and recovery were low for all experimental solutions, 
whereas samples incubated with DMSO for at least 1 hour exhibited a significant 
reduction in attached cells.  This indicates that total recovery observed post-thaw for 
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experimental solutions may better reflect their functional capacity vs. DMSO incubated 
cells. 
 
Cells were evaluated for well-accepted minimal characterization criteria[18] post-thaw to 
determine if freezing in experimental solutions altered fundamental aspects of cellular 
identity.  Cell surface marker expression and differentiation did not differ markedly 
between any fresh or frozen samples.  Additionally, proliferation was not substantially 
reduced in cells frozen in experimental vs. fresh cells.  The doubling rate was slightly 
lower in SMC and SGC samples between 2 and 24 hours post-thaw, and this may be 
reflective of the poor recovery (and increased dead cells present) in those samples post-
thaw.  These dead cells may release cytokines, or other cellular stress products that 
negatively impact proliferation. Cumulatively, these results are consistent with work by 
other groups that shows cryopreservation does not negatively impact MSC surface 
marker expression, differentiation, or proliferation [129–131, 164]. 
 
Senescence was not significantly different between frozen and fresh samples, and all 
conditions were significantly lower than a positive control induced for senescence via t-
BHP treatment.  Elevated senescence in some samples at 2hrs post-thaw followed by a 
reduction at 24 hours may indicate a transient stress response.  This phenomenon could 
be explained by a reversal of the senescent state or a drowning out/reduction of the 
senescent signal due to proliferation of non-senescent cells in the population, and is 
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similar to the senescence trends observed in cells immediately and 48 hours post-thaw in 
Chapter 4.   
 
Poor actin alignment/assembly is a known problem associated with MSC freezing in 
DMSO, and is suspected to correlate with poor homing and engraftment of these cells 
post-thaw[123].  An analysis of actin alignment in both fresh and frozen cells shows that 
DMSO incubation, and not freezing in general, may be responsible for this altered 
cytoskeletal behavior.  The reduced peak strength and standard deviation of binned actin 
fiber alignment angle in DMSO frozen samples may also play a role in the differences in 
cell area observed in these cells. Reduced actin alignment can result in reduced cellular 
extension, leading to reduced cell area. This altered cellular morphology may also 
influence gene expression, affecting functional behavior downstream of that expression. 
 
The genes analyzed in qRT-PCR were selected from recent literature summarizing 
functionality and potency recommendations including a recent ISCT review[165], and 
previous work by Samsonraj et al[155].  This panel included genes for growth factors, 
adhesion molecules, transcription factors, chemokines, and stress genes. All genes were 
compared to a GAPDH internal control, and the additional AKT1 internal housekeeping 
control confirms that the total amount of seeded RNA was similar for all samples.  
Trophic factors such as HGF, VEGF, and FGF-2, which share anti-apoptotic properties, 
did not show significant differences between frozen samples.  HGF, an important 
proliferation and migration regulating molecule[166], exhibited reduced expression in all 
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samples compared to a fresh 0hr control.  This implies that cellular challenges including 
room temperature incubation and freezing may reduce proliferative cell fitness.  
However, this phenomenon was observed in all frozen samples, indicating that 
experimentally frozen cells are no worse than DMSO frozen cells in this regard.  
Additionally, FGF-2 did not show differences between fresh or frozen samples. Based on 
this data, experimentally frozen cells do not show a reduction in angiogenic or anti-
apoptotic fitness in vitro immediately post-thaw compared to currently available 
alternatives such as DMSO. 
 
Comparatively, mesodermal lineage markers TWIST-1, TWIST-2, and MSX-2 exhibit 
upregulated expression in frozen samples compared to fresh.  Similar to the trophic genes 
above, these differences are consistent between experimental and DMSO freezing, 
indicating that experimental solutions did not have detrimental effects on mesodermal 
marker expression compared to current DMSO freezing.   These gene expression effects 
may be transient, as differentiation potential was maintained in all samples post-thaw as 
evidenced by the differentiation results presented in Figure 26. 
 
The chemokine CXCL12 (SDF-1α) is secreted by MSCs in response to tissue injury 
and/or inflammation. For frozen SMC and DMSO 1hr conditions, the levels of CXCL12 
were significantly higher, suggesting that SMC and DMSO treatments may create an 
adverse inflammatory environment in vitro, which the MSCs respond to by preparing to 
secrete CXCL12. It is interesting to note that CXCL12 expression for SMC freezing was 
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higher than for 0hr DMSO freezing, indicating that SMC freezing may have stronger 
negative effects on MSCs than current DMSO freezing protocols, contraindicating its use 
as a replacement for DMSO.  However, other stress response genes EGFR1 and NFE2L2 
were similar or reduced for all frozen samples compared to fresh media 0hr controls, 
indicating that experimental freezing did not significantly alter the stress state of the cell.  
 
The GAL (galanin) gene plays a role in osmotic regulation in cells and was found to be 
upregulated in MSCs subjected to experimental freezing conditions.  Expression of the 
anti-apoptotic marker BCL-2, and cell surface adhesion molecules CD106(VCAM1) and 
CD54 (ICAM1) showed similar trends.  These patterns are a promising indication that 
transcription of genes responsible for protecting different areas of the cell (including 
osmotic regulation, apoptosis and cell adhesion) during freezing is upregulated for 
experimental solutions, but not for DMSO.   The differences in expression of the cell 
surface adhesion molecules observed here may also help explain the downstream 
attachment and actin alignment differences observed between experimentally and DMSO 
frozen cells. 
  
DNA hydroxymethylation results indicated that as expected, fresh media 0hr control cells 
had the lowest levels of epigenetic alteration.  The only sample that exhibited 
significantly higher hydroxymethylation than the fresh 0hr control was SMC, although 
both 1hr incubated fresh and frozen DMSO samples had visibly darker dot blots than 
SGC and SGI samples in all three biological replicates.  Because the darkness trends for 
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all other samples remained consistent vs. fresh media 0hr controls, the large error bars 
present are likely due to the semi-quantitative nature of the assay and subsequent 
analysis.    
 
8.5 Conclusion 
This chapter shows that algorithm can be iterated for functionality metrics including 
attachment.  Cells frozen in algorithm optimized solutions exhibited similar post-thaw 
minimal functionality criteria, including cell surface marker expression, differentiation, 
and proliferation.  Senescence was not markedly different between fresh and frozen 
samples post-thaw, and was significantly lower than positive control t-BHP treated 
samples.  Experimentally frozen cells exhibited significantly better attachment than 1hr 
incubated DMSO fresh and frozen cells, and significantly better actin alignment 
according to peak strength and standard deviation analysis of fiber angle distribution 
histograms.  Fresh and experimentally frozen cells were also significantly larger than 
DMSO frozen cells.  RNA expression of most genes was not significantly different 
between frozen samples, but was upregulated in experimental samples for cell adhesion 
surface markers (CD106, CD54), osmotic regulation (GAL), and anti-apoptosis (BCL-2) 
genes.  DNA hydroxymethylation results showed no significant differences between 
samples apart from SMC, which was significantly higher than the fresh media 0hr 
control.   
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This chapter confirms that non-DMSO experimental solutions can be used to freeze cells 
effectively to preserve recovery, and results in maintenance or improvement of post-thaw 
function compared to DMSO frozen samples.
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Chapter 9 
Conclusions/Future Work 
9.1 Conclusions 
The replacement of DMSO as a cryoprotective is a necessary future step for some 
transfusion therapies.  This research proposed to eliminate DMSO for the 
cryopreservation of MSCs, and to fulfill this goal we hypothesized that: 
A combination of non-DMSO cryopreservative agents will act in concert to maintain 
cellular viability and function throughout the freezing process.  
We confirmed this hypothesis by fulfilling the following aims in Chapters 5-8.  
Aim 1 – Identify combinations of solution components likely to result in high post-
thaw cell recovery, and establish potential mechanisms of cryo-protection for these 
combinations.   
Aim 1.1 –Identify solution combinations most likely to result in high post-thaw cell 
recovery. 
In Chapter 5, candidate solutions that included compounds from several cryoprotective 
categories were screened to identify compositions that maximized recovery in cells after 
undergoing freezing and thawing. This chapter directly tested the hypothesis that 
combinations of compounds are capable of protecting cells during cryopreservation by 
comparing 1, 2, and 3 component solutions.  Constant concentrations of components 
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from each molecule family were incubated with cells and subsequently frozen in 96 well 
plates at different cooling rates. Thawed cells in these solutions were evaluated for 
recovery and analyzed statistically to determine which combinations maximized cellular 
viability and recovery post-thaw.  Findings from this chapter include that selection of 
cooling rate and sugar in solution appears to predict solution recovery more strongly than 
either alcohol or additive.  Additionally, 2 and 3 components outperformed single 
component solutions across the board, especially when they included a sugar.  Due to the 
high performance of sucrose at 3°C/min, this cooling rate was selected for future use in 
Chapters 6 and 8.  The experiments presented in Chapter 5 fulfill Aim 1.1. 
Aim 1.2 – Identify mechanisms of cryoprotection for multicomponent solutions 
In Chapter 6, solutions containing Sucrose/Glycerol/Creatine and 
Sucrose/Mannitol/Creatine (components identified as promising combinations in Chapter 
5/Aim 1.1) were combined with cells and evaluated to determine the mechanisms by 
which they protect cells during cryopreservation. Incubation time, osmolarity, component 
distribution in the frozen state, physical changes during freezing, and component 
specificity were evaluated to determine which elements of solution behavior are 
important to consider when performing optimization. Important findings from Chapter 6 
include that incubation time must be sufficient for penetration of all components included 
in solution to maximize recovery, concentration of components (not total osmolarity) 
determines recovery, and molecular substitution of monosaccharides to replace 
disaccharides results in a reduction in recovery.  We hypothesize that these differences 
are biological, as we have found no evidence of physical changes in ice crystal formation 
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between different solutions with similar osmolarity.  Ultimately, these observations 
increase our understanding of multicomponent solution behavior, and fulfill Aim 1.2.  
 
Aim 2 - Establish and validate differential evolution algorithm for predictive 
optimization of solution components, concentrations, and freezing rates. 
In Chapter 7, we validated that the DE algorithm could be used to optimize 3-5 
component solutions, with or without including cooling rate as an optimization variable. 
High throughput 96-well plate experiments were performed using MSCs and Jurkats as a 
model cell type, and recovery was iterated to the algorithm as the return metric for the 
cost function.  Optimized solution concentrations were converged upon within 6-9 
generations, and confirm that optimums can be identified using a DE algorithm with 
significantly fewer experiments than traditional factorial strategies. High throughput 
liquid handling experiments were performed to screen all potential combinations at a 
single cooling rate, and verify that the optimum identified by the algorithm was indeed 
the optimum of the system.  These experiments validated that the algorithm can be used 
for predictive optimization of cryopreservation solutions, and fulfill Aim 2. 
 
Aim 3 – Iterate algorithm to optimize cryopreservation solutions for MSCs, and 
confirm optimized solutions maintain cellular function post-thaw. 
In Chapter 8, MSCs were optimized for attachment (a functional metric) in solutions of 
SMC, SGC, and SGI.  The optimized solution compositions resulting from algorithm 
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iteration were frozen with cells and evaluated for additional post-thaw functionality 
metrics including attachment, proliferation, senescence, cell surface marker expression, 
multi-lineage differentiation capacity, cytoskeletal alteration, changes in RNA 
expression, and epigenetic changes. These functional characteristics were compared 
between cells frozen in experimental solutions, fresh cells, non-frozen cells incubated 
with DMSO, and cells frozen with traditional 10% DMSO. These comparisons were used 
to determine if freezing, DMSO incubation, or a combination of the two is responsible for 
the current changes observed in functionality for DMSO frozen cells.  
Important findings from Chapter 8 include that experimentally frozen cells exhibited 
significantly better attachment than 1hr incubated DMSO fresh and frozen cells, and 
significantly better actin alignment according to analysis of fiber angle distribution 
histograms. Additionally, RNA expression was upregulated in experimental samples for 
cell adhesion surface markers, osmotic regulation, and anti-apoptosis genes.  Other 
functional characterization metrics showed little difference between experimental and 
DMSO frozen samples.  Chapter 8 experiments fulfill Aim 3. 
 
In addressing these specific aims, we have found that it is possible to optimize non-
DMSO cryopreservation of MSCs using an evolutionary algorithm, and that the cells 
resultant from freezing in multicomponent solutions display functional behavior that is 
maintained or improved compared to DMSO freezing.  However, additional testing is 
necessary to validate these solutions as replacements for DMSO in cell therapy 
cryopreservation.   
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9.2 Future Work 
Before the results of this research can be translated into clinical cell therapies, additional 
in vitro, in vivo, and clinical studies should be performed to validate the functionality and 
effectiveness of cells frozen in these solutions. Additionally, this optimization platform 
and strategy can be applied to other applications. 
 
9.2.1 Validation and clinical application of current therapies 
The research described in chapters 5-8 was performed using H9 MSCs, a clonal culture 
cell line of embryonic stem cell derived Mesenchymal stem cells.  This decision was 
made due to the high variability in behavior between MSC samples from other sources, 
as shown in Chapter 4. H9 MSCs were selected for optimization experiments to eliminate 
this variability and make batch-to-batch comparisons possible. However, it is important 
to evaluate whether cryopreservation results from H9 MSC experiments are translatable 
to clinical sources of MSCs that would be used for patient cell therapy.  Work is currently 
underway in the Hubel lab to characterize the response of Bone marrow derived MSCs to 
freezing in solutions optimized for H9-MSCs, and these cells are being evaluated for the 
same post-thaw functionality characteristics described in Chapter 8.  
 
The work here comprises single cell type studies.  In order to better evaluate the 
physiological fitness of MSCs cryopreserved in experimental solutions, additional multi 
cell-type studies should be performed.  MSCs are known to modulate the immune system 
by inhibiting t-cell proliferation, and there are established assays to evaluate MSC 
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inhibition of t-cell proliferation in vitro.  Briefly, cryopreserved and control MSCs can be 
co-cultured with different ratios of peripheral blood mononuclear cells (PBMCs, t-cells) 
to determine the level of proliferation inhibition that results[10]. MSCs with higher 
fitness can more effectively inhibit t-cell proliferation.  
 
The experimental solutions optimized in Chapter 8 showed significant improvements in 
actin alignment and increases in cell surface adhesion molecule expression compared to 
cells frozen in DMSO. In order to determine if these in vitro characteristics correlate to in 
vivo improvements, murine studies should be performed to evaluate the migration and 
engraftment potential of these cells in an animal model.  Mouse models have been used 
previously by other groups to evaluate the bio distribution of DMSO frozen cells[74].  
Briefly, human MSCs with varying fitness (fresh, experimentally frozen, or DMSO 
frozen conditions) would be injected into mice intravenously via the tail vein.  If 
migration and engraftment fitness are high, the cells should be capable of engrafting into 
the mouse lung tissue, and if fitness is low, human cells will be cleared from the system 
after failing to engraft.  After 24 hours, lung tissue from the sacrificed mice can be 
processed to quantify the level of human DNA present, and thus determine the relative 
success of engraftment for various freezing conditions.  
 
If these co-culture and in vivo studies show that the experimental freezing solutions 
we’ve optimized in Chapter 8 display sufficient fitness, continued clinical translation 
might be indicated.  Solution components used in Chapter 8 are available as cGMP 
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products, and the concentrations present in Chapter 8 solutions are at or below the 
concentrations listed by the FDA for non-active ingredients in currently approved 
products.  The Dietz research group at Mayo hospital has identified groups of patients 
with advanced Crohn’s disease and fistulas that are not eligible to receive current DMSO 
cryopreserved MSC treatments due to the negative DMSO interactions predicted to occur 
upon transfusion.  This group represents a patient population that would benefit from 
compassionate care studies using cells cryopreserved in our non-DMSO solutions, as they 
have exhausted other treatment options.  
 
9.2.2 Alternative application of optimization strategy  
Thus far, we have utilized the DE algorithm to optimize 3-5 component solutions.  We 
have limited the composition of solutions to include a single sugar, a single sugar alcohol, 
and 1-3 small molecule additives.  The components that have undergone screening are 
summarized in Chapter 4 (Table 8), and represent a limited selection of molecules from 
each of these categories.  In the future, additional molecules from each of these categories 
should be screened, and different combinations of these molecules should also be 
evaluated.  For example, we have seen enhanced effectiveness in solutions that contain 
high levels of sugar alcohols, and it would be interesting to see whether solutions that 
include multiple sugar alcohols in solution exhibit improvements in freezing 
performance.   
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We have applied the DE optimization algorithm to a limited number of cell types, 
including Jurkats, a model lymphocyte suspension cell, and H9 MSCs.  Now that the 
algorithm platform is well established, it would be straightforward to apply algorithm 
optimization to other cryo-sensitive cell types.  Other cell types including 
cardiomyocytes, t-cells, natural killer cells, and iPS cells display high levels of cell death 
or impaired post-thaw cell function following cryopreservation with DMSO.  Algorithm 
optimization of non-DMSO solutions or DMSO containing solutions may produce cells 
with improved post-thaw recovery or fitness.   
 
The experiments performed in this work and experiments performed in the future will 
improve our understanding of cell responses during the cryopreservation process. 
Superior solutions identified through optimization can improve the fitness of 
cryopreserved cells, improve the quality and availability of treatments, and ultimately, 
improve patient care. 
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Appendix 
 
A.1 Chapter 7 raw algorithm data  
Emergent population data is presented here, including vectors for each solution 
composition used.  Corresponding solution concentrations and cooling rates for each 
vector are located in Table 12.  Cells highlighted in yellow indicate improvement when 
compared head to head vs the same slot in the previous generation. 
 
A.1.1 Jurkat single cooling rate TGE recovery algorithm raw emergent population data 
from Figure 18 
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Improved solutions Generation Emergent population Recovery Trehalose Glycerol Ectoine
1 0.259 0 5 4
2 0.033 2 2 2
3 0.188 1 3 3
4 0.201 4 4 3
5 0.147 2 4 3
6 0.295 2 5 5
7 0.021 3 3 3
8 0.099 1 1 2
9 0.187 1 5 1
10 0.031 1 1 1
11 0.025 2 1 5
12 0.022 2 1 5
13 0.027 5 2 0
14 0.050 1 2 3
15 0.021 1 3 4
16 0.025 1 0 1
17 0.023 1 2 3
18 0.024 0 1 4
1 0.259 0 5 4
20 0.170 2 4 4
3 0.188 1 3 3
4 0.201 4 4 3
5 0.147 2 4 3
24 0.333 4 5 3
25 0.271 4 5 5
8 0.099 1 1 2
9 0.187 1 5 1
28 0.191 3 4 2
29 0.173 0 4 4
30 0.027 3 3 5
31 0.146 2 5 3
14 0.050 1 2 3
33 0.125 4 4 2
34 0.040 4 2 4
35 0.152 2 4 5
36 0.128 2 4 5
1 0.259 0 5 4
38 0.231 2 5 3
3 0.188 1 3 3
40 0.278 5 5 4
5 0.147 2 4 3
24 0.333 4 5 3
25 0.271 4 5 5
44 0.116 4 4 5
9 0.187 1 5 1
46 0.221 5 5 0
47 0.194 0 5 4
48 0.212 5 5 3
31 0.146 2 5 3
50 0.195 2 4 2
51 0.162 2 5 1
34 0.040 4 2 4
53 0.218 5 5 5
36 0.128 2 4 5
JURKAT CELLS
18 0
11 1
9 2
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Improved solutions Generation Emergent population Recovery Trehalose Glycerol Ectoine
1 0.259 0 5 4
56 0.265 3 5 5
3 0.188 1 3 3
40 0.278 5 5 4
5 0.147 2 4 3
24 0.333 4 5 3
61 0.272 5 5 2
62 0.289 5 5 5
9 0.187 1 5 1
64 0.231 5 5 1
65 0.198 1 5 5
48 0.212 5 5 3
31 0.146 2 5 3
68 0.209 5 5 2
51 0.162 2 5 1
70 0.194 4 5 4
53 0.218 5 5 5
36 0.128 2 4 5
73 0.263 4 5 5
74 0.277 3 5 5
75 0.274 4 5 4
40 0.278 5 5 4
77 0.161 2 5 1
24 0.333 4 5 3
61 0.272 5 5 2
62 0.289 5 5 5
81 0.294 4 5 1
64 0.231 5 5 1
65 0.198 1 5 5
48 0.212 5 5 3
85 0.159 3 5 3
68 0.209 5 5 2
87 0.171 4 5 4
70 0.194 4 5 4
53 0.218 5 5 5
90 0.251 3 5 5
JURKAT CELLS
7 3
8 4
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Improved solutions Generation Emergent population Recovery Trehalose Glycerol Ectoine
73 0.263 4 5 5
74 0.277 3 5 5
75 0.274 4 5 4
40 0.278 5 5 4
95 0.165 4 5 0
24 0.333 4 5 3
61 0.272 5 5 2
62 0.289 5 5 5
81 0.294 4 5 1
64 0.231 5 5 1
65 0.198 1 5 5
48 0.212 5 5 3
85 0.159 3 5 3
68 0.209 5 5 2
87 0.171 4 5 4
70 0.194 4 5 4
53 0.218 5 5 5
90 0.251 3 5 5
73 0.263 4 5 5
74 0.277 3 5 5
75 0.274 4 5 4
40 0.278 5 5 4
95 0.165 4 5 0
24 0.333 4 5 3
61 0.272 5 5 2
62 0.289 5 5 5
81 0.294 4 5 1
64 0.231 5 5 1
65 0.198 1 5 5
48 0.212 5 5 3
85 0.159 3 5 3
68 0.209 5 5 2
87 0.171 4 5 4
70 0.194 4 5 4
53 0.218 5 5 5
90 0.251 3 5 5
0 6
JURKAT CELLS
1 5
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A.1.2 Jurkat multiple cooling rate TGE recovery algorithm raw emergent population 
data from Figure 19 
 
 
Improved solutions Generation Emergent population Recovery Trehalose Glycerol Ectoine Cooling rate
1 0.273 4 5 0 5
2 0.012 3 0 1 3
3 0.237 5 5 0 5
4 0.000 5 2 4 0
5 0.139 2 5 4 5
6 0.022 3 0 5 5
7 0.118 4 4 4 2
8 0.000 3 1 4 0
9 0.015 1 0 0 4
10 0.000 4 1 5 0
11 0.012 2 2 4 4
12 0.013 1 2 2 3
13 0.189 4 4 1 4
14 0.008 3 0 0 2
15 0.030 5 2 3 1
16 0.041 4 1 3 4
17 0.000 5 5 3 0
18 0.010 0 1 5 1
19 0.010 4 1 5 2
20 0.008 1 1 3 2
21 0.068 2 4 3 3
22 0.082 5 1 4 4
23 0.000 2 3 0 0
24 0.000 3 4 5 0
25 0.009 3 2 0 2
26 0.055 0 4 1 3
27 0.012 0 3 1 3
28 0.291 5 5 0 5
29 0.031 3 3 1 4
30 0.312 5 4 1 5
31 0.023 5 3 1 1
5 0.139 2 5 4 5
33 0.070 5 1 2 3
7 0.118 4 4 4 2
35 0.245 5 4 2 4
36 0.074 3 4 0 4
37 0.021 2 3 2 3
38 0.054 2 4 1 4
39 0.052 0 5 2 3
13 0.189 4 4 1 4
41 0.188 5 4 2 2
42 0.093 2 4 1 2
43 0.144 5 1 1 5
44 0.012 4 2 4 1
45 0.069 2 4 1 3
46 0.106 2 4 4 3
47 0.021 3 2 0 4
48 0.146 4 4 4 3
22 0.082 5 1 4 4
50 0.020 3 3 3 2
51 0.096 3 5 1 3
52 0.231 5 4 0 4
53 0.124 3 4 1 4
54 0.026 1 0 0 4
0
123
27
JURKAT CELLS
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Improved solutions Generation Emergent population Recovery Trehalose Glycerol Ectoine Cooling rate
28 0.291 5 5 0 5
56 0.084 5 1 0 4
30 0.312 5 4 1 5
58 0.099 5 3 1 4
59 0.161 5 4 1 4
60 0.123 5 1 5 5
61 0.187 5 5 1 4
35 0.245 5 4 2 4
36 0.074 3 4 0 4
64 0.157 5 4 1 4
38 0.054 2 4 1 4
39 0.052 0 5 2 3
13 0.189 4 4 1 4
68 0.205 2 4 5 5
69 0.111 5 4 1 2
70 0.237 5 4 1 5
71 0.052 5 3 3 3
45 0.069 2 4 1 3
73 0.217 5 5 2 5
74 0.047 3 4 0 4
48 0.146 4 4 4 3
76 0.258 5 4 1 5
77 0.025 4 2 0 4
51 0.096 3 5 1 3
52 0.231 5 4 0 4
53 0.124 3 4 1 4
54 0.026 1 0 0 4
28 0.291 5 5 0 5
83 0.168 5 4 0 5
30 0.312 5 4 1 5
85 0.146 4 4 1 5
59 0.161 5 4 1 4
87 0.141 5 4 2 3
61 0.187 5 5 1 4
35 0.245 5 4 2 4
90 0.092 5 1 4 5
91 0.169 5 5 1 5
92 0.068 3 4 0 4
39 0.052 0 5 2 3
13 0.189 4 4 1 4
68 0.205 2 4 5 5
69 0.111 5 4 1 2
70 0.237 5 4 1 5
98 0.195 5 4 0 5
99 0.094 3 5 2 5
73 0.217 5 5 2 5
101 0.120 5 3 0 5
48 0.146 4 4 4 3
76 0.258 5 4 1 5
104 0.069 5 3 2 5
51 0.096 3 5 1 3
52 0.231 5 4 0 4
53 0.124 3 4 1 4
54 0.026 1 0 0 4
2
3
JURKAT CELLS
12
9
  146 
 
 
 
Improved solutions Generation Emergent population Recovery Trehalose Glycerol Ectoine Cooling rate
28 0.291 5 5 0 5
83 0.168 5 4 0 5
30 0.312 5 4 1 5
85 0.146 4 4 1 5
59 0.161 5 4 1 4
87 0.141 5 4 2 3
61 0.187 5 5 1 4
35 0.245 5 4 2 4
117 0.147 5 4 1 4
118 0.202 5 4 0 5
119 0.207 5 4 2 5
120 0.066 0 5 3 5
121 0.204 4 5 3 5
68 0.205 2 4 5 5
69 0.111 5 4 1 2
70 0.237 5 4 1 5
98 0.195 5 4 0 5
99 0.094 3 5 2 5
73 0.217 5 5 2 5
128 0.180 4 5 3 3
48 0.146 4 4 4 3
76 0.258 5 4 1 5
131 0.202 5 4 0 5
132 0.111 4 3 2 5
52 0.231 5 4 0 4
134 0.143 5 4 2 4
54 0.026 1 0 0 4
28 0.291 5 5 0 5
83 0.168 5 4 0 5
30 0.312 5 4 1 5
139 0.162 3 4 4 3
140 0.197 4 5 4 2
141 0.245 5 4 4 4
142 0.266 4 5 2 3
35 0.245 5 4 2 4
144 0.183 4 5 4 2
145 0.225 4 4 4 3
119 0.207 5 4 2 5
147 0.278 4 5 2 5
148 0.239 4 5 3 4
68 0.205 2 4 5 5
150 0.188 4 5 4 2
70 0.237 5 4 1 5
152 0.229 4 4 3 4
153 0.128 3 5 4 2
154 0.290 4 5 4 3
155 0.269 5 5 1 4
156 0.288 4 5 1 3
76 0.258 5 4 1 5
158 0.220 4 5 4 2
159 0.162 3 5 4 2
52 0.231 5 4 0 4
161 0.353 5 5 1 5
54 0.026 1 0 0 4
4
5
9
17
JURKAT CELLS
  147 
 
 
 
Improved solutions Generation Emergent population Recovery Trehalose Glycerol Ectoine Cooling rate
28 0.291 5 5 0 5
83 0.168 5 4 0 5
30 0.312 5 4 1 5
166 0.259 5 5 4 4
140 0.197 4 5 4 2
141 0.245 5 4 4 4
142 0.266 4 5 2 3
35 0.245 5 4 2 4
171 0.217 4 5 3 4
145 0.225 4 4 4 3
119 0.207 5 4 2 5
147 0.278 4 5 2 5
148 0.239 4 5 3 4
176 0.222 5 4 2 4
150 0.188 4 5 4 2
70 0.237 5 4 1 5
152 0.229 4 4 3 4
180 0.139 4 5 3 5
154 0.290 4 5 4 3
155 0.269 5 5 1 4
156 0.288 4 5 1 3
76 0.258 5 4 1 5
158 0.220 4 5 4 2
186 0.262 5 5 1 4
52 0.231 5 4 0 4
161 0.353 5 5 1 5
54 0.095 4 4 0 5
28 0.291 5 5 0 5
83 0.168 5 4 0 5
30 0.312 5 4 1 5
166 0.259 5 5 4 4
140 0.197 4 5 4 2
141 0.245 5 4 4 4
142 0.266 4 5 2 3
35 0.245 5 4 2 4
171 0.217 4 5 3 4
145 0.225 4 4 4 3
119 0.207 5 4 2 5
147 0.278 4 5 2 5
148 0.239 4 5 3 4
176 0.222 5 4 2 4
150 0.188 4 5 4 2
70 0.237 5 4 1 5
152 0.229 4 4 3 4
180 0.139 4 5 3 5
154 0.290 4 5 4 3
155 0.269 5 5 1 4
156 0.288 4 5 1 3
76 0.258 5 4 1 5
158 0.220 4 5 4 2
186 0.262 5 5 1 4
52 0.231 5 4 0 4
161 0.353 5 5 1 5
54 0.095 4 4 0 5
0
6
7
5
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A.1.3 MSC multiple cooling rates SEGA recovery algorithm raw emergent population 
data from Figure 21 
 
 
 
 
Improved solutions Generation Emergent population Recovery Sucrose EG Alanine Taurine Ectoine Cooling rate
1 0.2475 4 5 0 5 3 0
2 0.1197 1 3 5 5 0 5
3 0.1808 5 2 4 0 2 5
4 0.2077 4 5 3 0 5 5
5 0.1643 4 4 4 2 3 1
6 0.1789 4 0 1 0 0 4
7 0.1301 4 1 5 0 2 2
8 0.1801 4 4 1 2 2 3
9 0.2481 4 4 1 4 3 0
10 0.0691 0 2 5 2 3 1
11 0.1365 4 1 3 4 5 5
12 0.1533 3 0 0 1 5 1
13 0.1562 4 1 5 2 1 1
14 0.0734 3 2 2 4 3 3
15 0.1074 5 1 4 4 2 3
16 0.1365 0 0 3 4 5 0
17 0.0749 3 2 0 2 0 4
18 0.0305 1 3 0 3 1 3
19 0.1928 4 4 2 0 1 5
20 0.1005 0 4 3 5 0 2
21 0.1559 0 5 0 4 4 5
22 0.0394 0 2 1 4 2 5
23 0.0951 1 1 0 0 5 3
24 0.1149 3 0 5 3 2 3
25 0.0359 2 0 1 0 1 1
26 0.0756 2 0 5 5 2 2
27 0.1390 2 5 2 0 4 2
1 0.2475 4 5 0 5 3 0
29 0.1409 4 3 1 4 2 2
30 0.1907 5 5 1 0 2 5
4 0.2077 4 5 3 0 5 5
5 0.1643 4 4 4 2 3 1
6 0.1789 4 0 1 0 0 4
7 0.1301 4 1 5 0 2 2
8 0.1801 4 4 1 2 2 3
9 0.2481 4 4 1 4 3 0
10 0.0691 0 2 5 2 3 1
11 0.1365 4 1 3 4 5 5
39 0.2061 2 3 0 3 3 1
40 0.2718 4 4 2 1 4 0
41 0.1568 5 4 0 4 3 5
42 0.1497 5 4 2 2 1 3
16 0.1365 0 0 3 4 5 0
44 0.1825 5 5 0 3 0 3
45 0.1143 4 3 3 4 4 4
19 0.1928 4 4 2 0 1 5
47 0.2539 4 3 1 3 2 1
21 0.1559 0 5 0 4 4 5
49 0.1582 3 4 4 5 3 4
23 0.0951 1 1 0 0 5 3
51 0.2072 5 2 2 1 4 0
52 0.0545 2 0 1 0 1 1
53 0.1645 4 4 1 3 2 3
27 0.1390 2 5 2 0 4 2
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Improved solutions Gen Solution # Scaled raw recovery Sucrose EG Alanine Taurine Ectoine Cooling rate
1 0.2475 4 5 0 5 3 0
29 0.1409 4 3 1 4 2 2
57 0.2177 4 5 4 0 2 4
4 0.2077 4 5 3 0 5 5
5 0.1643 4 4 4 2 3 1
6 0.1789 4 0 1 0 0 4
7 0.1301 4 1 5 0 2 2
8 0.1801 4 4 1 2 2 3
9 0.2481 4 4 1 4 3 0
10 0.0691 0 2 5 2 3 1
65 0.1922 2 4 0 3 5 2
39 0.2061 2 3 0 3 3 1
40 0.2718 4 4 2 1 4 0
68 0.1753 5 4 2 2 1 3
42 0.1497 5 4 2 2 1 3
16 0.1365 0 0 3 4 5 0
44 0.1825 5 5 0 3 0 3
45 0.1143 4 3 3 4 4 4
19 0.1928 4 4 2 0 1 5
47 0.2539 4 3 1 3 2 1
75 0.2076 4 5 0 4 2 2
76 0.1932 4 5 2 4 5 2
23 0.0951 1 1 0 0 5 3
51 0.2072 5 2 2 1 4 0
52 0.0545 2 0 1 0 1 1
53 0.1645 4 4 1 3 2 3
27 0.1390 2 5 2 0 4 2
1 0.2475 4 5 0 5 3 0
29 0.1409 4 3 1 4 2 2
84 0.3575 3 5 2 0 3 4
4 0.2077 4 5 3 0 5 5
5 0.1643 4 4 4 2 3 1
6 0.1789 4 0 1 0 0 4
88 0.2035 3 4 2 3 4 0
8 0.1801 4 4 1 2 2 3
9 0.2481 4 4 1 4 3 0
91 0.0821 3 3 2 1 4 3
65 0.1922 2 4 0 3 5 2
39 0.2061 2 3 0 3 3 1
40 0.2718 4 4 2 1 4 0
95 0.1999 4 5 1 0 2 0
42 0.1497 5 4 2 2 1 3
16 0.1365 0 0 3 4 5 0
44 0.1825 5 5 0 3 0 3
99 0.2742 1 4 0 1 5 1
100 0.2406 3 4 1 0 2 5
47 0.2539 4 3 1 3 2 1
102 0.2410 4 5 0 3 3 1
76 0.1932 4 5 2 4 5 2
23 0.0951 1 1 0 0 5 3
51 0.2072 5 2 2 1 4 0
106 0.0982 1 1 0 0 4 1
107 0.3147 3 5 1 1 5 0
108 0.2190 4 5 0 3 4 1
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Improved solutions Gen Solution # Scaled raw recovery Sucrose EG Alanine Taurine Ectoine Cooling rate
1 0.2475 4 5 0 5 3 0
29 0.1409 4 3 1 4 2 2
84 0.3575 3 5 2 0 3 4
4 0.2077 4 5 3 0 5 5
113 0.2051 4 5 2 2 3 4
6 0.1789 4 0 1 0 0 4
88 0.2035 3 4 2 3 4 0
8 0.1801 4 4 1 2 2 3
9 0.2481 4 4 1 4 3 0
91 0.0821 3 3 2 1 4 3
65 0.1922 2 4 0 3 5 2
39 0.2061 2 3 0 3 3 1
40 0.2718 4 4 2 1 4 0
122 0.3553 4 5 1 0 2 2
42 0.1497 5 4 2 2 1 3
16 0.1365 0 0 3 4 5 0
44 0.1825 5 5 0 3 0 3
99 0.2742 1 4 0 1 5 1
100 0.2406 3 4 1 0 2 5
128 0.2810 3 5 1 2 3 0
102 0.2410 4 5 0 3 3 1
76 0.1932 4 5 2 4 5 2
23 0.0951 1 1 0 0 5 3
51 0.2072 5 2 2 1 4 0
133 0.1820 4 4 0 0 1 4
107 0.3147 3 5 1 1 5 0
108 0.2190 4 5 0 3 4 1
1 0.2475 4 5 0 5 3 0
137 0.1624 5 5 0 2 2 1
84 0.3575 3 5 2 0 3 4
139 0.2188 4 3 3 0 2 2
113 0.2051 4 5 2 2 3 4
141 0.2478 4 4 0 0 0 2
88 0.2035 3 4 2 3 4 0
143 0.2322 4 5 3 1 2 5
9 0.2481 4 4 1 4 3 0
145 0.0895 3 0 2 1 1 4
146 0.2047 3 5 0 1 4 0
39 0.2061 2 3 0 3 3 1
40 0.2718 4 4 2 1 4 0
122 0.3553 4 5 1 0 2 2
150 0.2224 5 5 3 1 0 4
151 0.1566 4 4 2 4 5 0
44 0.1825 5 5 0 3 0 3
99 0.2742 1 4 0 1 5 1
100 0.2406 3 4 1 0 2 5
128 0.2810 3 5 1 2 3 0
102 0.2410 4 5 0 3 3 1
157 0.2257 3 5 2 1 5 1
23 0.0951 1 1 0 0 5 3
51 0.2072 5 2 2 1 4 0
160 0.2316 4 5 0 0 1 3
107 0.3147 3 5 1 1 5 0
162 0.2719 5 5 0 2 2 0
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Improved solutions Gen Solution # Scaled raw recovery Sucrose EG Alanine Taurine Ectoine Cooling rate
1 0.2475 4 5 0 5 3 0
137 0.1624 5 5 0 2 2 1
84 0.3575 3 5 2 0 3 4
139 0.2188 4 3 3 0 2 2
113 0.2051 4 5 2 2 3 4
141 0.2478 4 4 0 0 0 2
169 0.2102 1 5 0 2 5 1
143 0.2322 4 5 3 1 2 5
9 0.2481 4 4 1 4 3 0
145 0.0895 3 0 2 1 1 4
146 0.2047 3 5 0 1 4 0
39 0.2061 2 3 0 3 3 1
40 0.2718 4 4 2 1 4 0
122 0.3553 4 5 1 0 2 2
150 0.2224 5 5 3 1 0 4
151 0.1566 4 4 2 4 5 0
44 0.1825 5 5 0 3 0 3
180 0.2895 2 5 0 1 5 1
100 0.2406 3 4 1 0 2 5
128 0.2810 3 5 1 2 3 0
102 0.2410 4 5 0 3 3 1
157 0.2257 3 5 2 1 5 1
23 0.0951 1 1 0 0 5 3
51 0.2072 5 2 2 1 4 0
160 0.2316 4 5 0 0 1 3
107 0.3147 3 5 1 1 5 0
162 0.2719 5 5 0 2 2 0
1 0.2475 4 5 0 5 3 0
191 0.3738 3 5 0 4 4 0
84 0.3575 3 5 2 0 3 4
139 0.2188 4 3 3 0 2 2
113 0.2051 4 5 2 2 3 4
141 0.2478 4 4 0 0 0 2
196 0.3972 0 5 0 2 5 0
197 0.2793 2 5 2 0 5 4
9 0.2481 4 4 1 4 3 0
199 0.1150 1 3 0 1 3 3
200 0.2898 1 5 0 3 5 0
201 0.3501 3 5 0 1 4 0
40 0.2718 4 4 2 1 4 0
122 0.3553 4 5 1 0 2 2
150 0.2224 5 5 3 1 0 4
205 0.2225 2 5 1 2 5 0
44 0.1825 5 5 0 3 0 3
180 0.2895 2 5 0 1 5 1
100 0.2406 3 4 1 0 2 5
128 0.2810 3 5 1 2 3 0
102 0.2410 4 5 0 3 3 1
157 0.2257 3 5 2 1 5 1
23 0.0951 1 1 0 0 5 3
213 0.2090 0 5 0 1 5 1
160 0.2316 4 5 0 0 1 3
107 0.3147 3 5 1 1 5 0
216 0.2881 3 5 0 3 5 0
6
7
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Improved solutions Gen Solution # Scaled raw recovery Sucrose EG Alanine Taurine Ectoine Cooling rate
217 0.3273 2 5 2 2 5 3
191 0.3738 3 5 0 4 4 0
84 0.3575 3 5 2 0 3 4
139 0.2188 4 3 3 0 2 2
113 0.2051 4 5 2 2 3 4
141 0.2478 4 4 0 0 0 2
196 0.3972 0 5 0 2 5 0
224 0.2892 0 5 2 1 5 3
9 0.2481 4 4 1 4 3 0
199 0.1150 1 3 0 1 3 3
200 0.2898 1 5 0 3 5 0
201 0.3501 3 5 0 1 4 0
40 0.2718 4 4 2 1 4 0
122 0.3553 4 5 1 0 2 2
150 0.2224 5 5 3 1 0 4
205 0.2225 2 5 1 2 5 0
44 0.1825 5 5 0 3 0 3
180 0.2895 2 5 0 1 5 1
100 0.2406 3 4 1 0 2 5
128 0.2810 3 5 1 2 3 0
102 0.2410 4 5 0 3 3 1
157 0.2257 3 5 2 1 5 1
239 0.1491 1 1 0 0 5 3
213 0.2090 0 5 0 1 5 1
160 0.2316 4 5 0 0 1 3
107 0.3147 3 5 1 1 5 0
216 0.2881 3 5 0 3 5 0
217 0.3273 2 5 2 2 5 3
191 0.3738 3 5 0 4 4 0
84 0.3575 3 5 2 0 3 4
139 0.2188 4 3 3 0 2 2
113 0.2051 4 5 2 2 3 4
141 0.2478 4 4 0 0 0 2
196 0.3972 0 5 0 2 5 0
224 0.2892 0 5 2 1 5 3
9 0.2481 4 4 1 4 3 0
199 0.1150 1 3 0 1 3 3
200 0.2898 1 5 0 3 5 0
201 0.3501 3 5 0 1 4 0
40 0.2718 4 4 2 1 4 0
122 0.3553 4 5 1 0 2 2
150 0.2224 5 5 3 1 0 4
205 0.2225 2 5 1 2 5 0
44 0.1825 5 5 0 3 0 3
180 0.2895 2 5 0 1 5 1
100 0.2406 3 4 1 0 2 5
128 0.2810 3 5 1 2 3 0
102 0.2410 4 5 0 3 3 1
157 0.2257 3 5 2 1 5 1
239 0.1491 1 1 0 0 5 3
213 0.2090 0 5 0 1 5 1
160 0.2316 4 5 0 0 1 3
107 0.3147 3 5 1 1 5 0
216 0.2881 3 5 0 3 5 0
8
9
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A.2 Chapter 8 raw algorithm data 
A.2.1 MSC single cooling rate SGI attachment algorithm emergent population data from 
Figure 23 
 
 
 
 
 
 
 
 
 
 
Improved solutions Generation Emergent population Sucrose Glycerol Isoleucine Recovered Attached
Recovered-Attached 
(corrected to 0 if 
attached > recovery)
1 4 0 1 0.40 0.14 0.26
2 0 0 4 0.11 0.00 0.11
3 4 1 5 0.26 0.08 0.18
4 0 2 2 0.72 0.38 0.34
5 4 4 1 0.83 0.60 0.23
6 1 3 4 0.61 0.40 0.21
7 0 2 1 0.46 0.46 0.00
8 1 4 3 0.65 0.62 0.03
4 0 2 2 0.72 0.38 0.34
5 4 4 1 0.83 0.60 0.23
11 1 3 4 0.42 0.42 0.00
12 0 3 1 0.61 0.54 0.07
8 1 4 3 0.65 0.62 0.03
4 0 2 2 0.72 0.38 0.34
5 4 4 1 0.83 0.60 0.23
16 1 3 2 0.63 0.80 0.00
17 2 4 4 0.63 0.74 0.00
18 1 5 1 0.54 0.96 0.00
19 0 2 1 0.47 0.48 0.00
20 5 5 1 0.75 0.70 0.05
16 1 3 2 0.70 0.80 0.00
22 0 4 3 0.45 0.82 0.00
18 1 5 1 0.52 0.96 0.00
24 0 2 1 0.51 0.56 0.00
20 5 5 1 0.77 0.70 0.07
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A.3 Chapter 5 screening data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combo%number Sugar Sugar%Alcohol Additive Average 1 2 3 4 5 6 7 8
0 0.0468 0.0313 0.0446 0.0353 0.0587 0.0855 0.0522 0.0330 0.0359
1 Sucrose 0.0512 0.0572 0.0449 0.0594 0.0594
2 Glycerol 0.0247 0.0256 0.0229 0.0233 0.0175 0.0229 0.0194 0.0149 0.0168
3 Sorbitol 0.0306 0.0330 0.0228 0.0292 0.0176 0.0249 0.0288 0.0162 0.0176
4 Arabitol 0.0110 0.0247 0.0092 0.0068 0.0128 0.0140 C0.0039 C0.0051 C0.0122
5 Inositol 0.0155 0.0133 0.0120 0.0101 0.0107 0.0120 0.0120 0.0133 0.0230
6 Erythritol 0.0040 0.0008 0.0021 0.0008 C0.0025 C0.0018 0.0002 0.0008 C0.0005
7 Xylitol 0.0094 C0.0002 0.0060 0.0005 0.0060 0.0054 0.0095 0.0005 C0.0002
8 Mannitol 0.0060 0.0002 0.0024 C0.0028 C0.0013 C0.0021 0.0092 0.0002 0.0032
9 Ribitol(adonitol) 0.0594 missing missing missing missing missing missing missing missing
10 Proline 0.0168 C0.0258
11 Alanine 0.0037 C0.0183
12 Isoleucine 0.0048 C0.0134
13 Creatine 0.0071 C0.0092
14 Valine 0.0038 C0.0099
15 Taurine 0.0046 C0.0138
16 Ectoine C0.0052 C0.0299
17 Sucrose Glycerol 0.0636 0.0799 0.0821 0.0724 0.0687
18 Sucrose Sorbitol 0.0497 0.0698 0.0607 0.0570 0.0441
19 Sucrose Arabitol 0.0892 0.1319 0.0914 0.0936 0.0959
20 Sucrose Inositol 0.0632 0.0735 0.0876 0.0584 0.0735
21 Sucrose Erythritol 0.0556 0.0628 0.0609 0.0798 0.0453
22 Sucrose Xylitol 0.0621 0.0853 0.0773 0.0662 0.0642
23 Sucrose Mannitol 0.0554 0.0805 0.0670 0.0529 0.0515
24 Sucrose Ribitol(adonitol) 0.0288 missing missing missing missing
25 Sucrose Proline 0.0394 0.0461 0.0297 0.0451 0.0600
26 Sucrose Alanine 0.0443 0.0461 0.0467 0.0520 0.0590
27 Sucrose Isoleucine 0.0239 0.0324 0.0234 0.0419 C0.0030
28 Sucrose Creatine 0.0289 0.0416 0.0337 0.0587 0.0014
29 Sucrose Valine 0.0388 0.0200 0.0469 0.0507 0.0695
30 Sucrose Taurine 0.0316 0.0539 0.0528 0.0496 C0.0109
31 Sucrose Ectoine 0.0739 0.0706 0.0565 0.0528 0.1754
32 Glycerol Proline 0.0118 0.0275
33 Glycerol Alanine 0.0181 0.0412
34 Glycerol Isoleucine 0.0040 0.0202
35 Glycerol Creatine 0.0209 0.0285
36 Glycerol Valine 0.0175 0.0231
37 Glycerol Taurine 0.0132 0.0164
38 Glycerol Ectoine 0.0337 0.0566
39 Sorbitol Proline 0.0120 0.0121
40 Sorbitol Alanine 0.0160 0.0201
41 Sorbitol Isoleucine 0.0131 0.0129
42 Sorbitol Creatine 0.0225 0.0221
43 Sorbitol Valine 0.0103 0.0199
44 Sorbitol Taurine 0.0069 0.0116
45 Sorbitol Ectoine 0.0149 0.0290
46 Arabitol Proline 0.0150 0.0325
47 Arabitol Alanine 0.0181 0.0380
48 Arabitol Isoleucine C0.0004 C0.0009
49 Arabitol Creatine 0.0101 0.0194
50 Arabitol Valine 0.0061 0.0128
51 Arabitol Taurine 0.0189 0.0380
52 Arabitol Ectoine 0.0088 0.0116
53 Inositol Proline 0.0100 0.0194
54 Inositol Alanine 0.0163 0.0265
55 Inositol Isoleucine 0.0015 C0.0024
56 Inositol Creatine 0.0148 0.0200
57 Inositol Valine 0.0016 0.0027
58 Inositol Taurine 0.0171 0.0343
59 Inositol Ectoine 0.0095 0.0188
60 Erythritol Proline C0.0224 C0.0472
61 Erythritol Alanine C0.0010 0.0008
62 Erythritol Isoleucine 0.0024 0.0061
63 Erythritol Creatine 0.0045 0.0111
64 Erythritol Valine 0.0065 0.0038
65 Erythritol Taurine C0.0069 C0.0140
66 Erythritol Ectoine 0.0027 0.0021
67 Xylitol Proline 0.0085 0.0085
68 Xylitol Alanine 0.0102 0.0102
69 Xylitol Isoleucine C0.0002 C0.0002
70 Xylitol Creatine 0.0009 0.0009
71 Xylitol Valine 0.0015 0.0015
72 Xylitol Taurine C0.0057 C0.0057
73 Xylitol Ectoine C0.0002 C0.0002
74 Mannitol Proline C0.0203 C0.0203
75 Mannitol Alanine C0.0188 C0.0117
76 Mannitol Isoleucine C0.0159 C0.0136
77 Mannitol Creatine C0.0101 C0.0069
78 Mannitol Valine C0.0078 C0.0065
79 Mannitol Taurine C0.0086 C0.0073
80 Mannitol Ectoine 0.0024 0.0186
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Combo%number Sugar Sugar%Alcohol Additive Average 1 2 3 4 5 6 7 8
81 Ribitol(adonitol) Proline A0.0299 missing
82 Ribitol(adonitol) Alanine 0.0799 missing
83 Ribitol(adonitol) Isoleucine 0.0821 missing
84 Ribitol(adonitol) Creatine 0.0724 missing
85 Ribitol(adonitol) Valine 0.0687 missing
86 Ribitol(adonitol) Taurine 0.0698 missing
87 Ribitol(adonitol) Ectoine 0.0607 missing
88 Sucrose Glycerol Proline 0.0504 0.0659 0.0415 0.0531 0.0344
89 Sucrose Glycerol Alanine 0.0414 0.0422 0.0323 0.0448 0.0437
90 Sucrose Glycerol Isoleucine 0.0668 0.0514 0.0514 0.0453 0.0540
91 Sucrose Glycerol Creatine 0.0598 0.0652 0.0534 0.0419 0.0469
92 Sucrose Glycerol Valine 0.0596 0.0615 0.0611 0.0487 0.0330
93 Sucrose Glycerol Taurine 0.0563 0.0507 0.0642 0.0321 0.0388
94 Sucrose Glycerol Ectoine 0.0630 0.0754 0.0844 0.0374 0.0442
95 Sucrose Sorbitol Proline 0.0487 0.0352 0.0381 0.0456 0.0368
96 Sucrose Sorbitol Alanine 0.0502 0.0397 0.0582 0.0473 0.0473
97 Sucrose Sorbitol Isoleucine 0.0542 0.0427 0.0602 0.0466 0.0482
98 Sucrose Sorbitol Creatine 0.0582 0.0570 0.0604 0.0530 0.0577
99 Sucrose Sorbitol Valine 0.0527 0.0574 0.0474 0.0468 0.0510
100 Sucrose Sorbitol Taurine 0.0544 0.0530 0.0514 0.0315 0.0564
101 Sucrose Sorbitol Ectoine 0.0609 0.0723 0.0615 0.0646 0.0609
102 Sucrose Arabitol Proline 0.0642 0.0714 0.0592 0.0482 0.0570
103 Sucrose Arabitol Alanine 0.0739 0.0869 0.0758 0.0780 0.0515
104 Sucrose Arabitol Isoleucine 0.0549 0.0609 0.0487 0.0575 0.0411
105 Sucrose Arabitol Creatine 0.0837 0.0948 0.0948 0.0948 0.0703
106 Sucrose Arabitol Valine 0.0586 0.0719 0.0400 0.0553 0.0454
107 Sucrose Arabitol Taurine 0.0566 0.0647 0.0581 0.0504 0.0427
108 Sucrose Arabitol Ectoine 0.0642 0.0841 0.0609 0.0664 0.0564
109 Sucrose Inositol Proline 0.0559 0.0818 0.0696 0.0306 0.0460
110 Sucrose Inositol Alanine 0.0607 0.0699 0.0753 0.0463 0.0511
111 Sucrose Inositol Isoleucine 0.0414 0.0484 0.0460 0.0383 0.0329
112 Sucrose Inositol Creatine 0.0704 0.0987 0.0668 0.0565 0.0596
113 Sucrose Inositol Valine 0.0515 0.0523 0.0668 0.0451 0.0416
114 Sucrose Inositol Taurine 0.0592 0.0638 0.0711 0.0596 0.0553
115 Sucrose Inositol Ectoine 0.0700 0.0790 0.0827 0.0790 0.0796
116 Sucrose Erythritol Proline 0.0403 0.0584 0.0336 0.0503 0.0140
117 Sucrose Erythritol Alanine 0.0458 0.0641 0.0367 0.0385 0.0299
118 Sucrose Erythritol Isoleucine 0.0307 0.0358 0.0376 0.0180 0.0162
119 Sucrose Erythritol Creatine 0.0581 0.0808 0.0606 0.0625 0.0401
120 Sucrose Erythritol Valine 0.0433 0.0491 0.0299 0.0503 0.0355
121 Sucrose Erythritol Taurine 0.0442 0.0410 0.0472 0.0460 0.0281
122 Sucrose Erythritol Ectoine 0.0495 0.0534 0.0710 0.0584 0.0324
123 Sucrose Xylitol Proline 0.0348 0.0463 0.0328 0.0450 0.0264
124 Sucrose Xylitol Alanine 0.0509 0.0596 0.0531 0.0629 0.0370
125 Sucrose Xylitol Isoleucine 0.0384 0.0512 0.0551 0.0473 0.0415
126 Sucrose Xylitol Creatine 0.0580 0.0593 0.0554 0.0632 0.0704
127 Sucrose Xylitol Valine 0.0395 0.0444 0.0392 0.0457 0.0347
128 Sucrose Xylitol Taurine 0.0437 0.0402 0.0392 0.0457 0.0347
129 Sucrose Xylitol Ectoine 0.0475 0.0603 0.0583 0.0583 0.0590
130 Sucrose Mannitol Proline 0.0203 0.0491 0.0193 0.0070 0.0063
131 Sucrose Mannitol Alanine 0.0392 0.0526 0.0324 0.0366 0.0276
132 Sucrose Mannitol Isoleucine 0.0336 0.0345 0.0234 0.0331 0.0262
133 Sucrose Mannitol Creatine 0.0440 0.0452 0.0494 0.0286 0.0272
134 Sucrose Mannitol Valine 0.0406 0.0442 0.0400 0.0372 0.0276
135 Sucrose Mannitol Taurine 0.0465 0.0582 0.0631 0.0338 0.0248
136 Sucrose Mannitol Ectoine 0.0516 0.0614 0.0628 0.0473 0.0369
137 Sucrose Ribitol(adonitol) Proline A0.0109 missing missing missing missing
138 Sucrose Ribitol(adonitol) Alanine 0.0706 missing missing missing missing
139 Sucrose Ribitol(adonitol) Isoleucine 0.0565 missing missing missing missing
140 Sucrose Ribitol(adonitol) Creatine 0.0528 missing missing missing missing
141 Sucrose Ribitol(adonitol) Valine 0.1754 missing missing missing missing
142 Sucrose Ribitol(adonitol) Taurine 0.0275 missing missing missing missing
143 Sucrose Ribitol(adonitol) Ectoine 0.0412 missing missing missing missing
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0 >0.0111 >0.0114 >0.0108 >0.0161 >0.0161 >0.0161 >0.0125 >0.0114 0.0052
1 Sucrose 0.0649 0.0842 0.0932 0.0804 0.0829
2 Glycerol 0.0232 0.0145 0.0333 0.0212 0.0456 0.0356 0.0234 0.0123 0.0389
3 Sorbitol 0.0163 0.0079 0.0092 0.0319 0.0221 0.0279 0.0214 0.0221 0.0201
4 Arabitol 0.0098 0.0093 0.0153 0.0127 0.0084 0.0119 >0.0054 0.0214 0.0275
5 Inositol 0.0105 0.0170 0.0079 0.0133 0.0111 0.0124 0.0156 0.0143 0.0138
6 Erythritol 0.0052 missing missing missing missing missing missing missing missing
7 Xylitol 0.0316 0.0284 0.0234 0.0209 0.0230 0.0168 0.0247 0.0276 0.0356
8 Mannitol 0.0362 0.0382 0.0205 0.0188 0.0176 0.0264 0.0329 0.0430 0.0353
9 Ribitol(adonitol) 0.0060 0.0096 >0.0043 >0.0049 >0.0049 >0.0105 >0.0030 >0.0049 >0.0036
10 Proline 0.0403 >0.0024
11 Alanine 0.0030 >0.0086
12 Isoleucine 0.0088 >0.0158
13 Creatine 0.0055 >0.0102
14 Valine 0.0147 >0.0162
15 Taurine 0.0185 0.0015
16 Ectoine 0.0181 0.0128
17 Sucrose Glycerol 0.1168 0.1278 0.1549 0.1788 0.1102
18 Sucrose Sorbitol 0.1007 0.1084 0.1275 0.1182 0.1105
19 Sucrose Arabitol 0.0490 0.0819 0.0447 0.0646 0.0456
20 Sucrose Inositol 0.0721 0.0942 0.0947 0.0987 0.0638
21 Sucrose Erythritol 0.0319 missing missing missing missing
22 Sucrose Xylitol 0.0722 0.0918 0.1015 0.0932 0.0524
23 Sucrose Mannitol 0.0765 0.0922 0.0696 0.1042 0.0884
24 Sucrose Ribitol(adonitol) 0.0659 0.0707 0.0741 0.0815 0.0815
25 Sucrose Proline 0.0500 0.0697 0.0552 0.0678 0.0351
26 Sucrose Alanine 0.0782 0.0876 0.1188 0.0921 0.0722
27 Sucrose Isoleucine 0.0484 0.0646 0.0691 0.0564 0.0426
28 Sucrose Creatine 0.0749 0.0957 0.1067 0.0789 0.0777
29 Sucrose Valine 0.0521 0.0637 0.0675 0.0599 0.0567
30 Sucrose Taurine 0.0733 0.0957 0.1028 0.0892 0.0707
31 Sucrose Ectoine 0.0934 0.1126 0.1087 0.1165 0.1172
32 Glycerol Proline 0.0051 0.0157
33 Glycerol Alanine 0.0352 0.0489
34 Glycerol Isoleucine 0.2204 0.4133
35 Glycerol Creatine 0.0177 0.0184
36 Glycerol Valine 0.0005 >0.0069
37 Glycerol Taurine 0.0095 0.0057
38 Glycerol Ectoine 0.0161 0.0212
39 Sorbitol Proline 0.0357 0.0589
40 Sorbitol Alanine 0.0179 0.0201
41 Sorbitol Isoleucine 0.0096 0.0050
42 Sorbitol Creatine 0.0215 0.0293
43 Sorbitol Valine 0.0374 0.0374
44 Sorbitol Taurine 0.0414 0.0414
45 Sorbitol Ectoine 0.0211 0.0211
46 Arabitol Proline 0.0114 0.0114
47 Arabitol Alanine 0.0084 0.0084
48 Arabitol Isoleucine >0.0041 >0.0041
49 Arabitol Creatine 0.0097 0.0097
50 Arabitol Valine 0.0041 0.0041
51 Arabitol Taurine 0.0154 0.0024
52 Arabitol Ectoine 0.0172 0.0110
53 Inositol Proline 0.0101 >0.0008
54 Inositol Alanine 0.0181 0.0131
55 Inositol Isoleucine 0.0069 >0.0030
56 Inositol Creatine 0.0259 0.0272
57 Inositol Valine 0.0116 >0.0043
58 Inositol Taurine 0.0307 0.0258
59 Inositol Ectoine 0.0311 0.0240
60 Erythritol Proline 0.0205 missing
61 Erythritol Alanine 0.0188 missing
62 Erythritol Isoleucine 0.0176 missing
63 Erythritol Creatine 0.0264 missing
64 Erythritol Valine 0.0329 missing
65 Erythritol Taurine 0.0430 missing
66 Erythritol Ectoine 0.0353 missing
67 Xylitol Proline 0.0214 0.0333
68 Xylitol Alanine 0.0146 0.0335
69 Xylitol Isoleucine 0.0006 0.0060
70 Xylitol Creatine 0.0056 0.0161
71 Xylitol Valine 0.0043 0.0190
72 Xylitol Taurine 0.0171 0.0373
73 Xylitol Ectoine 0.0239 0.0526
74 Mannitol Proline 0.0039 0.0115
75 Mannitol Alanine 0.0047 0.0118
76 Mannitol Isoleucine >0.0087 >0.0088
77 Mannitol Creatine 0.0069 0.0297
78 Mannitol Valine 0.0052 0.0205
79 Mannitol Taurine 0.0128 0.0418
80 Mannitol Ectoine 0.0242 0.0469
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Combo%number Sugar Sugar%Alcohol Additive Average 1 2 3 4 5 6 7 8
81 Ribitol(adonitol) Proline A0.0031 A0.0189
82 Ribitol(adonitol) Alanine 0.0649 0.0020
83 Ribitol(adonitol) Isoleucine 0.0706 A0.0136
84 Ribitol(adonitol) Creatine 0.0847 A0.0093
85 Ribitol(adonitol) Valine 0.0472 A0.0158
86 Ribitol(adonitol) Taurine 0.0565 0.0046
87 Ribitol(adonitol) Ectoine 0.0751 0.0227
88 Sucrose Glycerol Proline 0.1043 0.1295 0.1938 0.0598 0.0200
89 Sucrose Glycerol Alanine 0.1477 0.2498 0.1878 0.1307 0.0598
90 Sucrose Glycerol Isoleucine 0.4834 0.7772 0.6676 0.6896 0.2004
91 Sucrose Glycerol Creatine 0.0573 0.0783 0.0461 0.0644 0.0530
92 Sucrose Glycerol Valine 0.0845 0.0461 0.1272 0.1178 0.0667
93 Sucrose Glycerol Taurine 0.1105 0.2028 0.1149 0.0835 0.1055
94 Sucrose Glycerol Ectoine 0.1175 0.1113 0.0593 0.1561 0.1668
95 Sucrose Sorbitol Proline 0.0840 0.0740 0.1017 0.0941 0.0556
96 Sucrose Sorbitol Alanine 0.1043 0.1066 0.1108 0.1066 0.0989
97 Sucrose Sorbitol Isoleucine 0.0822 0.0843 0.0961 0.0899 0.0768
98 Sucrose Sorbitol Creatine 0.1153 0.0909 0.1239 0.1324 0.1140
99 Sucrose Sorbitol Valine 0.1036 0.1077 0.1021 0.1324 0.0723
100 Sucrose Sorbitol Taurine 0.1128 0.1000 0.1063 0.1317 0.1133
101 Sucrose Sorbitol Ectoine 0.1470 0.1471 0.1507 0.1572 0.1328
102 Sucrose Arabitol Proline 0.0151 0.0064 0.0197 A0.0191 A0.0235
103 Sucrose Arabitol Alanine 0.0477 0.0556 0.0259 0.0268 0.0286
104 Sucrose Arabitol Isoleucine 0.0432 0.0461 0.0398 0.0184 0.0184
105 Sucrose Arabitol Creatine 0.0666 0.0911 0.0810 0.0583 0.0501
106 Sucrose Arabitol Valine 0.0464 0.0623 0.0282 0.0255 0.0237
107 Sucrose Arabitol Taurine 0.0459 0.0438 0.0447 0.0331 0.0384
108 Sucrose Arabitol Ectoine 0.0762 0.0842 0.0669 0.0605 0.0651
109 Sucrose Inositol Proline 0.0648 0.0840 0.0870 0.0340 0.0307
110 Sucrose Inositol Alanine 0.0708 0.0682 0.0750 0.0696 0.0706
111 Sucrose Inositol Isoleucine 0.0533 0.0592 0.0530 0.0439 0.0363
112 Sucrose Inositol Creatine 0.0890 0.1037 0.0987 0.0987 0.0623
113 Sucrose Inositol Valine 0.0728 0.0532 0.0858 0.0750 0.0686
114 Sucrose Inositol Taurine 0.0668 0.0503 0.0818 0.0789 0.0532
115 Sucrose Inositol Ectoine 0.0944 0.0619 0.1255 0.1188 0.1107
116 Sucrose Erythritol Proline 0.0678 missing missing missing missing
117 Sucrose Erythritol Alanine 0.0351 missing missing missing missing
118 Sucrose Erythritol Isoleucine 0.0876 missing missing missing missing
119 Sucrose Erythritol Creatine 0.1188 missing missing missing missing
120 Sucrose Erythritol Valine 0.0921 missing missing missing missing
121 Sucrose Erythritol Taurine 0.0722 missing missing missing missing
122 Sucrose Erythritol Ectoine 0.0646 missing missing missing missing
123 Sucrose Xylitol Proline 0.0530 0.0619 0.0561 0.0417 0.0365
124 Sucrose Xylitol Alanine 0.0642 0.0733 0.0715 0.0697 0.0502
125 Sucrose Xylitol Isoleucine 0.0562 0.0670 0.0594 0.0577 0.0541
126 Sucrose Xylitol Creatine 0.0913 0.0852 0.0902 0.0889 0.0966
127 Sucrose Xylitol Valine 0.0696 0.0628 0.0686 0.0583 0.0517
128 Sucrose Xylitol Taurine 0.0701 0.0927 0.0686 0.0583 0.0517
129 Sucrose Xylitol Ectoine 0.0857 0.0923 0.0932 0.0855 0.0800
130 Sucrose Mannitol Proline 0.0557 0.0551 0.0643 0.0404 0.0551
131 Sucrose Mannitol Alanine 0.0785 0.1039 0.0674 0.0761 0.0774
132 Sucrose Mannitol Isoleucine 0.0730 0.0837 0.0588 0.0830 0.0799
133 Sucrose Mannitol Creatine 0.0906 0.0846 0.0721 0.1138 0.1260
134 Sucrose Mannitol Valine 0.0804 0.0551 0.0843 0.0931 0.0737
135 Sucrose Mannitol Taurine 0.0970 0.1083 0.0619 0.1090 0.1032
136 Sucrose Mannitol Ectoine 0.1108 0.1144 0.1029 0.1119 0.1357
137 Sucrose Ribitol(adonitol) Proline 0.0594 0.0550 0.0610 0.0556 0.0550
138 Sucrose Ribitol(adonitol) Alanine 0.0831 0.1069 0.0802 0.0520 0.0640
139 Sucrose Ribitol(adonitol) Isoleucine 0.0636 0.0717 0.0331 0.0550 0.0496
140 Sucrose Ribitol(adonitol) Creatine 0.0869 0.0945 0.0680 0.0775 0.0782
141 Sucrose Ribitol(adonitol) Valine 0.0705 0.0677 0.0596 0.0523 0.0556
142 Sucrose Ribitol(adonitol) Taurine 0.0392 0.0443 0.0490 0.0403 0.0470
143 Sucrose Ribitol(adonitol) Ectoine 0.0631 0.0761 0.0653 0.0580 0.0674
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0 0.0207 0.0082 0.0204 0.0248 0.0237 0.0299 0.0207 0.0181 0.0201
1 Sucrose 0.0663 0.0981 0.0583 0.0807 0.0694
2 Glycerol 0.0645 0.0739 0.0622 0.0715 0.0557 0.0858 0.0810 0.0640 0.0631
3 Sorbitol 0.0407 0.0463 0.0442 0.0345 0.0289 0.0415 0.0447 0.0469 0.0491
4 Arabitol 0.0330 0.0283 0.0277 0.0379 0.0359 0.0275 0.0374 0.0433 0.0383
5 Inositol 0.0411 0.0503 0.0399 0.0506 0.0371 0.0503 0.0428 0.0337 0.0468
6 Erythritol 0.0358 0.0442 0.0469 0.0288 0.0461 0.0298 0.0429 0.0373 0.0260
7 Xylitol 0.0405 0.0382 0.0339 0.0348 0.0342 0.0296 0.0227 0.0336 0.0397
8 Mannitol 0.0633 0.0655 0.0780 0.0668 0.0389 0.0616 0.0663 0.0595 0.0745
9 Ribitol(adonitol) 0.0294 0.0270 0.0299 0.0383 0.0203 0.0295 0.0186 0.0199 0.0001
10 Proline 0.0587 0.0480
11 Alanine 0.0581 0.0424
12 Isoleucine 0.0387 0.0153
13 Creatine 0.0526 0.0337
14 Valine 0.0386 0.0215
15 Taurine 0.0682 0.0506
16 Ectoine 0.0816 0.0822
17 Sucrose Glycerol 0.0424 missing 0.0057 0.0634 0.0365
18 Sucrose Sorbitol 0.0982 0.1231 0.0875 0.1268 0.0903
19 Sucrose Arabitol 0.0708 0.0802 0.0700 0.0844 0.0732
20 Sucrose Inositol 0.0846 0.1198 0.0975 0.0799 0.0814
21 Sucrose Erythritol 0.0965 0.1191 0.1163 0.1109 0.1019
22 Sucrose Xylitol 0.0871 0.1153 0.1012 0.1016 0.0886
23 Sucrose Mannitol 0.0705 0.1051 0.0786 0.0701 0.0574
24 Sucrose Ribitol(adonitol) 0.0790 0.0891 0.0880 0.0957 0.0776
25 Sucrose Proline 0.0572 0.0742 0.0534 0.0523 0.0591
26 Sucrose Alanine 0.0813 0.1026 0.0910 0.0887 0.0753
27 Sucrose Isoleucine 0.0574 0.0707 0.0664 0.0660 0.0557
28 Sucrose Creatine 0.0790 0.1130 0.0689 0.1036 0.0818
29 Sucrose Valine 0.0617 0.0724 0.0685 0.0712 0.0586
30 Sucrose Taurine 0.0776 0.0861 0.0877 0.0889 0.0893
31 Sucrose Ectoine 0.0985 0.1269 0.0936 0.1274 0.1170
32 Glycerol Proline 0.0611 0.0848
33 Glycerol Alanine 0.0676 0.0920
34 Glycerol Isoleucine 0.0324 0.0264
35 Glycerol Creatine 0.0782 0.1062
36 Glycerol Valine 0.0601 0.0803
37 Glycerol Taurine 0.0989 0.1472
38 Glycerol Ectoine 0.0769 0.1167
39 Sorbitol Proline 0.0494 0.0485
40 Sorbitol Alanine 0.0495 0.0562
41 Sorbitol Isoleucine 0.0256 0.0176
42 Sorbitol Creatine 0.0539 0.0609
43 Sorbitol Valine 0.0369 0.0296
44 Sorbitol Taurine 0.0559 0.0650
45 Sorbitol Ectoine 0.0366 0.0443
46 Arabitol Proline 0.0435 0.0409
47 Arabitol Alanine 0.0373 0.0449
48 Arabitol Isoleucine 0.0285 0.0142
49 Arabitol Creatine 0.0383 0.0393
50 Arabitol Valine 0.0262 0.0264
51 Arabitol Taurine 0.0370 0.0359
52 Arabitol Ectoine 0.0426 0.0513
53 Inositol Proline 0.0461 0.0574
54 Inositol Alanine 0.0545 0.0749
55 Inositol Isoleucine 0.0213 0.0130
56 Inositol Creatine 0.0526 0.0825
57 Inositol Valine 0.0298 0.0260
58 Inositol Taurine 0.0655 0.0914
59 Inositol Ectoine 0.0783 0.0910
60 Erythritol Proline 0.0605 0.0430
61 Erythritol Alanine 0.0530 0.0392
62 Erythritol Isoleucine 0.0259 0.0130
63 Erythritol Creatine 0.0507 0.0399
64 Erythritol Valine 0.0416 0.0168
65 Erythritol Taurine 0.0622 0.0649
66 Erythritol Ectoine 0.0690 0.0635
67 Xylitol Proline 0.0368 0.0466
68 Xylitol Alanine 0.0419 0.0540
69 Xylitol Isoleucine 0.0310 0.0236
70 Xylitol Creatine 0.0298 0.0392
71 Xylitol Valine 0.0348 0.0402
72 Xylitol Taurine 0.0208 0.0230
73 Xylitol Ectoine 0.0275 0.0351
74 Mannitol Proline 0.0177 0.0353
75 Mannitol Alanine 0.0474 0.0468
76 Mannitol Isoleucine 0.0258 0.0091
77 Mannitol Creatine 0.0450 0.0747
78 Mannitol Valine 0.0382 0.0426
79 Mannitol Taurine 0.0461 0.0706
80 Mannitol Ectoine 0.0513 0.0521
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81 Ribitol(adonitol) Proline 0.0497 0.0172
82 Ribitol(adonitol) Alanine 0.0215 0.0215
83 Ribitol(adonitol) Isoleucine 0.0072 0.0087
84 Ribitol(adonitol) Creatine 0.0448 0.0261
85 Ribitol(adonitol) Valine 0.0225 0.0085
86 Ribitol(adonitol) Taurine 0.0690 0.0149
87 Ribitol(adonitol) Ectoine 0.0653 0.0432
88 Sucrose Glycerol Proline 0.0886 missing 0.1079 0.0266 0.0930
89 Sucrose Glycerol Alanine 0.1190 missing 0.1108 0.1554 0.1193
90 Sucrose Glycerol Isoleucine 0.1015 missing 0.0927 0.1238 0.1093
91 Sucrose Glycerol Creatine 0.1190 missing 0.1253 0.1529 0.1277
92 Sucrose Glycerol Valine 0.1003 missing 0.1084 0.1031 0.1055
93 Sucrose Glycerol Taurine 0.1209 missing 0.1433 0.1433 0.1238
94 Sucrose Glycerol Ectoine 0.1461 missing 0.1545 0.1625 0.1476
95 Sucrose Sorbitol Proline 0.0773 0.0802 0.0602 0.0894 0.0591
96 Sucrose Sorbitol Alanine 0.0883 0.0884 0.0862 0.1074 0.0795
97 Sucrose Sorbitol Isoleucine 0.0788 0.0795 0.0660 0.0959 0.0712
98 Sucrose Sorbitol Creatine 0.1038 0.1098 0.1007 0.0950 0.0942
99 Sucrose Sorbitol Valine 0.0892 0.0878 0.0686 0.1025 0.0707
100 Sucrose Sorbitol Taurine 0.0909 0.0878 0.1000 0.0885 0.0672
101 Sucrose Sorbitol Ectoine 0.0990 0.0987 0.0998 0.1118 0.0827
102 Sucrose Arabitol Proline 0.0698 0.0656 0.0553 0.0533 0.0596
103 Sucrose Arabitol Alanine 0.0722 0.0796 0.0530 0.0633 0.0639
104 Sucrose Arabitol Isoleucine 0.0699 0.0777 0.0537 0.0614 0.0551
105 Sucrose Arabitol Creatine 0.0754 0.0868 0.0711 0.0676 0.0627
106 Sucrose Arabitol Valine 0.0724 0.0649 0.0719 0.0620 0.0580
107 Sucrose Arabitol Taurine 0.0736 0.0919 0.0685 0.0723 0.0564
108 Sucrose Arabitol Ectoine 0.0859 0.0969 0.0831 0.0972 0.0822
109 Sucrose Inositol Proline 0.0740 0.1283 0.0727 0.0521 0.0596
110 Sucrose Inositol Alanine 0.0926 0.1285 0.0941 0.0740 0.0773
111 Sucrose Inositol Isoleucine 0.0726 0.1038 0.0676 0.0538 0.0499
112 Sucrose Inositol Creatine 0.0869 0.0968 0.0926 0.0810 0.0685
113 Sucrose Inositol Valine 0.0759 0.1048 0.0888 0.0587 0.0497
114 Sucrose Inositol Taurine 0.0840 0.1071 0.1101 0.0729 0.0558
115 Sucrose Inositol Ectoine 0.0908 0.1234 0.1086 0.0907 0.0781
116 Sucrose Erythritol Proline 0.0877 0.1136 0.1012 0.0864 0.0851
117 Sucrose Erythritol Alanine 0.0856 0.0976 0.0999 0.0936 0.0777
118 Sucrose Erythritol Isoleucine 0.0837 0.0951 0.0636 0.0744 0.0827
119 Sucrose Erythritol Creatine 0.1033 0.1162 0.0954 0.1070 0.1067
120 Sucrose Erythritol Valine 0.0883 0.0992 0.0887 0.0933 0.0717
121 Sucrose Erythritol Taurine 0.0886 0.1062 0.0868 0.0874 0.0871
122 Sucrose Erythritol Ectoine 0.1065 0.1259 0.1246 0.1019 0.1096
123 Sucrose Xylitol Proline 0.0578 0.0548 0.0544 0.0697 0.0436
124 Sucrose Xylitol Alanine 0.0763 0.0910 0.0818 0.0862 0.0562
125 Sucrose Xylitol Isoleucine 0.0661 0.0715 0.0687 0.0806 0.0538
126 Sucrose Xylitol Creatine 0.0868 0.0896 0.0888 0.0728 0.0697
127 Sucrose Xylitol Valine 0.0762 0.0925 0.0756 0.0792 0.0646
128 Sucrose Xylitol Taurine 0.0796 0.0750 0.0756 0.0792 0.0646
129 Sucrose Xylitol Ectoine 0.0859 0.0878 0.0910 0.1004 0.0683
130 Sucrose Mannitol Proline 0.0457 0.0566 0.0415 0.0363 0.0219
131 Sucrose Mannitol Alanine 0.0791 0.1005 0.0940 0.0666 0.0656
132 Sucrose Mannitol Isoleucine 0.0799 0.0886 0.0934 0.0682 0.0778
133 Sucrose Mannitol Creatine 0.1119 0.1555 0.1379 0.1073 0.1002
134 Sucrose Mannitol Valine 0.0956 0.1275 0.0956 0.0972 0.0714
135 Sucrose Mannitol Taurine 0.1107 0.1432 0.1309 0.0967 0.0951
136 Sucrose Mannitol Ectoine 0.1121 0.1509 0.1062 0.0894 0.1250
137 Sucrose Ribitol(adonitol) Proline 0.0792 0.0823 0.0633 0.0828 0.0784
138 Sucrose Ribitol(adonitol) Alanine 0.1043 0.1102 0.1007 0.0891 0.0946
139 Sucrose Ribitol(adonitol) Isoleucine 0.0799 0.0763 0.0719 0.0877 0.0698
140 Sucrose Ribitol(adonitol) Creatine 0.0996 0.0990 0.1024 0.0869 0.0825
141 Sucrose Ribitol(adonitol) Valine 0.0895 0.0938 0.0806 0.0850 0.0708
142 Sucrose Ribitol(adonitol) Taurine 0.0730 0.0665 0.0828 0.0628 0.0681
143 Sucrose Ribitol(adonitol) Ectoine 0.0963 0.0908 0.1102 0.1024 0.0864
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0 0.0107 0.0104 0.0119 0.0138 0.0130 0.0085 0.0126 0.0062 0.0081
1 Sucrose 0.1463 0.1891 0.1803 0.1896 0.1585
2 Glycerol 0.0558 0.0486 0.0724 0.0526 0.0822 0.0724 0.0497 0.0562 0.0555
3 Sorbitol 0.0590 0.0521 0.0684 0.0654 0.0450 0.0777 0.0669 0.0658 0.0808
4 Arabitol 0.0360 0.0283 0.0248 0.0258 0.0455 0.0501 0.0487 0.0580 0.0303
5 Inositol 0.0494 0.0520 0.0457 0.0446 0.0418 0.0559 0.0443 0.0696 0.0849
6 Erythritol 0.0521 0.0763 0.0718 0.0396 0.0510 0.0466 0.0414 0.0664 0.0678
7 Xylitol 0.0647 0.0628 0.0608 0.0574 0.0386 0.0640 0.0675 0.0010 0.0414
8 Mannitol 0.0896 0.0944 0.0928 0.0800 0.0554 0.0845 0.0924 0.0832 0.0430
9 Ribitol(adonitol) 0.0402 0.0168 0.0194 0.0227 0.0157 0.0349 0.0357 0.0175 0.0099
10 Proline 0.1156 0.0727
11 Alanine 0.0378 0.0270
12 Isoleucine 0.0398 0.0072
13 Creatine 0.0394 0.0263
14 Valine 0.0445 0.0069
15 Taurine 0.0440 0.0156
16 Ectoine 0.0579 0.0661
17 Sucrose Glycerol 0.1066 0.1258 0.1306 0.1334 0.0871
18 Sucrose Sorbitol 0.0673 0.0840 0.0720 0.0590 0.0662
19 Sucrose Arabitol 0.0840 0.1000 0.0939 0.0992 0.0749
20 Sucrose Inositol 0.1047 0.1132 0.1198 0.1221 0.0999
21 Sucrose Erythritol 0.0787 0.0953 0.0907 0.0775 0.0645
22 Sucrose Xylitol 0.0765 0.0662 0.1005 0.0941 0.0767
23 Sucrose Mannitol 0.1113 0.1413 0.1559 0.0449 0.1367
24 Sucrose Ribitol(adonitol) 0.0983 0.1067 0.1002 0.1067 0.1108
25 Sucrose Proline 0.1266 0.1365 0.1577 0.1457 0.1274
26 Sucrose Alanine 0.1370 0.1740 0.1278 0.1493 0.1532
27 Sucrose Isoleucine 0.0909 0.1352 0.0878 0.1120 0.0911
28 Sucrose Creatine 0.1198 0.1495 0.1385 0.1289 0.1575
29 Sucrose Valine 0.0969 0.1350 0.1255 0.0992 0.0992
30 Sucrose Taurine 0.1024 0.1367 0.1190 0.1072 0.1038
31 Sucrose Ectoine 0.1353 0.1843 0.1237 0.1742 0.1442
32 Glycerol Proline 0.0702 0.0917
33 Glycerol Alanine 0.0930 0.1280
34 Glycerol Isoleucine 0.0219 0.0135
35 Glycerol Creatine 0.0489 0.0459
36 Glycerol Valine 0.0390 0.0323
37 Glycerol Taurine 0.0604 0.0762
38 Glycerol Ectoine 0.0427 0.0435
39 Sorbitol Proline 0.0570 0.0582
40 Sorbitol Alanine 0.0586 0.0730
41 Sorbitol Isoleucine 0.0446 0.0196
42 Sorbitol Creatine 0.0729 0.0608
43 Sorbitol Valine 0.0660 0.0557
44 Sorbitol Taurine 0.0647 0.0576
45 Sorbitol Ectoine 0.0646 0.0895
46 Arabitol Proline 0.0387 0.0264
47 Arabitol Alanine 0.0373 0.0279
48 Arabitol Isoleucine 0.0256 0.0099
49 Arabitol Creatine 0.0559 0.0453
50 Arabitol Valine 0.0515 0.0352
51 Arabitol Taurine 0.0475 0.0321
52 Arabitol Ectoine 0.0510 0.0412
53 Inositol Proline 0.0573 0.0572
54 Inositol Alanine 0.0631 0.0877
55 Inositol Isoleucine 0.0339 0.0037
56 Inositol Creatine 0.0607 0.0540
57 Inositol Valine 0.0037 0.0064
58 Inositol Taurine 0.0550 0.0686
59 Inositol Ectoine 0.0628 0.0312
60 Erythritol Proline 0.0641 0.0355
61 Erythritol Alanine 0.0674 0.0549
62 Erythritol Isoleucine 0.0313 0.0072
63 Erythritol Creatine 0.0592 0.0338
64 Erythritol Valine 0.0499 0.0074
65 Erythritol Taurine 0.0707 0.0582
66 Erythritol Ectoine 0.0428 0.0427
67 Xylitol Proline 0.0373 0.0578
68 Xylitol Alanine 0.0397 0.0600
69 Xylitol Isoleucine 0.0210 0.0192
70 Xylitol Creatine 0.0310 0.0462
71 Xylitol Valine 0.0390 0.0432
72 Xylitol Taurine 0.0275 0.0192
73 Xylitol Ectoine 0.0303 0.0430
74 Mannitol Proline 0.0466 0.0834
75 Mannitol Alanine 0.0846 0.0964
76 Mannitol Isoleucine 0.0193 0.0116
77 Mannitol Creatine 0.0314 0.0556
78 Mannitol Valine 0.0353 0.0442
79 Mannitol Taurine 0.0316 0.0564
80 Mannitol Ectoine 0.0265 0.0374
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81 Ribitol(adonitol) Proline 0.0430 0.0199
82 Ribitol(adonitol) Alanine 0.0775 0.0293
83 Ribitol(adonitol) Isoleucine 0.0679 0.0051
84 Ribitol(adonitol) Creatine 0.0780 0.0227
85 Ribitol(adonitol) Valine 0.0458 0.0046
86 Ribitol(adonitol) Taurine 0.0502 0.0164
87 Ribitol(adonitol) Ectoine 0.0439 0.0159
88 Sucrose Glycerol Proline 0.0924 0.1184 0.0763 0.0923 0.1160
89 Sucrose Glycerol Alanine 0.0961 0.1031 0.0976 0.0965 0.1172
90 Sucrose Glycerol Isoleucine 0.0952 0.0886 0.0898 0.0967 0.1009
91 Sucrose Glycerol Creatine 0.0999 0.0980 0.1007 0.1011 0.1058
92 Sucrose Glycerol Valine 0.0902 0.0756 0.0793 0.1023 0.0946
93 Sucrose Glycerol Taurine 0.0886 0.0761 0.1040 0.0882 0.0998
94 Sucrose Glycerol Ectoine 0.1104 0.1123 0.1115 0.0959 0.1190
95 Sucrose Sorbitol Proline 0.0514 0.0367 0.0249 0.0319 0.0437
96 Sucrose Sorbitol Alanine 0.0744 0.0649 0.0699 0.0680 0.0471
97 Sucrose Sorbitol Isoleucine 0.0759 0.0803 0.0558 0.0929 0.0505
98 Sucrose Sorbitol Creatine 0.0817 0.0833 0.0670 0.0825 0.0805
99 Sucrose Sorbitol Valine 0.0763 0.0825 0.0825 0.0712 0.0544
100 Sucrose Sorbitol Taurine 0.0740 0.1034 0.0556 0.0701 0.0635
101 Sucrose Sorbitol Ectoine 0.0833 0.1077 0.0858 0.0807 0.0780
102 Sucrose Arabitol Proline 0.0553 0.0617 0.0537 0.0512 0.0437
103 Sucrose Arabitol Alanine 0.0682 0.0686 0.0638 0.0537 0.0544
104 Sucrose Arabitol Isoleucine 0.0649 0.0669 0.0481 0.0557 0.0597
105 Sucrose Arabitol Creatine 0.0789 0.0815 0.0675 0.0793 0.0894
106 Sucrose Arabitol Valine 0.0771 0.0648 0.0496 0.0702 0.0597
107 Sucrose Arabitol Taurine 0.0863 0.0708 0.0682 0.0613 0.0752
108 Sucrose Arabitol Ectoine 0.0785 0.0825 0.0847 0.0881 0.0926
109 Sucrose Inositol Proline 0.0991 0.0836 0.0974 0.0829 0.0948
110 Sucrose Inositol Alanine 0.0961 0.1117 0.0976 0.0871 0.0772
111 Sucrose Inositol Isoleucine 0.0849 0.0799 0.0832 0.0873 0.0740
112 Sucrose Inositol Creatine 0.1107 0.1284 0.0984 0.1245 0.0957
113 Sucrose Inositol Valine 0.0895 0.1021 0.0768 0.0845 0.0735
114 Sucrose Inositol Taurine 0.1051 0.1048 0.0879 0.0976 0.0987
115 Sucrose Inositol Ectoine 0.1262 0.1252 0.1229 0.1186 0.1067
116 Sucrose Erythritol Proline 0.0689 0.0485 0.0507 0.0534 0.0459
117 Sucrose Erythritol Alanine 0.0816 0.0743 0.0649 0.0622 0.0793
118 Sucrose Erythritol Isoleucine 0.0744 0.0510 0.0457 0.0580 0.0431
119 Sucrose Erythritol Creatine 0.0900 0.0804 0.0882 0.0804 0.0732
120 Sucrose Erythritol Valine 0.0740 0.0516 0.0547 0.0521 0.0622
121 Sucrose Erythritol Taurine 0.0805 0.0591 0.0605 0.0645 0.0654
122 Sucrose Erythritol Ectoine 0.0941 0.0730 0.0698 0.0962 0.0962
123 Sucrose Xylitol Proline 0.0485 0.0247 0.0446 0.0404 0.0449
124 Sucrose Xylitol Alanine 0.0656 0.0459 0.0607 0.0495 0.0601
125 Sucrose Xylitol Isoleucine 0.0673 0.0601 0.0696 0.0578 0.0581
126 Sucrose Xylitol Creatine 0.0875 0.0692 0.0867 0.0617 0.0707
127 Sucrose Xylitol Valine 0.0740 0.0551 0.0724 0.0565 0.0477
128 Sucrose Xylitol Taurine 0.0720 0.0544 0.0724 0.0565 0.0477
129 Sucrose Xylitol Ectoine 0.0937 0.0691 0.0908 0.0767 0.0746
130 Sucrose Mannitol Proline 0.1007 0.0846 0.0948 0.0928 0.0961
131 Sucrose Mannitol Alanine 0.1046 0.0905 0.1175 0.0865 0.1032
132 Sucrose Mannitol Isoleucine 0.0981 0.0846 0.1012 0.1062 0.0995
133 Sucrose Mannitol Creatine 0.1021 0.1000 0.1174 0.1074 0.0864
134 Sucrose Mannitol Valine 0.0945 0.0700 0.0865 0.0823 0.0972
135 Sucrose Mannitol Taurine 0.0876 0.0636 0.0912 0.0855 0.0787
136 Sucrose Mannitol Ectoine 0.1028 0.0930 0.1143 0.1108 0.0887
137 Sucrose Ribitol(adonitol) Proline 0.0854 0.0863 0.0635 0.0919 0.0815
138 Sucrose Ribitol(adonitol) Alanine 0.1099 0.0990 0.0802 0.0921 0.0941
139 Sucrose Ribitol(adonitol) Isoleucine 0.0922 0.0839 0.0831 0.0812 0.0891
140 Sucrose Ribitol(adonitol) Creatine 0.1197 0.1120 0.1190 0.0921 0.1010
141 Sucrose Ribitol(adonitol) Valine 0.0956 0.0875 0.0851 0.0744 0.0867
142 Sucrose Ribitol(adonitol) Taurine 0.0765 0.0827 0.0546 0.0725 0.0812
143 Sucrose Ribitol(adonitol) Ectoine 0.0906 0.0857 0.0802 0.0625 0.0965
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0 0.0067 ?0.0026 0.0024 0.0054 0.0059 0.0079 0.0110 0.0160 0.0120
1 Trehalose 0.0272 0.0471 0.0394 0.0294 0.0148
2 Glycerol 0.0101 0.0047 0.0137 0.0137 0.0105 0.0137 0.0098 0.0085 0.0105
3 Sorbitol 0.0083 0.0116 0.0149 0.0067 0.0132 0.0092 0.0083 0.0010 0.0018
4 Arabitol 0.0087 0.0085 0.0093 0.0101 0.0101 0.0093 0.0093 0.0085 0.0022
5 Inositol 0.0006 0.0030 ?0.0012 ?0.0074 ?0.0094 0.0014 0.0019 0.0019 ?0.0012
6 Erythritol 0.0069 0.0051 0.0074 0.0040 0.0057 0.0074 0.0057 0.0068 0.0085
7 Xylitol 0.0153 0.0092 0.0136 0.0161 0.0142 0.0117 0.0123 0.0042 0.0092
8 Mannitol 0.0152 0.0136 0.0106 0.0106 0.0136 0.0069 0.0144 0.0159 0.0114
9 Ribitol(adonitol) 0.0027 ?0.0022 ?0.0022 ?0.0027 ?0.0018 0.0006 0.0010 0.0024 0.0001
10 Proline 0.0054 ?0.0040
11 Alanine ?0.0018 ?0.0083
12 Isoleucine 0.0044 ?0.0049
13 Creatine 0.0063 ?0.0011
14 Valine 0.0041 ?0.0023
15 Taurine 0.0055 ?0.0028
16 Ectoine 0.0050 0.0002
17 Trehalose Glycerol 0.0300 0.0334 0.0400 0.0303 0.0376
18 Trehalose Sorbitol 0.0376 0.0564 0.0395 0.0388 0.0426
19 Trehalose Arabitol 0.0231 0.0348 0.0274 0.0267 0.0148
20 Trehalose Inositol 0.0055 0.0094 0.0133 ?0.0039 ?0.0063
21 Trehalose Erythritol 0.0271 0.0396 0.0280 0.0343 0.0270
22 Trehalose Xylitol 0.0440 0.0530 0.0542 0.0501 0.0495
23 Trehalose Mannitol 0.0320 0.0426 0.0334 0.0377 0.0370
24 Trehalose Ribitol(adonitol) 0.0129 0.0247 0.0129 0.0159 0.0029
25 Trehalose Proline 0.0026 0.0159 0.0066 0.0029 ?0.0137
26 Trehalose Alanine 0.0175 0.0349 0.0249 0.0178 0.0080
27 Trehalose Isoleucine 0.0170 0.0230 0.0254 0.0178 0.0103
28 Trehalose Creatine 0.0360 0.0401 0.0468 0.0444 0.0391
29 Trehalose Valine 0.0238 0.0284 0.0303 0.0223 0.0280
30 Trehalose Taurine 0.0280 0.0294 0.0375 0.0337 0.0294
31 Trehalose Ectoine 0.0365 0.0447 0.0485 0.0389 0.0413
32 Glycerol Proline 0.0041 ?0.0011
33 Glycerol Alanine 0.0101 0.0118
34 Glycerol Isoleucine 0.0034 0.0047
35 Glycerol Creatine 0.0082 0.0134
36 Glycerol Valine 0.0016 0.0043
37 Glycerol Taurine ?0.0033 0.0008
38 Glycerol Ectoine ?0.0004 0.0085
39 Sorbitol Proline 0.0008 0.0002
40 Sorbitol Alanine 0.0105 0.0190
41 Sorbitol Isoleucine ?0.0008 ?0.0035
42 Sorbitol Creatine 0.0060 0.0132
43 Sorbitol Valine 0.0037 0.0022
44 Sorbitol Taurine 0.0003 ?0.0067
45 Sorbitol Ectoine 0.0097 0.0153
46 Arabitol Proline 0.0022 ?0.0014
47 Arabitol Alanine 0.0111 0.0149
48 Arabitol Isoleucine 0.0010 ?0.0038
49 Arabitol Creatine 0.0075 0.0081
50 Arabitol Valine 0.0057 0.0030
51 Arabitol Taurine 0.0029 ?0.0034
52 Arabitol Ectoine 0.0095 0.0053
53 Inositol Proline ?0.0075 ?0.0310
54 Inositol Alanine 0.0208 0.0273
55 Inositol Isoleucine 0.0649 0.1181
56 Inositol Creatine 0.0062 0.0001
57 Inositol Valine 0.0027 0.0012
58 Inositol Taurine 0.0008 ?0.0076
59 Inositol Ectoine 0.0071 0.0006
60 Erythritol Proline 0.0033 ?0.0040
61 Erythritol Alanine 0.0096 0.0085
62 Erythritol Isoleucine 0.0083 0.0029
63 Erythritol Creatine 0.0087 0.0104
64 Erythritol Valine 0.0091 0.0037
65 Erythritol Taurine 0.0140 0.0121
66 Erythritol Ectoine 0.0119 0.0124
67 Xylitol Proline 0.0068 0.0158
68 Xylitol Alanine 0.0082 0.0186
69 Xylitol Isoleucine 0.0029 0.0086
70 Xylitol Creatine 0.0077 0.0171
71 Xylitol Valine 0.0041 0.0076
72 Xylitol Taurine 0.0045 0.0080
73 Xylitol Ectoine 0.0102 0.0180
74 Mannitol Proline ?0.0045 ?0.0091
75 Mannitol Alanine 0.0026 0.0091
76 Mannitol Isoleucine ?0.0083 ?0.0084
77 Mannitol Creatine 0.0001 0.0050
78 Mannitol Valine ?0.0016 ?0.0021
79 Mannitol Taurine ?0.0018 ?0.0013
80 Mannitol Ectoine 0.0041 0.0110
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81 Ribitol(adonitol) Proline A0.0050 A0.0103
82 Ribitol(adonitol) Alanine 0.0191 0.0048
83 Ribitol(adonitol) Isoleucine 0.0189 A0.0022
84 Ribitol(adonitol) Creatine 0.0166 0.0029
85 Ribitol(adonitol) Valine 0.0187 A0.0001
86 Ribitol(adonitol) Taurine 0.0294 0.0024
87 Ribitol(adonitol) Ectoine 0.0220 0.0045
88 Trehalose Glycerol Proline 0.0334 0.0337 0.0409 0.0234 0.0300
89 Trehalose Glycerol Alanine 0.0413 0.0418 0.0394 0.0486 0.0340
90 Trehalose Glycerol Isoleucine 0.0306 0.0297 0.0327 0.0291 0.0267
91 Trehalose Glycerol Creatine 0.0337 0.0385 0.0288 0.0409 0.0331
92 Trehalose Glycerol Valine 0.0283 0.0324 0.0300 0.0300 0.0222
93 Trehalose Glycerol Taurine 0.0309 0.0343 0.0397 0.0300 0.0355
94 Trehalose Glycerol Ectoine 0.0290 0.0225 0.0449 0.0364 0.0315
95 Trehalose Sorbitol Proline 0.0306 0.0441 0.0365 0.0380 0.0213
96 Trehalose Sorbitol Alanine 0.0399 0.0584 0.0584 0.0537 0.0330
97 Trehalose Sorbitol Isoleucine 0.0317 0.0480 0.0372 0.0395 0.0403
98 Trehalose Sorbitol Creatine 0.0562 0.0595 0.0665 0.0719 0.0434
99 Trehalose Sorbitol Valine 0.0350 0.0395 0.0426 0.0365 0.0281
100 Trehalose Sorbitol Taurine 0.0452 0.0568 0.0445 0.0491 0.0414
101 Trehalose Sorbitol Ectoine 0.0462 0.0591 0.0537 0.0476 0.0437
102 Trehalose Arabitol Proline 0.0166 0.0241 0.0013 0.0035 0.0013
103 Trehalose Arabitol Alanine 0.0243 0.0241 0.0159 0.0159 0.0115
104 Trehalose Arabitol Isoleucine 0.0237 0.0200 0.0193 0.0148 0.0141
105 Trehalose Arabitol Creatine 0.0306 0.0296 0.0237 0.0274 0.0230
106 Trehalose Arabitol Valine 0.0216 0.0215 0.0200 0.0126 0.0112
107 Trehalose Arabitol Taurine 0.0258 0.0304 0.0222 0.0222 0.0207
108 Trehalose Arabitol Ectoine 0.0326 0.0348 0.0296 0.0318 0.0289
109 Trehalose Inositol Proline A0.0148 A0.0323 A0.0323 A0.0117 A0.0347
110 Trehalose Inositol Alanine 0.0021 0.0111 0.0006 A0.0094 A0.0165
111 Trehalose Inositol Isoleucine 0.0438 0.0046 0.1535 0.0555 A0.0072
112 Trehalose Inositol Creatine 0.0126 0.0213 0.0213 0.0140 A0.0094
113 Trehalose Inositol Valine 0.0154 0.0184 0.0111 0.0237 0.0208
114 Trehalose Inositol Taurine 0.0180 0.0201 0.0220 0.0032 0.0288
115 Trehalose Inositol Ectoine 0.0314 0.0393 0.0252 0.0522 0.0335
116 Trehalose Erythritol Proline 0.0241 0.0346 0.0247 0.0314 0.0267
117 Trehalose Erythritol Alanine 0.0211 0.0328 0.0291 0.0301 0.0270
118 Trehalose Erythritol Isoleucine 0.0208 0.0247 0.0153 0.0143 0.0148
119 Trehalose Erythritol Creatine 0.0295 0.0399 0.0320 0.0241 0.0267
120 Trehalose Erythritol Valine 0.0217 0.0288 0.0210 0.0226 0.0184
121 Trehalose Erythritol Taurine 0.0249 0.0343 0.0275 0.0286 0.0260
122 Trehalose Erythritol Ectoine 0.0347 0.0412 0.0349 0.0380 0.0364
123 Trehalose Xylitol Proline 0.0344 0.0409 0.0344 0.0374 0.0338
124 Trehalose Xylitol Alanine 0.0349 0.0430 0.0382 0.0453 0.0300
125 Trehalose Xylitol Isoleucine 0.0336 0.0430 0.0436 0.0365 0.0347
126 Trehalose Xylitol Creatine 0.0393 0.0376 0.0459 0.0382 0.0347
127 Trehalose Xylitol Valine 0.0340 0.0309 0.0332 0.0332 0.0256
128 Trehalose Xylitol Taurine 0.0323 0.0250 0.0332 0.0332 0.0256
129 Trehalose Xylitol Ectoine 0.0380 0.0409 0.0368 0.0409 0.0321
130 Trehalose Mannitol Proline 0.0181 0.0230 0.0167 0.0119 0.0105
131 Trehalose Mannitol Alanine 0.0240 0.0324 0.0171 0.0212 0.0192
132 Trehalose Mannitol Isoleucine 0.0217 0.0244 0.0153 0.0216 0.0251
133 Trehalose Mannitol Creatine 0.0353 0.0440 0.0320 0.0341 0.0384
134 Trehalose Mannitol Valine 0.0257 0.0286 0.0202 0.0237 0.0265
135 Trehalose Mannitol Taurine 0.0257 0.0240 0.0185 0.0240 0.0247
136 Trehalose Mannitol Ectoine 0.0426 0.0503 0.0447 0.0426 0.0419
137 Trehalose Ribitol(adonitol) Proline 0.0130 0.0170 0.0118 0.0061 0.0005
138 Trehalose Ribitol(adonitol) Alanine 0.0248 0.0288 0.0148 0.0218 0.0139
139 Trehalose Ribitol(adonitol) Isoleucine 0.0222 0.0209 0.0170 0.0135 0.0109
140 Trehalose Ribitol(adonitol) Creatine 0.0301 0.0313 0.0291 0.0308 0.0203
141 Trehalose Ribitol(adonitol) Valine 0.0287 0.0308 0.0264 0.0255 0.0194
142 Trehalose Ribitol(adonitol) Taurine 0.0170 0.0260 0.0203 0.0225 0.0176
143 Trehalose Ribitol(adonitol) Ectoine 0.0291 0.0355 0.0341 0.0337 0.0306
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0 >0.0001 >0.0001 0.0022 0.0008 >0.0058 >0.0077 0.0004 >0.0020 0.0094
1 Trehalose 0.0221 0.0364 0.0287 0.0251 0.0195
2 Glycerol 0.0565 0.0898 0.0596 0.0497 0.0539 0.0497 0.0554 0.0682 0.0883
3 Sorbitol 0.0349 0.0278 0.0432 0.0528 0.0417 0.0486 0.0296 0.0429 0.0353
4 Arabitol 0.0347 0.0334 0.0389 0.0430 0.0462 0.0389 0.0398 0.0343 0.0375
5 Inositol 0.0268 0.0176 0.0364 0.0440 0.0364 0.0277 0.0262 0.0258 0.0288
6 Erythritol 0.0315 0.0438 0.0258 0.0466 0.0495 0.0290 0.0192 0.0293 0.0307
7 Xylitol 0.0208 0.0237 0.0165 0.0279 0.0225 0.0093 0.0237 0.0117 0.0159
8 Mannitol 0.0331 0.0220 0.0185 0.0378 0.0378 0.0170 0.0428 0.0409 0.0522
9 Ribitol(adonitol) 0.0197 0.0422 0.0124 0.0081 0.0124 0.0063 0.0230 0.0111 0.0371
10 Proline 0.0159 0.0124
11 Alanine 0.0441 >0.0017
12 Isoleucine 0.0252 >0.0093
13 Creatine 0.0274 0.0051
14 Valine 0.0252 >0.0035
15 Taurine 0.0491 0.0485
16 Ectoine 0.0557 0.0560
17 Trehalose Glycerol 0.0767 0.0776 0.0754 0.0852 0.0769
18 Trehalose Sorbitol 0.0703 0.0697 0.0656 0.0713 0.0566
19 Trehalose Arabitol 0.0455 0.0686 0.0481 0.0447 0.0384
20 Trehalose Inositol 0.0405 0.0578 0.0400 0.0340 0.0272
21 Trehalose Erythritol 0.0647 0.0687 0.0668 0.0710 0.0641
22 Trehalose Xylitol 0.0617 0.0667 0.0713 0.0687 0.0602
23 Trehalose Mannitol 0.0658 0.0719 0.0741 0.0707 0.0635
24 Trehalose Ribitol(adonitol) 0.0698 0.0792 0.0807 0.0843 0.0753
25 Trehalose Proline 0.0198 0.0320 0.0132 0.0086 0.0021
26 Trehalose Alanine 0.0396 0.0495 0.0480 0.0351 0.0300
27 Trehalose Isoleucine 0.0336 0.0407 0.0351 0.0284 0.0305
28 Trehalose Creatine 0.0366 0.0501 0.0377 0.0289 0.0274
29 Trehalose Valine 0.0434 0.0457 0.0545 0.0348 0.0389
30 Trehalose Taurine 0.0367 0.0353 0.0472 0.0302 0.0246
31 Trehalose Ectoine 0.0452 0.0587 0.0509 0.0389 0.0384
32 Glycerol Proline 0.0286 0.0174
33 Glycerol Alanine 0.0269 0.0195
34 Glycerol Isoleucine 0.0240 0.0105
35 Glycerol Creatine 0.0349 0.0522
36 Glycerol Valine 0.0355 0.0345
37 Glycerol Taurine 0.0658 0.0876
38 Glycerol Ectoine 0.0580 0.0797
39 Sorbitol Proline 0.0219 0.0162
40 Sorbitol Alanine 0.0374 0.0486
41 Sorbitol Isoleucine 0.0183 0.0109
42 Sorbitol Creatine 0.0426 0.0563
43 Sorbitol Valine 0.0406 0.0374
44 Sorbitol Taurine 0.0252 0.0246
45 Sorbitol Ectoine 0.0554 0.0643
46 Arabitol Proline 0.0438 0.0382
47 Arabitol Alanine 0.0408 0.0527
48 Arabitol Isoleucine 0.0152 0.0112
49 Arabitol Creatine 0.0263 0.0233
50 Arabitol Valine 0.0242 0.0176
51 Arabitol Taurine 0.0178 0.0118
52 Arabitol Ectoine 0.0198 0.0230
53 Inositol Proline 0.0281 0.0282
54 Inositol Alanine 0.0301 0.0377
55 Inositol Isoleucine 0.0086 0.0078
56 Inositol Creatine 0.0430 0.0624
57 Inositol Valine 0.0116 0.0115
58 Inositol Taurine 0.0417 0.0675
59 Inositol Ectoine 0.0420 0.0620
60 Erythritol Proline 0.0275 0.0365
61 Erythritol Alanine 0.0420 0.0463
62 Erythritol Isoleucine 0.0245 0.0113
63 Erythritol Creatine 0.0294 0.0418
64 Erythritol Valine 0.0271 0.0115
65 Erythritol Taurine 0.0492 0.0576
66 Erythritol Ectoine 0.0530 0.0538
67 Xylitol Proline 0.0226 0.0031
68 Xylitol Alanine 0.0076 0.0028
69 Xylitol Isoleucine 0.0028 >0.0025
70 Xylitol Creatine 0.0125 0.0126
71 Xylitol Valine 0.0074 0.0084
72 Xylitol Taurine 0.0120 0.0010
73 Xylitol Ectoine 0.0135 0.0159
74 Mannitol Proline 0.0337 0.0302
75 Mannitol Alanine 0.0272 0.0420
76 Mannitol Isoleucine 0.0025 0.0066
77 Mannitol Creatine 0.0194 0.0481
78 Mannitol Valine 0.0133 0.0216
79 Mannitol Taurine 0.0194 0.0424
80 Mannitol Ectoine 0.0517 0.0548
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81 Ribitol(adonitol) Proline 0.0350 0.0141
82 Ribitol(adonitol) Alanine 0.0450 0.0124
83 Ribitol(adonitol) Isoleucine 0.0387 0.0021
84 Ribitol(adonitol) Creatine 0.0459 0.0066
85 Ribitol(adonitol) Valine 0.0394 0.0019
86 Ribitol(adonitol) Taurine 0.0479 0.0261
87 Ribitol(adonitol) Ectoine 0.0472 0.0288
88 Trehalose Glycerol Proline 0.0405 0.0584 0.0287 0.0243 0.0199
89 Trehalose Glycerol Alanine 0.0640 0.0799 0.0454 0.0648 0.0731
90 Trehalose Glycerol Isoleucine 0.0512 0.0416 0.0424 0.0513 0.0521
91 Trehalose Glycerol Creatine 0.0562 0.0517 0.0592 0.0532 0.0690
92 Trehalose Glycerol Valine 0.0482 0.0465 0.0383 0.0667 0.0450
93 Trehalose Glycerol Taurine 0.0507 0.0562 0.0539 0.0532 0.0517
94 Trehalose Glycerol Ectoine 0.0702 0.0693 0.0708 0.0814 0.0716
95 Trehalose Sorbitol Proline 0.0382 0.0424 0.0380 0.0388 0.0317
96 Trehalose Sorbitol Alanine 0.0530 0.0584 0.0547 0.0596 0.0580
97 Trehalose Sorbitol Isoleucine 0.0452 0.0477 0.0493 0.0533 0.0485
98 Trehalose Sorbitol Creatine 0.0580 0.0606 0.0481 0.0602 0.0525
99 Trehalose Sorbitol Valine 0.0623 0.0668 0.0668 0.0525 0.0586
100 Trehalose Sorbitol Taurine 0.0639 0.0803 0.0584 0.0613 0.0487
101 Trehalose Sorbitol Ectoine 0.0693 0.0744 0.0703 0.0666 0.0711
102 Trehalose Arabitol Proline 0.0374 0.0396 0.0353 0.0238 0.0215
103 Trehalose Arabitol Alanine 0.0524 0.0473 0.0536 0.0449 0.0449
104 Trehalose Arabitol Isoleucine 0.0505 0.0505 0.0490 0.0451 0.0394
105 Trehalose Arabitol Creatine 0.0572 0.0632 0.0553 0.0524 0.0549
106 Trehalose Arabitol Valine 0.0536 0.0553 0.0456 0.0481 0.0471
107 Trehalose Arabitol Taurine 0.0522 0.0500 0.0490 0.0423 0.0456
108 Trehalose Arabitol Ectoine 0.0638 0.0642 0.0726 0.0519 0.0597
109 Trehalose Inositol Proline 0.0311 0.0322 0.0258 0.0188 0.0152
110 Trehalose Inositol Alanine 0.0488 0.0531 0.0426 0.0374 0.0318
111 Trehalose Inositol Isoleucine 0.0503 0.0582 0.0408 0.0392 0.0324
112 Trehalose Inositol Creatine 0.0529 0.0487 0.0638 0.0366 0.0314
113 Trehalose Inositol Valine 0.0462 0.0495 0.0442 0.0310 0.0310
114 Trehalose Inositol Taurine 0.0398 0.0529 0.0384 0.0408 0.0348
115 Trehalose Inositol Ectoine 0.0348 0.0479 0.0438 0.0330 0.0362
116 Trehalose Erythritol Proline 0.0290 0.0345 0.0412 0.0348 0.0260
117 Trehalose Erythritol Alanine 0.0380 0.0492 0.0451 0.0462 0.0473
118 Trehalose Erythritol Isoleucine 0.0422 0.0475 0.0426 0.0367 0.0345
119 Trehalose Erythritol Creatine 0.0516 0.0574 0.0547 0.0472 0.0509
120 Trehalose Erythritol Valine 0.0442 0.0438 0.0472 0.0517 0.0434
121 Trehalose Erythritol Taurine 0.0464 0.0534 0.0557 0.0473 0.0458
122 Trehalose Erythritol Ectoine 0.0548 0.0526 0.0625 0.0507 0.0671
123 Trehalose Xylitol Proline 0.0298 0.0234 0.0285 0.0361 0.0259
124 Trehalose Xylitol Alanine 0.0384 0.0371 0.0396 0.0447 0.0422
125 Trehalose Xylitol Isoleucine 0.0414 0.0486 0.0377 0.0467 0.0435
126 Trehalose Xylitol Creatine 0.0539 0.0628 0.0589 0.0544 0.0435
127 Trehalose Xylitol Valine 0.0415 0.0361 0.0412 0.0476 0.0451
128 Trehalose Xylitol Taurine 0.0402 0.0380 0.0412 0.0476 0.0451
129 Trehalose Xylitol Ectoine 0.0516 0.0521 0.0618 0.0580 0.0586
130 Trehalose Mannitol Proline 0.0402 0.0440 0.0431 0.0341 0.0341
131 Trehalose Mannitol Alanine 0.0478 0.0537 0.0466 0.0396 0.0446
132 Trehalose Mannitol Isoleucine 0.0444 0.0407 0.0543 0.0464 0.0460
133 Trehalose Mannitol Creatine 0.0504 0.0539 0.0597 0.0493 0.0501
134 Trehalose Mannitol Valine 0.0470 0.0639 0.0493 0.0423 0.0440
135 Trehalose Mannitol Taurine 0.0546 0.0624 0.0566 0.0562 0.0504
136 Trehalose Mannitol Ectoine 0.0513 0.0555 0.0564 0.0669 0.0473
137 Trehalose Ribitol(adonitol) Proline 0.0403 0.0465 0.0542 0.0417 0.0347
138 Trehalose Ribitol(adonitol) Alanine 0.0542 0.0553 0.0594 0.0530 0.0445
139 Trehalose Ribitol(adonitol) Isoleucine 0.0576 0.0681 0.0597 0.0516 0.0579
140 Trehalose Ribitol(adonitol) Creatine 0.0632 0.0750 0.0656 0.0712 0.0653
141 Trehalose Ribitol(adonitol) Valine 0.0579 0.0715 0.0688 0.0610 0.0498
142 Trehalose Ribitol(adonitol) Taurine 0.0515 0.0724 0.0621 0.0532 0.0523
143 Trehalose Ribitol(adonitol) Ectoine 0.0559 0.0707 0.0785 0.0553 0.0556
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Combo%number Sugar Sugar%Alcohol Additive Average 1 2 3 4 5 6 7 8
0 0.0055 ?0.0038 0.0047 0.0137 0.0186 0.0047 0.0059 0.0035 ?0.0020
1 Trehalose 0.0963 0.1240 0.1199 0.1128 0.1110
2 Glycerol 0.0658 0.0584 0.0928 0.0656 0.0686 0.0632 0.0680 0.0794 0.0776
3 Sorbitol 0.0686 0.0874 0.0744 0.0790 0.0575 0.0786 0.0719 0.0782 0.0857
4 Arabitol 0.0492 0.0455 0.0620 0.0735 0.0360 0.0698 0.0551 0.0328 0.0620
5 Inositol 0.0604 0.0618 0.0723 0.0778 0.0509 0.0820 0.0654 0.0631 0.0668
6 Erythritol 0.0223 0.0499 0.0383 0.0160 0.0112 0.0144 0.0172 0.0132 0.0424
7 Xylitol 0.0851 0.1224 0.1287 0.1001 0.0339 0.0339 0.0512 0.0877 0.0836
8 Mannitol 0.0702 0.0802 0.0686 0.0482 0.0488 0.0565 0.0638 0.0738 0.0717
9 Ribitol(adonitol) 0.0414 0.0411 0.0441 0.0447 0.0061 0.0318 0.0101 0.0349 0.0472
10 Proline 0.0940 0.0770
11 Alanine 0.0492 0.0399
12 Isoleucine 0.0414 ?0.0100
13 Creatine 0.0312 ?0.0032
14 Valine 0.0344 0.0003
15 Taurine 0.0399 0.0166
16 Ectoine 0.0558 0.0436
17 Trehalose Glycerol 0.1118 0.1140 0.1207 0.1224 0.1224
18 Trehalose Sorbitol 0.0898 0.0933 0.0833 0.0926 0.1023
19 Trehalose Arabitol 0.0945 0.1025 0.0897 0.0951 0.0978
20 Trehalose Inositol 0.1062 0.1354 0.1089 0.1007 0.1115
21 Trehalose Erythritol 0.0876 0.1014 0.0692 0.0867 0.1018
22 Trehalose Xylitol 0.1017 0.1198 0.1287 0.1097 0.0927
23 Trehalose Mannitol 0.0953 0.0901 0.1004 0.1122 0.0955
24 Trehalose Ribitol(adonitol) 0.1022 0.1205 0.1071 0.1091 0.1026
25 Trehalose Proline 0.0778 0.0845 0.0880 0.0724 0.0662
26 Trehalose Alanine 0.0995 0.1048 0.1089 0.0967 0.1013
27 Trehalose Isoleucine 0.0715 0.0903 0.0851 0.0707 0.0662
28 Trehalose Creatine 0.0927 0.1160 0.1095 0.0926 0.0833
29 Trehalose Valine 0.0829 0.0911 0.0894 0.0877 0.0727
30 Trehalose Taurine 0.0775 0.0940 0.1004 0.0784 0.0784
31 Trehalose Ectoine 0.1011 0.1211 0.1372 0.0946 0.0830
32 Glycerol Proline 0.0712 0.0873
33 Glycerol Alanine 0.0857 0.1387
34 Glycerol Isoleucine 0.0339 0.0059
35 Glycerol Creatine 0.0600 0.0581
36 Glycerol Valine 0.0709 0.0695
37 Glycerol Taurine 0.0747 0.0716
38 Glycerol Ectoine 0.0774 0.1038
39 Sorbitol Proline 0.0822 0.0823
40 Sorbitol Alanine 0.0716 0.0777
41 Sorbitol Isoleucine 0.0402 0.0173
42 Sorbitol Creatine 0.0777 0.0887
43 Sorbitol Valine 0.0608 0.0717
44 Sorbitol Taurine 0.0602 0.0821
45 Sorbitol Ectoine 0.0495 0.0830
46 Arabitol Proline 0.0296 0.0481
47 Arabitol Alanine 0.0417 0.0689
48 Arabitol Isoleucine 0.0096 0.0020
49 Arabitol Creatine 0.0255 0.0377
50 Arabitol Valine 0.0424 0.0423
51 Arabitol Taurine 0.0851 0.0479
52 Arabitol Ectoine 0.0790 0.0293
53 Inositol Proline 0.0968 0.0934
54 Inositol Alanine 0.0672 0.1005
55 Inositol Isoleucine 0.0187 0.0035
56 Inositol Creatine 0.0391 0.0271
57 Inositol Valine 0.0450 0.0023
58 Inositol Taurine 0.0892 0.0948
59 Inositol Ectoine 0.0612 0.0422
60 Erythritol Proline 0.0392 0.0098
61 Erythritol Alanine 0.0482 0.0482
62 Erythritol Isoleucine 0.0236 ?0.0015
63 Erythritol Creatine 0.0510 0.0455
64 Erythritol Valine 0.0317 ?0.0005
65 Erythritol Taurine 0.0672 0.0605
66 Erythritol Ectoine 0.0575 0.0432
67 Xylitol Proline 0.0715 0.1018
68 Xylitol Alanine 0.0896 0.1350
69 Xylitol Isoleucine 0.0456 0.0465
70 Xylitol Creatine 0.0561 0.1060
71 Xylitol Valine 0.0579 0.0840
72 Xylitol Taurine 0.0489 0.0877
73 Xylitol Ectoine 0.0724 0.1098
74 Mannitol Proline 0.0468 0.0464
75 Mannitol Alanine 0.0768 0.0765
76 Mannitol Isoleucine 0.0276 0.0154
77 Mannitol Creatine 0.0320 0.0741
78 Mannitol Valine 0.0385 0.0802
79 Mannitol Taurine 0.0408 0.0812
80 Mannitol Ectoine 0.0557 0.0949
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81 Ribitol(adonitol) Proline 0.0453 0.0470
82 Ribitol(adonitol) Alanine 0.0926 0.0712
83 Ribitol(adonitol) Isoleucine 0.0619 0.0031
84 Ribitol(adonitol) Creatine 0.0794 0.0364
85 Ribitol(adonitol) Valine 0.0602 G0.0021
86 Ribitol(adonitol) Taurine 0.0700 0.0467
87 Ribitol(adonitol) Ectoine 0.0657 0.0480
88 Trehalose Glycerol Proline 0.0939 0.1041 0.0919 0.0936 0.0875
89 Trehalose Glycerol Alanine 0.1134 0.1128 0.1134 0.1224 0.1162
90 Trehalose Glycerol Isoleucine 0.0903 0.0844 0.0883 0.0861 0.0900
91 Trehalose Glycerol Creatine 0.1036 0.1131 0.1053 0.1047 0.1053
92 Trehalose Glycerol Valine 0.0902 0.0864 0.0908 0.0902 0.0886
93 Trehalose Glycerol Taurine 0.0988 0.1114 0.1008 0.0902 0.0936
94 Trehalose Glycerol Ectoine 0.1168 0.1095 0.1253 0.1123 0.1016
95 Trehalose Sorbitol Proline 0.0635 0.0574 0.0456 0.0559 0.0496
96 Trehalose Sorbitol Alanine 0.0743 0.0778 0.0672 0.0620 0.0639
97 Trehalose Sorbitol Isoleucine 0.0711 0.0607 0.0596 0.0607 0.0629
98 Trehalose Sorbitol Creatine 0.0839 0.0772 0.0788 0.0788 0.0833
99 Trehalose Sorbitol Valine 0.0692 0.0641 0.0727 0.0652 0.0750
100 Trehalose Sorbitol Taurine 0.0657 0.0665 0.0702 0.0527 0.0524
101 Trehalose Sorbitol Ectoine 0.0866 0.0782 0.1009 0.0736 0.0786
102 Trehalose Arabitol Proline 0.0750 0.0548 0.0599 0.0789 0.0618
103 Trehalose Arabitol Alanine 0.0755 0.0673 0.0464 0.0673 0.0677
104 Trehalose Arabitol Isoleucine 0.0665 0.0612 0.0550 0.0531 0.0535
105 Trehalose Arabitol Creatine 0.0758 0.0776 0.0634 0.0720 0.0735
106 Trehalose Arabitol Valine 0.0666 0.0653 0.0642 0.0572 0.0564
107 Trehalose Arabitol Taurine 0.0724 0.0627 0.0649 0.0686 0.0653
108 Trehalose Arabitol Ectoine 0.0917 0.0940 0.0761 0.0894 0.0871
109 Trehalose Inositol Proline 0.0934 0.0927 0.1004 0.0885 0.0897
110 Trehalose Inositol Alanine 0.0974 0.0821 0.0876 0.0996 0.0970
111 Trehalose Inositol Isoleucine 0.0836 0.0785 0.0810 0.0735 0.0781
112 Trehalose Inositol Creatine 0.1067 0.1074 0.1078 0.1030 0.1065
113 Trehalose Inositol Valine 0.0853 0.0775 0.0695 0.0880 0.0889
114 Trehalose Inositol Taurine 0.0863 0.0887 0.0899 0.0916 0.0768
115 Trehalose Inositol Ectoine 0.0973 0.0974 0.0961 0.0974 0.1074
116 Trehalose Erythritol Proline 0.0679 0.0583 0.0549 0.0737 0.0803
117 Trehalose Erythritol Alanine 0.0685 0.0646 0.0704 0.0781 0.0631
118 Trehalose Erythritol Isoleucine 0.0650 0.0717 0.0583 0.0432 0.0470
119 Trehalose Erythritol Creatine 0.0865 0.0713 0.0932 0.0709 0.0881
120 Trehalose Erythritol Valine 0.0603 0.0436 0.0671 0.0474 0.0470
121 Trehalose Erythritol Taurine 0.0685 0.0631 0.0708 0.0551 0.0524
122 Trehalose Erythritol Ectoine 0.0776 0.0638 0.0677 0.0781 0.0883
123 Trehalose Xylitol Proline 0.0724 0.0689 0.0862 0.0671 0.0549
124 Trehalose Xylitol Alanine 0.0786 0.0822 0.0760 0.0847 0.0797
125 Trehalose Xylitol Isoleucine 0.0723 0.0859 0.0772 0.0729 0.0595
126 Trehalose Xylitol Creatine 0.1015 0.1009 0.1109 0.0865 0.0934
127 Trehalose Xylitol Valine 0.0841 0.0887 0.0800 0.0732 0.0689
128 Trehalose Xylitol Taurine 0.0798 0.0843 0.0800 0.0732 0.0689
129 Trehalose Xylitol Ectoine 0.0941 0.1049 0.0862 0.0962 0.0999
130 Trehalose Mannitol Proline 0.0670 0.0651 0.0604 0.0613 0.0571
131 Trehalose Mannitol Alanine 0.0728 0.0711 0.0649 0.0692 0.0696
132 Trehalose Mannitol Isoleucine 0.0681 0.0680 0.0627 0.0590 0.0632
133 Trehalose Mannitol Creatine 0.0805 0.0853 0.0809 0.0916 0.0723
134 Trehalose Mannitol Valine 0.0647 0.0599 0.0590 0.0590 0.0514
135 Trehalose Mannitol Taurine 0.0820 0.0860 0.0763 0.0749 0.0725
136 Trehalose Mannitol Ectoine 0.0943 0.0964 0.1132 0.0974 0.0857
137 Trehalose Ribitol(adonitol) Proline 0.0816 0.1004 0.0685 0.0843 0.0761
138 Trehalose Ribitol(adonitol) Alanine 0.0862 0.0810 0.0761 0.0800 0.0728
139 Trehalose Ribitol(adonitol) Isoleucine 0.0821 0.0642 0.0704 0.0647 0.0742
140 Trehalose Ribitol(adonitol) Creatine 0.0848 0.0968 0.0846 0.0711 0.0769
141 Trehalose Ribitol(adonitol) Valine 0.0667 0.0673 0.0616 0.0588 0.0630
142 Trehalose Ribitol(adonitol) Taurine 0.0713 0.0697 0.0683 0.0644 0.0668
143 Trehalose Ribitol(adonitol) Ectoine 0.1016 0.0887 0.0994 0.0877 0.0936
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0 >0.0167 >0.0260 >0.0098 >0.0117 >0.0174 >0.0184 >0.0203 >0.0165 >0.0203
1 Trehalose 0.0872 0.1454 0.0606 0.1184 0.1232
2 Glycerol 0.0263 0.0677 0.0197 0.0485 0.0493 0.0091 0.0325 0.0069 0.0204
3 Sorbitol 0.0440 0.0541 0.0541 0.0432 0.0383 0.0545 0.0503 0.0609 0.0586
4 Arabitol 0.0359 0.0380 0.0473 0.0348 0.0435 0.0417 0.0575 0.0380 0.0426
5 Inositol 0.0203 0.0126 0.0242 0.0340 0.0318 0.0215 0.0304 0.0144 0.0300
6 Erythritol 0.0086 0.0278 0.0252 0.0001 0.0179 0.0084 0.0015 0.0190 >0.0021
7 Xylitol 0.0411 0.0350 0.0248 0.0263 0.0248 0.0279 0.0173 0.0324 0.0360
8 Mannitol 0.0484 0.0637 0.0618 0.0521 0.0385 0.0482 0.0405 0.0337 0.0366
9 Ribitol(adonitol) 0.0111 0.0135 >0.0049 >0.0077 0.0052 >0.0086 >0.0086 >0.0017 >0.0054
10 Proline 0.0746 0.0260
11 Alanine 0.0360 0.0043
12 Isoleucine >0.0039 >0.0274
13 Creatine 0.0127 >0.0231
14 Valine 0.0059 >0.0375
15 Taurine >0.0147 >0.0385
16 Ectoine 0.0256 0.0187
17 Trehalose Glycerol 0.0858 0.1117 0.1178 0.1042 0.0885
18 Trehalose Sorbitol 0.0532 0.0675 0.0598 0.0532 0.0649
19 Trehalose Arabitol 0.0631 0.0590 0.0657 0.0694 0.0671
20 Trehalose Inositol 0.0642 0.0739 0.0704 0.0611 0.0615
21 Trehalose Erythritol 0.0764 0.0684 0.0987 0.0796 0.0922
22 Trehalose Xylitol 0.0479 0.0347 0.0400 0.0666 0.0597
23 Trehalose Mannitol 0.0952 0.0858 0.1075 0.1132 0.1151
24 Trehalose Ribitol(adonitol) 0.0630 0.0667 0.0667 0.0709 0.0606
25 Trehalose Proline 0.0258 0.0443 >0.0152 0.0093 0.0295
26 Trehalose Alanine 0.0604 0.0827 0.0185 0.0705 0.0714
27 Trehalose Isoleucine 0.0556 0.0592 0.0360 0.0649 0.0799
28 Trehalose Creatine 0.0766 0.0912 0.0518 0.0960 0.0969
29 Trehalose Valine 0.0585 0.0813 0.0337 0.0634 0.0794
30 Trehalose Taurine 0.0551 0.0719 0.0125 0.0804 0.0672
31 Trehalose Ectoine 0.0862 0.1041 0.0513 0.1060 0.1280
32 Glycerol Proline 0.0473 0.0371
33 Glycerol Alanine 0.0432 0.0485
34 Glycerol Isoleucine 0.0173 >0.0080
35 Glycerol Creatine 0.0262 0.0397
36 Glycerol Valine 0.0240 0.0238
37 Glycerol Taurine 0.0344 0.0348
38 Glycerol Ectoine 0.0325 0.0333
39 Sorbitol Proline 0.0271 0.0327
40 Sorbitol Alanine 0.0370 0.0435
41 Sorbitol Isoleucine 0.0161 0.0179
42 Sorbitol Creatine 0.0373 0.0447
43 Sorbitol Valine 0.0317 0.0355
44 Sorbitol Taurine 0.0291 0.0329
45 Sorbitol Ectoine 0.0228 0.0456
46 Arabitol Proline 0.0079 >0.0021
47 Arabitol Alanine 0.0207 0.0329
48 Arabitol Isoleucine >0.0030 >0.0075
49 Arabitol Creatine 0.0219 0.0249
50 Arabitol Valine 0.0081 0.0183
51 Arabitol Taurine 0.0262 0.0174
52 Arabitol Ectoine 0.0225 0.0201
53 Inositol Proline 0.0234 0.0204
54 Inositol Alanine 0.0302 0.0356
55 Inositol Isoleucine 0.0096 >0.0086
56 Inositol Creatine 0.0319 0.0465
57 Inositol Valine 0.0130 >0.0064
58 Inositol Taurine 0.0306 0.0253
59 Inositol Ectoine 0.0569 0.0502
60 Erythritol Proline 0.0397 0.0177
61 Erythritol Alanine 0.0308 0.0095
62 Erythritol Isoleucine 0.0159 >0.0067
63 Erythritol Creatine 0.0335 0.0188
64 Erythritol Valine 0.0171 >0.0062
65 Erythritol Taurine 0.0186 0.0035
66 Erythritol Ectoine 0.0326 0.0286
67 Xylitol Proline 0.0103 0.0071
68 Xylitol Alanine 0.0120 0.0289
69 Xylitol Isoleucine >0.0007 0.0063
70 Xylitol Creatine 0.0146 0.0241
71 Xylitol Valine 0.0057 0.0200
72 Xylitol Taurine 0.0104 0.0294
73 Xylitol Ectoine 0.0225 0.0467
74 Mannitol Proline >0.0066 >0.0078
75 Mannitol Alanine 0.0303 0.0347
76 Mannitol Isoleucine >0.0098 >0.0239
77 Mannitol Creatine 0.0140 0.0555
78 Mannitol Valine 0.0169 0.0569
79 Mannitol Taurine 0.0058 0.0492
80 Mannitol Ectoine 0.0168 0.0721
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81 Ribitol(adonitol) Proline 0.0123 0.0059
82 Ribitol(adonitol) Alanine 0.0673 0.0229
83 Ribitol(adonitol) Isoleucine 0.0521 F0.0136
84 Ribitol(adonitol) Creatine 0.0476 F0.0091
85 Ribitol(adonitol) Valine 0.0380 F0.0125
86 Ribitol(adonitol) Taurine 0.0276 F0.0123
87 Ribitol(adonitol) Ectoine 0.0312 0.0026
88 Trehalose Glycerol Proline 0.0652 0.0836 0.0725 0.0666 0.0498
89 Trehalose Glycerol Alanine 0.0881 0.1049 0.0840 0.0989 0.0877
90 Trehalose Glycerol Isoleucine 0.0824 0.0974 0.0929 0.0832 0.0795
91 Trehalose Glycerol Creatine 0.0983 0.1227 0.0918 0.1076 0.1038
92 Trehalose Glycerol Valine 0.0866 0.0807 0.1076 0.0926 0.0829
93 Trehalose Glycerol Taurine 0.0778 0.0755 0.0926 0.0836 0.0703
94 Trehalose Glycerol Ectoine 0.1021 0.1117 0.1170 0.1155 0.0922
95 Trehalose Sorbitol Proline 0.0454 0.0425 0.0343 0.0361 0.0439
96 Trehalose Sorbitol Alanine 0.0446 0.0405 0.0363 0.0434 0.0416
97 Trehalose Sorbitol Isoleucine 0.0454 0.0461 0.0428 0.0403 0.0361
98 Trehalose Sorbitol Creatine 0.0533 0.0576 0.0407 0.0468 0.0529
99 Trehalose Sorbitol Valine 0.0601 0.0547 0.0428 0.0475 0.0569
100 Trehalose Sorbitol Taurine 0.0598 0.0596 0.0549 0.0466 0.0581
101 Trehalose Sorbitol Ectoine 0.0660 0.0621 0.0640 0.0611 0.0509
102 Trehalose Arabitol Proline 0.0393 0.0326 0.0485 0.0529 0.0278
103 Trehalose Arabitol Alanine 0.0525 0.0547 0.0655 0.0574 0.0449
104 Trehalose Arabitol Isoleucine 0.0602 0.0603 0.0648 0.0603 0.0487
105 Trehalose Arabitol Creatine 0.0690 0.0762 0.0794 0.0675 0.0621
106 Trehalose Arabitol Valine 0.0590 0.0550 0.0505 0.0585 0.0452
107 Trehalose Arabitol Taurine 0.0716 0.0630 0.0734 0.0639 0.0500
108 Trehalose Arabitol Ectoine 0.0841 0.0707 0.0890 0.0753 0.0721
109 Trehalose Inositol Proline 0.0567 0.0503 0.0403 0.0399 0.0377
110 Trehalose Inositol Alanine 0.0641 0.0630 0.0582 0.0688 0.0639
111 Trehalose Inositol Isoleucine 0.0643 0.0730 0.0545 0.0637 0.0637
112 Trehalose Inositol Creatine 0.0736 0.0809 0.0697 0.0800 0.0666
113 Trehalose Inositol Valine 0.0674 0.0670 0.0764 0.0648 0.0679
114 Trehalose Inositol Taurine 0.0535 0.0471 0.0646 0.0606 0.0510
115 Trehalose Inositol Ectoine 0.0621 0.0733 0.0813 0.0849 0.0863
116 Trehalose Erythritol Proline 0.0459 0.0348 0.0576 0.0546 0.0731
117 Trehalose Erythritol Alanine 0.0513 0.0436 0.0629 0.0596 0.0607
118 Trehalose Erythritol Isoleucine 0.0621 0.0445 0.0709 0.0557 0.0568
119 Trehalose Erythritol Creatine 0.0620 0.0576 0.0776 0.0768 0.0795
120 Trehalose Erythritol Valine 0.0570 0.0412 0.0561 0.0561 0.0609
121 Trehalose Erythritol Taurine 0.0574 0.0414 0.0599 0.0523 0.0621
122 Trehalose Erythritol Ectoine 0.0699 0.0512 0.0872 0.0774 0.0744
123 Trehalose Xylitol Proline 0.0150 0.0053 0.0048 0.0167 0.0124
124 Trehalose Xylitol Alanine 0.0403 0.0299 0.0357 0.0386 0.0328
125 Trehalose Xylitol Isoleucine 0.0400 0.0246 0.0236 0.0420 0.0299
126 Trehalose Xylitol Creatine 0.0565 0.0454 0.0483 0.0547 0.0430
127 Trehalose Xylitol Valine 0.0371 0.0248 0.0325 0.0427 0.0335
128 Trehalose Xylitol Taurine 0.0506 0.0481 0.0325 0.0427 0.0335
129 Trehalose Xylitol Ectoine 0.0651 0.0614 0.0481 0.0708 0.0481
130 Trehalose Mannitol Proline 0.0483 0.0302 0.0302 0.0458 0.0542
131 Trehalose Mannitol Alanine 0.0497 0.0435 0.0620 0.0620 0.0472
132 Trehalose Mannitol Isoleucine 0.0761 0.0727 0.0625 0.0981 0.0840
133 Trehalose Mannitol Creatine 0.0991 0.1199 0.0877 0.0981 0.1104
134 Trehalose Mannitol Valine 0.0665 0.0634 0.0644 0.0458 0.0868
135 Trehalose Mannitol Taurine 0.0516 0.0555 0.0555 0.0863 0.0481
136 Trehalose Mannitol Ectoine 0.0970 0.0943 0.1237 0.1085 0.0783
137 Trehalose Ribitol(adonitol) Proline 0.0411 0.0353 0.0371 0.0357 0.0303
138 Trehalose Ribitol(adonitol) Alanine 0.0630 0.0411 0.0462 0.0627 0.0609
139 Trehalose Ribitol(adonitol) Isoleucine 0.0499 0.0416 0.0581 0.0498 0.0489
140 Trehalose Ribitol(adonitol) Creatine 0.0707 0.0542 0.0593 0.0727 0.0611
141 Trehalose Ribitol(adonitol) Valine 0.0691 0.0569 0.0468 0.0634 0.0500
142 Trehalose Ribitol(adonitol) Taurine 0.0428 0.0455 0.0368 0.0468 0.0478
143 Trehalose Ribitol(adonitol) Ectoine 0.0626 0.0632 0.0674 0.0688 0.0650
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